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etection, management, or prevention of disease states.
igorous and expert analysis of the available data docu-
enting absolute and relative benefits and risks of those
rocedures and therapies can produce helpful guidelines
hat improve the effectiveness of care, optimize patient
utcomes, and favorably affect the overall cost of care by
ocusing resources on the most effective strategies.
The American College of Cardiology Foundation
ACCF) and the American Heart Association (AHA) have
ointly engaged in the production of such guidelines in the
rea of cardiovascular disease since 1980. The American
ollege of Cardiology (ACC)/AHA Task Force on Practice
uidelines, whose charge is to develop, update, or revise
ractice guidelines for important cardiovascular diseases and
rocedures, directs this effort. Writing committees are
harged with the task of performing an assessment of the
vidence and acting as an independent group of authors to
evelop, update, or revise written recommendations for
linical practice.
Experts in the subject under consideration have been
elected from both organizations to examine subject-specific
ata and write guidelines. The process includes additional
epresentatives from other medical practitioner and specialty
roups when appropriate. Writing committees are specifi-
ally charged to perform a formal literature review, weigh
he strength of evidence for or against a particular treatment
r procedure, and include estimates of expected health
utcomes where data exist. Patient-specific modifiers and
omorbidities and issues of patient preference that may
nfluence the choice of particular tests or therapies are
onsidered, as well as frequency of follow-up and cost-
ffectiveness. When available, information from studies on
ost will be considered; however, review of data on efficacy
nd clinical outcomes will constitute the primary basis for
reparing recommendations in these guidelines.
The ACC/AHA Task Force on Practice Guidelines
akes every effort to avoid any actual, potential, or per-
eived conflicts of interest that may arise as a result of an
ndustry relationship or personal interest of the writing
ommittee. Specifically, all members of the writing com-
ittee, as well as peer reviewers of the document, were
sked to provide disclosure statements of all such relation-
hips that may be perceived as real or potential conflicts of
nterest. Writing committee members are also strongly
ncouraged to declare a previous relationship with industry
hat may be perceived as relevant to guideline development.
f a writing committee member develops a new relationship
ith industry during his or her tenure, he or she is required
o notify guideline staff in writing. The continued partici-
ation of the writing committee member will be reviewed.
hese statements are reviewed by the parent task force,
eported orally to all members of the writing committee at
ach meeting, and updated and reviewed by the writing
ommittee as changes occur. Please refer to the methodol-
gy manual for ACC/AHA guideline writing committees 1or further description of the relationships with industry
olicy (1). See Appendix 1 for author relationships with
ndustry and Appendix 2 for peer reviewer relationships
ith industry that are pertinent to this guideline.
These practice guidelines are intended to assist health
are providers in clinical decision making by describing a
ange of generally acceptable approaches for the diagnosis,
anagement, and prevention of specific diseases or condi-
ions. Clinical decision making should consider the quality
nd availability of expertise in the area where care is
rovided. These guidelines attempt to define practices that
eet the needs of most patients in most circumstances.
hese guideline recommendations reflect a consensus of
xpert opinion after a thorough review of the available
urrent scientific evidence and are intended to improve
atient care.
Patient adherence to prescribed and agreed upon medical
egimens and lifestyles is an important aspect of treatment.
rescribed courses of treatment in accordance with these
ecommendations will only be effective if they are followed.
ecause lack of patient understanding and adherence may
dversely affect treatment outcomes, physicians and other
ealth care providers should make every effort to engage the
atient in active participation with prescribed medical reg-
mens and lifestyles.
If these guidelines are used as the basis for regulatory or
ayer decisions, the ultimate goal is quality of care and serving
he patient’s best interests. The ultimate judgment regarding
are of a particular patient must be made by the health care
rovider and the patient in light of all of the circumstances
resented by that patient. There are circumstances in which
eviations from these guidelines are appropriate.
The guidelines will be reviewed annually by the ACC/
HA Task Force on Practice Guidelines and will be
onsidered current unless they are updated, revised, or
unsetted and withdrawn from distribution. The executive
ummary and recommendations are published in the May
7, 2008, issue of the Journal of the American College of
ardiology, May 27, 2008, issue of Circulation, and the June
008 issue of Heart Rhythm. The full-text guidelines are
-published in the same issue of the journals noted above, as
ell as posted on the ACC (www.acc.org), AHA (http://
y.americanheart.org), and Heart Rhythm Society (HRS)
www.hrsonline.org) Web sites. Copies of the full-text and
he executive summary are available from each organization.
Sidney C. Smith, Jr, MD, FACC, FAHA
Chair, ACC/AHA Task Force on Practice Guidelines
. Introduction
.1. Organization of Committee
his revision of the “ACC/AHA/NASPE Guidelines for
mplantation of Cardiac Pacemakers and Antiarrhythmia
evices” updates the previous versions published in 1984,991, 1998, and 2002. Revision of the statement was
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ACC/AHA/HRS Guidelines for Device-Based Therapy May 27, 2008:e1–62eemed necessary for multiple reasons: 1) Major studies
ave been reported that have advanced our knowledge of the
atural history of bradyarrhythmias and tachyarrhythmias,
hich may be treated optimally with device therapy; 2)
here have been tremendous changes in the management of
eart failure that involve both drug and device therapy; and
) major advances in the technology of devices to treat,
elay, and even prevent morbidity and mortality from
radyarrhythmias, tachyarrhythmias, and heart failure have
ccurred.
The committee to revise the “ACC/AHA/NASPE
uidelines for Implantation of Cardiac Pacemakers and
ntiarrhythmia Devices” was composed of physicians who
re experts in the areas of device therapy and follow-up and
enior clinicians skilled in cardiovascular care, internal
edicine, cardiovascular surgery, ethics, and socioeconom-
cs. The committee included representatives of the Ameri-
an Association for Thoracic Surgery, Heart Failure Society
f America, and Society of Thoracic Surgeons.
.2. Document Review and Approval
he document was reviewed by 2 official reviewers nomi-
ated by each of the ACC, AHA, and HRS and by 11
dditional peer reviewers. Of the total 17 peer reviewers, 10
ad no significant relevant relationships with industry. In
ddition, this document has been reviewed and approved by
he governing bodies of the ACC, AHA, and HRS, which
nclude 19 ACC Board of Trustees members (none of
hom had any significant relevant relationships with indus-
ry), 15 AHA Science Advisory Coordinating Committee
embers (none of whom had any significant relevant
elationships with industry), and 14 HRS Board of Trustees
embers (6 of whom had no significant relevant relation-
hips with industry). All guideline recommendations under-
ent a formal, blinded writing committee vote. Writing
ommittee members were required to recuse themselves if
hey had a significant relevant relationship with industry.
he guideline recommendations were unanimously ap-
roved by all members of the writing committee who were
ligible to vote. The section “Pacing in Children and
dolescents” was reviewed by additional reviewers with
pecial expertise in pediatric electrophysiology. The com-
ittee thanks all the reviewers for their comments. Many of
heir suggestions were incorporated into the final document.
.3. Methodology and Evidence
he recommendations listed in this document are, when-
ver possible, evidence based. An extensive literature survey
as conducted that led to the incorporation of 527 refer-
nces. Searches were limited to studies, reviews, and other
vidence conducted in human subjects and published in
nglish. Key search words included but were not limited to
ntiarrhythmic, antibradycardia, atrial fibrillation, brady-
rrhythmia, cardiac, CRT, defibrillator, device therapy,
evices, dual chamber, heart, heart failure, ICD, implant-
ble defibrillator, device implantation, long-QT syndrome, pedical therapy, pacemaker, pacing, quality-of-life, resyn-
hronization, rhythm, sinus node dysfunction, sleep apnea,
udden cardiac death, syncope, tachyarrhythmia, terminal
are, and transplantation. Additionally, the committee re-
iewed documents related to the subject matter previously
ublished by the ACC, AHA, and HRS. References se-
ected and published in this document are representative
nd not all-inclusive.
The committee reviewed and ranked evidence supporting
urrent recommendations, with the weight of evidence
anked as Level A if the data were derived from multiple
andomized clinical trials that involved a large number of
ndividuals. The committee ranked available evidence as
evel B when data were derived either from a limited
umber of trials that involved a comparatively small number
f patients or from well-designed data analyses of nonran-
omized studies or observational data registries. Evidence
as ranked as Level C when the consensus of experts was
he primary source of the recommendation. In the narrative
ortions of these guidelines, evidence is generally presented
n chronological order of development. Studies are identi-
ed as observational, randomized, prospective, or retrospec-
ive. The committee emphasizes that for certain conditions
or which no other therapy is available, the indications for
evice therapy are based on expert consensus and years of
linical experience and are thus well supported, even though
he evidence was ranked as Level C. An analogous example
s the use of penicillin in pneumococcal pneumonia, for
hich there are no randomized trials and only clinical
xperience. When indications at Level C are supported by
istorical clinical data, appropriate references (e.g., case
eports and clinical reviews) are cited if available. When
evel C indications are based strictly on committee consen-
us, no references are cited. In areas where sparse data were
vailable (e.g., pacing in children and adolescents), a survey
f current practices of major centers in North America was
onducted to determine whether there was a consensus
egarding specific pacing indications. The schema for clas-
ification of recommendations and level of evidence is
ummarized in Table 1, which also illustrates how the
rading system provides an estimate of the size of the
reatment effect and an estimate of the certainty of the
reatment effect.
The focus of these guidelines is the appropriate use of
eart pacing devices (e.g., pacemakers for bradyarrhythmias
nd heart failure management, cardiac resynchronization,
nd implantable cardioverter-defibrillators [ICDs]), not the
reatment of cardiac arrhythmias. The fact that the use of a
evice for treatment of a particular condition is listed as a
lass I indication (beneficial, useful, and effective) does not
reclude the use of other therapeutic modalities that may be
qually effective. As with all clinical practice guidelines, the
ecommendations in this document focus on treatment of an
verage patient with a specific disorder and may be modified by
atient comorbidities, limitation of life expectancy because of
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reating physician may evaluate appropriately.
These guidelines include sections on selection of pace-
akers and ICDs, optimization of technology, cost, and
ollow-up of implanted devices. Although the section on
ollow-up is relatively brief, its importance cannot be over-
mphasized: First, optimal results from an implanted device
an be obtained only if the device is adjusted to changing
able 1. Applying Classification of Recommendations and Levelinical conditions; second, recent advisories and recalls (erve as warnings that devices are not infallible, and failure
f electronics, batteries, and leads can occur (2,3).
The committee considered including a section on extrac-
ion of failed/unused leads, a topic of current interest, but
lected not to do so in the absence of convincing evidence to
upport specific criteria for timing and methods of lead
xtraction. A policy statement on lead extraction from the
orth American Society of Pacing and Electrophysiology
videncel of Enow the HRS) provides information on this topic (4).
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ACC/AHA/HRS Guidelines for Device-Based Therapy May 27, 2008:e1–62imilarly, the issue of when to discontinue long-term
ardiac pacing or defibrillator therapy has not been studied
ufficiently to allow formulation of appropriate guidelines
5); however, the question is of such importance that this
opic is addressed to emphasize the importance of patient-
amily-physician discussion and ethical principles.
The text that accompanies the listed indications should
e read carefully, because it includes the rationale and
upporting evidence for many of the indications, and in
everal instances, it includes a discussion of alternative
cceptable therapies. Many of the indications are modified
y the term “potentially reversible.” This term is used to
ndicate abnormal pathophysiology (e.g., complete heart
lock) that may be the result of reversible factors. Examples
nclude complete heart block due to drug toxicity (digitalis),
lectrolyte abnormalities, diseases with periatrioventricular
ode inflammation (Lyme disease), and transient injury to
he conduction system at the time of open heart surgery.
hen faced with a potentially reversible situation, the
reating physician must decide how long of a waiting period
s justified before device therapy is begun. The committee
ecognizes that this statement does not address the issue of
ength of hospital stay vis-à-vis managed-care regulations. It
s emphasized that these guidelines are not intended to
ddress this issue, which falls strictly within the purview of
he treating physician.
The term “symptomatic bradycardia” is used in this
ocument. Symptomatic bradycardia is defined as a docu-
ented bradyarrhythmia that is directly responsible for
evelopment of the clinical manifestations of syncope or
ear syncope, transient dizziness or lightheadedness, or
onfusional states resulting from cerebral hypoperfusion
ttributable to slow heart rate. Fatigue, exercise intolerance,
nd congestive heart failure may also result from bradycar-
ia. These symptoms may occur at rest or with exertion.
efinite correlation of symptoms with a bradyarrhythmia is
equired to fulfill the criteria that define symptomatic
radycardia. Caution should be exercised not to confuse
hysiological sinus bradycardia (as occurs in highly trained
thletes) with pathological bradyarrhythmias. Occasionally,
ymptoms may become apparent only in retrospect after
ntibradycardia pacing. Nevertheless, the universal applica-
ion of pacing therapy to treat a specific heart rate cannot be
ecommended except in specific circumstances, as detailed
ubsequently.
In these guidelines, the terms “persistent,” “transient,”
nd “not expected to resolve” are used but not specifically
efined because the time element varies in different clinical
onditions. The treating physician must use appropriate
linical judgment and available data in deciding when a
ondition is persistent or when it can be expected to be
ransient. Section 2.1.4, “Pacing for Atrioventricular Block
ssociated With Acute Myocardial Infarction,” overlaps
ith the “ACC/AHA Guidelines for the Management of
atients With ST-Elevation Myocardial Infarction” (6) andncludes expanded indications and stylistic changes. The gtatement “incidental finding at electrophysiological study”
s used several times in this document and does not mean
hat such a study is indicated. Appropriate indications for
lectrophysiological studies have been published (7).
The section on indications for ICDs has been updated to
eflect the numerous new developments in this field and the
oluminous literature related to the efficacy of these devices
n the treatment and prophylaxis of sudden cardiac death
SCD) and malignant ventricular arrhythmias. As previ-
usly noted, indications for ICDs, cardiac resynchronization
herapy (CRT) devices, and combined ICDs and CRT
evices (hereafter called CRT-Ds) are continuously chang-
ng and can be expected to change further as new trials are
eported. Indeed, it is inevitable that the indications for
evice therapy will be refined with respect to both expanded
se and the identification of patients expected to benefit the
ost from these therapies. Furthermore, it is emphasized
hat when a patient has an indication for both a pacemaker
whether it be single-chamber, dual-chamber, or biventricu-
ar) and an ICD, a combined device with appropriate
rogramming is indicated.
In this document, the term “mortality” is used to indicate
ll-cause mortality unless otherwise specified. The commit-
ee elected to use all-cause mortality because of the variable
efinition of sudden death and the developing consensus to
se all-cause mortality as the most appropriate end point of
linical trials (8,9).
These guidelines are not designed to specify training or
redentials required for physicians to use device therapy.
evertheless, in view of the complexity of both the cognitive
nd technical aspects of device therapy, only appropriately
rained physicians should use device therapy. Appropriate
raining guidelines for physicians have been published
reviously (10–13).
The 2008 revision reflects what the committee believes
re the most relevant and significant advances in pacemaker/
CD therapy since the publication of these guidelines in the
ournal of the American College of Cardiology and Circulation
n 2002 (14,15).
All recommendations assume that patients are treated
ith optimal medical therapy according to published guide-
ines, as had been required in all the randomized controlled
linical trials on which these guidelines are based, and that
uman issues related to individual patients are addressed.
he committee believes that comorbidities, life expectancy,
nd quality-of-life (QOL) issues must be addressed forth-
ightly with patients and their families. We have repeatedly
sed the phrase “reasonable expectation of survival with a
ood functional status for more than 1 year” to emphasize
his integration of factors in decision-making. Even when
hysicians believe that the anticipated benefits warrant
evice implantation, patients have the option to decline
ntervention after having been provided with a full explana-
ion of the potential risks and benefits of device therapy.
inally, the committee is aware that other guideline/expert
roups have interpreted the same data differently (16–19).
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May 27, 2008:e1–62 ACC/AHA/HRS Guidelines for Device-Based TherapyIn preparing this revision, the committee was guided by
he following principles:
. Changes in recommendations and levels of evidence
were made either because of new randomized trials or
because of the accumulation of new clinical evidence and
the development of clinical consensus.
. The committee was cognizant of the health care, logistic,
and financial implications of recent trials and factored in
these considerations to arrive at the classification of
certain recommendations.
. For recommendations taken from other guidelines,
wording changes were made to render some of the
original recommendations more precise.
. The committee would like to reemphasize that the
recommendations in this guideline apply to most pa-
tients but may require modification because of existing
situations that only the primary treating physician can
evaluate properly.
. All of the listed recommendations for implantation of a
device presume the absence of inciting causes that may
be eliminated without detriment to the patient (e.g.,
nonessential drug therapy).
. The committee endeavored to maintain consistency of
recommendations in this and other previously published
guidelines. In the section on atrioventricular (AV) block
associated with acute myocardial infarction (AMI), the
recommendations follow closely those in the “ACC/
AHA Guidelines for the Management of Patients With
ST-Elevation Myocardial Infarction” (6). However, be-
cause of the rapid evolution of pacemaker/ICD science,
it has not always been possible to maintain consistency
with other published guidelines.
. Indications for Pacing
.1. Pacing for Bradycardia Due to Sinus and
trioventricular Node Dysfunction
n some patients, bradycardia is the consequence of essential
ong-term drug therapy of a type and dose for which there
s no acceptable alternative. In these patients, pacing therapy
s necessary to allow maintenance of ongoing medical
reatment.
.1.1. Sinus Node Dysfunction
inus node dysfunction (SND) was first described as a
linical entity in 1968 (20), although Wenckebach reported
he electrocardiographic (ECG) manifestation of SND in
923. SND refers to a broad array of abnormalities in sinus
ode and atrial impulse formation and propagation. These
nclude persistent sinus bradycardia and chronotropic in-
ompetence without identifiable causes, paroxysmal or per-
istent sinus arrest with replacement by subsidiary escape
hythms in the atrium, AV junction, or ventricular myocar-
ium. The frequent association of paroxysmal atrial fibril-ation (AF) and sinus bradycardia or sinus bradyarrhyth- nias, which may oscillate suddenly from one to the other,
sually accompanied by symptoms, is termed “tachy-brady
yndrome.”
SND is primarily a disease of the elderly and is presumed
o be due to senescence of the sinus node and atrial muscle.
ollected data from 28 different studies on atrial pacing for
ND showed a median annual incidence of complete AV
lock of 0.6% (range 0% to 4.5%) with a total prevalence of
.1% (range 0% to 11.9%) (21). This suggests that the
egenerative process also affects the specialized conduction
ystem, although the rate of progression is slow and does not
ominate the clinical course of disease (21). SND is typi-
ally diagnosed in the seventh and eighth decades of life,
hich is also the average age at enrollment in clinical trials
f pacemaker therapy for SND (22,23). Identical clinical
anifestations may occur at any age as a secondary phe-
omenon of any condition that results in destruction of sinus
ode cells, such as ischemia or infarction, infiltrative disease,
ollagen vascular disease, surgical trauma, endocrinologic ab-
ormalities, autonomic insufficiency, and others (24).
The clinical manifestations of SND are diverse, reflecting
he range of typical sinoatrial rhythm disturbances. The
ost dramatic presentation is syncope. The mechanism of
yncope is a sudden pause in sinus impulse formation or
inus exit block, either spontaneously or after the termina-
ion of an atrial tachyarrhythmia, that causes cerebral
ypoperfusion. The pause in sinus node activity is frequently
ccompanied by an inadequate, delayed, or absent response
f subsidiary escape pacemakers in the AV junction or
entricular myocardium, which aggravates the hemody-
amic consequences.
However, in many patients, the clinical manifestations of
ND are more insidious and relate to an inadequate heart
ate response to activities of daily living that can be difficult
o diagnose (25). The term “chronotropic incompetence” is
sed to denote an inadequate heart rate response to physical
ctivity. Although many experienced clinicians claim to
ecognize chronotropic incompetence in individual patients,
o single metric has been established as a diagnostic
tandard upon which therapeutic decisions can be based.
he most obvious example of chronotropic incompetence is
monotonic daily heart rate profile in an ambulatory
atient. Various protocols have been proposed to quantify
ubphysiological heart rate responses to exercise (26,27),
nd many clinicians would consider failure to achieve 80%
f the maximum predicted heart rate (220 minus age) at
eak exercise as evidence of a blunted heart rate response
28,29). However, none of these approaches have been
alidated clinically, and it is likely that the appropriate heart
ate response to exercise in individual patients is too
diosyncratic for standardized testing.
The natural history of untreated SND may be highly
ariable. The majority of patients who have experienced
yncope because of a sinus pause or marked sinus bradycar-
ia will have recurrent syncope (30). Not uncommonly, the
atural history of SND is interrupted by other necessary
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ACC/AHA/HRS Guidelines for Device-Based Therapy May 27, 2008:e1–62edical therapies that aggravate the underlying tendency to
radycardia (24). MOST (Mode Selection Trial) included
ymptomatic pauses greater than or equal to 3 seconds or
inus bradycardia with rates greater than 50 bpm, which
estricted the use of indicated long-term medical therapy.
upraventricular tachycardia (SVT) including AF was
resent in 47% and 53% of patients, respectively, enrolled in
large randomized clinical trial of pacing mode selection in
ND (22,31). The incidence of sudden death is extremely
ow, and SND does not appear to affect survival whether
ntreated (30) or treated with pacemaker therapy (32,33).
The only effective treatment for symptomatic bradycardia
s permanent cardiac pacing. The decision to implant a
acemaker for SND is often accompanied by uncertainty
hat arises from incomplete linkage between sporadic symp-
oms and ECG evidence of coexisting bradycardia. It is
rucial to distinguish between physiological bradycardia due
o autonomic conditions or training effects and circumstan-
ially inappropriate bradycardia that requires permanent
ardiac pacing. For example, sinus bradycardia is accepted as
physiological finding that does not require cardiac pacing
n trained athletes. Such individuals may have heart rates of
0 to 50 bpm while at rest and awake and may have a
leeping rate as slow as 30 bpm, with sinus pauses or
rogressive sinus slowing accompanied by AV conduction
elay (PR prolongation), sometimes culminating in type I
econd-degree AV block (34,35). The basis of the distinc-
ion between physiological and pathological bradycardia,
hich may overlap in ECG presentation, therefore pivots
n correlation of episodic bradycardia with symptoms com-
atible with cerebral hypoperfusion. Intermittent ECG
onitoring with Holter monitors and event recorders may
e helpful (36,37), although the duration of monitoring
equired to capture such evidence may be very long (38).
he use of insertable loop recorders offers the advantages of
ompliance and convenience during very long-term moni-
oring efforts (39).
The optimal pacing system for prevention of symptom-
tic bradycardia in SND is unknown. Recent evidence
uggests that ventricular desynchronization due to right
entricular apical (RVA) pacing may have adverse effects on
eft ventricular (LV) and left atrial structure and function
40–47). These adverse effects likely explain the association
f RVA pacing, independent of AV synchrony, with in-
reased risks of AF and heart failure in randomized clinical
rials of pacemaker therapy (45,48,49) and, additionally,
entricular arrhythmias and death during ICD therapy
50,51). Likewise, although simulation of the normal sinus
ode response to exercise in bradycardia patients with
acemaker sensors seems logical, a clinical benefit on a
opulation scale has not been demonstrated in large ran-
omized controlled trials of pacemaker therapy (52). These
apidly evolving areas of clinical investigation should inform
he choice of pacing system in SND (see Section 2.6,
Selection of Pacemaker Device”). wecommendations for Permanent Pacing in Sinus
ode Dysfunction
LASS I
. Permanent pacemaker implantation is indicated for SND with
documented symptomatic bradycardia, including frequent sinus
pauses that produce symptoms. (Level of Evidence: C) (53–55)
. Permanent pacemaker implantation is indicated for symptomatic
chronotropic incompetence. (Level of Evidence: C) (53–57)
. Permanent pacemaker implantation is indicated for symptomatic
sinus bradycardia that results from required drug therapy for
medical conditions. (Level of Evidence: C)
LASS IIa
. Permanent pacemaker implantation is reasonable for SND with
heart rate less than 40 bpm when a clear association between
significant symptoms consistent with bradycardia and the actual
presence of bradycardia has not been documented. (Level of
Evidence: C) (53–55,58–60)
. Permanent pacemaker implantation is reasonable for syncope of
unexplained origin when clinically significant abnormalities of
sinus node function are discovered or provoked in electrophysi-
ological studies. (Level of Evidence: C) (61,62)
LASS IIb
. Permanent pacemaker implantation may be considered in mini-
mally symptomatic patients with chronic heart rate less than 40
bpm while awake. (Level of Evidence: C) (53,55,56,58–60)
LASS III
. Permanent pacemaker implantation is not indicated for SND in
asymptomatic patients. (Level of Evidence: C)
. Permanent pacemaker implantation is not indicated for SND in
patients for whom the symptoms suggestive of bradycardia have
been clearly documented to occur in the absence of bradycardia.
(Level of Evidence: C)
. Permanent pacemaker implantation is not indicated for SND with
symptomatic bradycardia due to nonessential drug therapy.
(Level of Evidence: C)
.1.2. Acquired Atrioventricular Block in Adults
V block is classified as first-, second-, or third-degree
complete) block; anatomically, it is defined as supra-,
ntra-, or infra-His. First-degree AV block is defined as
bnormal prolongation of the PR interval (greater than 0.20
econds). Second-degree AV block is subclassified as type I
nd type II. Type I second-degree AV block is characterized
y progressive prolongation of the interval between the
nset of atrial (P wave) and ventricular (R wave) conduction
PR) before a nonconducted beat and is usually seen in
onjunction with QRS. Type I second-degree AV block is
haracterized by progressive prolongation of the PR interval
efore a nonconducted beat and a shorter PR interval after
he blocked beat. Type II second-degree AV block is
haracterized by fixed PR intervals before and after blocked
eats and is usually associated with a wide QRS complex.
hen AV conduction occurs in a 2:1 pattern, block cannot
e classified unequivocally as type I or type II, although the
idth of the QRS can be suggestive, as just described.
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May 27, 2008:e1–62 ACC/AHA/HRS Guidelines for Device-Based Therapydvanced second-degree AV block refers to the blocking of
or more consecutive P waves with some conducted beats,
hich indicates some preservation of AV conduction. In the
etting of AF, a prolonged pause (e.g., greater than 5
econds) should be considered to be due to advanced
econd-degree AV block. Third-degree AV block (complete
eart block) is defined as absence of AV conduction.
Patients with abnormalities of AV conduction may be
symptomatic or may experience serious symptoms related
o bradycardia, ventricular arrhythmias, or both. Decisions
egarding the need for a pacemaker are importantly influ-
nced by the presence or absence of symptoms directly
ttributable to bradycardia. Furthermore, many of the indi-
ations for pacing have evolved over the past 40 years on the
asis of experience without the benefit of comparative
andomized clinical trials, in part because no acceptable
lternative options exist to treat most bradycardias.
Nonrandomized studies strongly suggest that permanent
acing does improve survival in patients with third-degree
V block, especially if syncope has occurred (63–68).
lthough there is little evidence to suggest that pacemakers
mprove survival in patients with isolated first-degree AV
lock (69), it is now recognized that marked (PR more than
00 milliseconds) first-degree AV block can lead to symp-
oms even in the absence of higher degrees of AV block
70). When marked first-degree AV block for any reason
auses atrial systole in close proximity to the preceding
entricular systole and produces hemodynamic conse-
uences usually associated with retrograde (ventriculoatrial)
onduction, signs and symptoms similar to the pacemaker
yndrome may occur (71). With marked first-degree AV
lock, atrial contraction occurs before complete atrial filling,
entricular filling is compromised, and an increase in pul-
onary capillary wedge pressure and a decrease in cardiac
utput follow. Small uncontrolled trials have suggested
ome symptomatic and functional improvement by pacing
f patients with PR intervals more than 0.30 seconds by
ecreasing the time for AV conduction (70). Finally, a long
R interval may identify a subgroup of patients with LV
ysfunction, some of whom may benefit from dual-chamber
acing with a short(er) AV delay (72). These same princi-
les also may be applied to patients with type I second-
egree AV block who experience hemodynamic compro-
ise due to loss of AV synchrony, even without bradycardia.
lthough echocardiographic or invasive techniques may be
sed to assess hemodynamic improvement before perma-
ent pacemaker implantation, such studies are not required.
Type I second-degree AV block is usually due to delay in
he AV node irrespective of QRS width. Because progres-
ion to advanced AV block in this situation is uncommon
73–75), pacing is usually not indicated unless the patient is
ymptomatic. Although controversy exists, pacemaker im-
lantation is supported for this finding (76–78). Type II
econd-degree AV block is usually infranodal (either intra-
r infra-His), especially when the QRS is wide. In these
atients, symptoms are frequent, prognosis is compromised, bnd progression to third-degree AV block is common and
udden (73,75,79). Thus, type II second-degree AV block
ith a wide QRS typically indicates diffuse conduction
ystem disease and constitutes an indication for pacing even
n the absence of symptoms. However, it is not always
ossible to determine the site of AV block without electro-
hysiological evaluation, because type I second-degree AV
lock can be infranodal even when the QRS is narrow (80).
f type I second-degree AV block with a narrow or wide
RS is found to be intra- or infra-Hisian at electrophysi-
logical study, pacing should be considered.
Because it may be difficult for both patients and their
hysicians to attribute ambiguous symptoms such as fatigue
o bradycardia, special vigilance must be exercised to ac-
nowledge the patient’s concerns about symptoms that may
e caused by a slow heart rate. In a patient with third-degree
V block, permanent pacing should be strongly considered
ven when the ventricular rate is more than 40 bpm, because
he choice of a 40 bpm cutoff in these guidelines was not
etermined from clinical trial data. Indeed, it is not the
scape rate that is necessarily critical for safety but rather the
ite of origin of the escape rhythm (i.e., in the AV node, the
is bundle, or infra-His).
AV block can sometimes be provoked by exercise. If not
econdary to myocardial ischemia, AV block in this circum-
tance usually is due to disease in the His-Purkinje system
nd is associated with a poor prognosis; thus, pacing is
ndicated (81,82). Long sinus pauses and AV block can also
ccur during sleep apnea. In the absence of symptoms, these
bnormalities are reversible and do not require pacing (83).
f symptoms are present, pacing is indicated as in other
onditions.
Recommendations for permanent pacemaker implanta-
ion in patients with AV block in AMI, congenital AV
lock, and AV block associated with enhanced vagal tone
re discussed in separate sections. Neurocardiogenic causes
n young patients with AV block should be assessed before
roceeding with permanent pacing. Physiological AV block
n the presence of supraventricular tachyarrhythmias does
ot constitute an indication for pacemaker implantation except
s specifically defined in the recommendations that follow.
In general, the decision regarding implantation of a
acemaker must be considered with respect to whether AV
lock will be permanent. Reversible causes of AV block,
uch as electrolyte abnormalities, should be corrected first.
ome diseases may follow a natural history to resolution
e.g., Lyme disease), and some AV block can be expected to
everse (e.g., hypervagotonia due to recognizable and avoid-
ble physiological factors, perioperative AV block due to
ypothermia, or inflammation near the AV conduction
ystem after surgery in this region). Conversely, some
onditions may warrant pacemaker implantation because of
he possibility of disease progression even if the AV block
everses transiently (e.g., sarcoidosis, amyloidosis, and neu-
omuscular diseases). Finally, permanent pacing for AV
lock after valve surgery follows a variable natural history;
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hysician’s discretion (84).
ecommendations for Acquired Atrioventricular Block
n Adults
LASS I
. Permanent pacemaker implantation is indicated for third-degree
and advanced second-degree AV block at any anatomic level
associated with bradycardia with symptoms (including heart
failure) or ventricular arrhythmias presumed to be due to AV
block. (Level of Evidence: C) (59,63,76,85)
. Permanent pacemaker implantation is indicated for third-degree
and advanced second-degree AV block at any anatomic level
associated with arrhythmias and other medical conditions that
require drug therapy that results in symptomatic bradycardia.
(Level of Evidence: C) (59,63,76,85)
. Permanent pacemaker implantation is indicated for third-degree
and advanced second-degree AV block at any anatomic level in
awake, symptom-free patients in sinus rhythm, with documented
periods of asystole greater than or equal to 3.0 seconds (86) or
any escape rate less than 40 bpm, or with an escape rhythm that
is below the AV node. (Level of Evidence: C) (53,58)
. Permanent pacemaker implantation is indicated for third-degree
and advanced second-degree AV block at any anatomic level in
awake, symptom-free patients with AF and bradycardia with 1 or
more pauses of at least 5 seconds or longer. (Level of Evidence: C)
. Permanent pacemaker implantation is indicated for third-degree
and advanced second-degree AV block at any anatomic level after
catheter ablation of the AV junction. (Level of Evidence: C) (87,88)
. Permanent pacemaker implantation is indicated for third-degree
and advanced second-degree AV block at any anatomic level
associated with postoperative AV block that is not expected to
resolve after cardiac surgery. (Level of Evidence: C) (84,85,89,90)
. Permanent pacemaker implantation is indicated for third-degree
and advanced second-degree AV block at any anatomic level
associated with neuromuscular diseases with AV block, such as
myotonic muscular dystrophy, Kearns-Sayre syndrome, Erb dystro-
phy (limb-girdle muscular dystrophy), and peroneal muscular atro-
phy, with or without symptoms. (Level of Evidence: B) (91–97)
. Permanent pacemaker implantation is indicated for second-
degree AV block with associated symptomatic bradycardia re-
gardless of type or site of block. (Level of Evidence: B) (74)
. Permanent pacemaker implantation is indicated for asymptom-
atic persistent third-degree AV block at any anatomic site with
average awake ventricular rates of 40 bpm or faster if cardio-
megaly or LV dysfunction is present or if the site of block is below
the AV node. (Level of Evidence: B) (76,78)
0. Permanent pacemaker implantation is indicated for second- or
third-degree AV block during exercise in the absence of myo-
cardial ischemia. (Level of Evidence: C) (81,82)
LASS IIa
. Permanent pacemaker implantation is reasonable for persistent
third-degree AV block with an escape rate greater than 40 bpm
in asymptomatic adult patients without cardiomegaly. (Level of
Evidence: C) (59,63,64,76,82,85)
. Permanent pacemaker implantation is reasonable for asymptom-
atic second-degree AV block at intra- or infra-His levels found at
electrophysiological study. (Level of Evidence: B) (74,76,78) v. Permanent pacemaker implantation is reasonable for first- or
second-degree AV block with symptoms similar to those of
pacemaker syndrome or hemodynamic compromise. (Level of
Evidence: B) (70,71)
. Permanent pacemaker implantation is reasonable for asymptom-
atic type II second-degree AV block with a narrow QRS. When
type II second-degree AV block occurs with a wide QRS, includ-
ing isolated right bundle-branch block, pacing becomes a Class I
recommendation. (See Section 2.1.3, “Chronic Bifascicular
Block.”) (Level of Evidence: B) (70,76,80,85)
LASS IIb
. Permanent pacemaker implantation may be considered for neu-
romuscular diseases such as myotonic muscular dystrophy, Erb
dystrophy (limb-girdle muscular dystrophy), and peroneal muscu-
lar atrophy with any degree of AV block (including first-degree AV
block), with or without symptoms, because there may be unpre-
dictable progression of AV conduction disease. (Level of Evi-
dence: B) (91–97)
. Permanent pacemaker implantation may be considered for AV
block in the setting of drug use and/or drug toxicity when the
block is expected to recur even after the drug is withdrawn.
(Level of Evidence: B) (98,99)
LASS III
. Permanent pacemaker implantation is not indicated for asymp-
tomatic first-degree AV block. (Level of Evidence: B) (69) (See
Section 2.1.3, “Chronic Bifascicular Block.”)
. Permanent pacemaker implantation is not indicated for asymp-
tomatic type I second-degree AV block at the supra-His (AV
node) level or that which is not known to be intra- or infra-Hisian.
(Level of Evidence: C) (74)
. Permanent pacemaker implantation is not indicated for AV block
that is expected to resolve and is unlikely to recur (100) (e.g.,
drug toxicity, Lyme disease, or transient increases in vagal tone
or during hypoxia in sleep apnea syndrome in the absence of
symptoms). (Level of Evidence: B) (99,100)
.1.3. Chronic Bifascicular Block
ifascicular block refers to ECG evidence of impaired conduc-
ion below the AV node in the right and left bundles.
lternating bundle-branch block (also known as bilateral
undle-branch block) refers to situations in which clear ECG
vidence for block in all 3 fascicles is manifested on successive
CGs. Examples are right bundle-branch block and left
undle-branch block on successive ECGs or right bundle-
ranch block with associated left anterior fascicular block on 1
CG and associated left posterior fascicular block on another
CG. Patients with first-degree AV block in association with
ifascicular block and symptomatic, advanced AV block have a
igh mortality rate and a substantial incidence of sudden death
64,101). Although third-degree AV block is most often
receded by bifascicular block, there is evidence that the rate of
rogression of bifascicular block to third-degree AV block is
low (102). Furthermore, no single clinical or laboratory
ariable, including bifascicular block, identifies patients at high
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undle-branch block (103).
Syncope is common in patients with bifascicular block.
lthough syncope may be recurrent, it is not associated with an
ncreased incidence of sudden death (73,102–112). Even
hough pacing relieves the neurological symptoms, it does not
educe the occurrence of sudden death (108). An electrophys-
ological study may be helpful to evaluate and direct the
reatment of inducible ventricular arrhythmias (113,114) that
re common in patients with bifascicular block. There is
onvincing evidence that in the presence of permanent or
ransient third-degree AV block, syncope is associated with an
ncreased incidence of sudden death regardless of the results of
he electrophysiological study (64,114,115). Finally, if the
ause of syncope in the presence of bifascicular block cannot be
etermined with certainty, or if treatments used (such as drugs)
ay exacerbate AV block, prophylactic permanent pacing is
ndicated, especially if syncope may have been due to transient
hird-degree AV block (102–112,116).
Of the many laboratory variables, the PR and HV intervals
ave been identified as possible predictors of third-degree AV
lock and sudden death. Although PR-interval prolongation is
ommon in patients with bifascicular block, the delay is often
t the level of the AV node. There is no correlation between
he PR and HV intervals or between the length of the PR
nterval, progression to third-degree AV block, and sudden
eath (107,109,116). Although most patients with chronic or
ntermittent third-degree AV block demonstrate prolongation
f the HV interval during anterograde conduction, some
nvestigators (110,111) have suggested that asymptomatic pa-
ients with bifascicular block and a prolonged HV interval
hould be considered for permanent pacing, especially if the
V interval is greater than or equal to 100 milliseconds (109).
lthough the prevalence of HV-interval prolongation is high,
he incidence of progression to third-degree AV block is low.
ecause HV prolongation accompanies advanced cardiac
isease and is associated with increased mortality, death is
ften not sudden or due to AV block but rather is due to the
nderlying heart disease itself and nonarrhythmic cardiac
auses (102,103,108,109,111,114–117).
Atrial pacing at electrophysiological study in asymptomatic
atients as a means of identifying patients at increased risk of
uture high- or third-degree AV block is controversial. The
robability of inducing block distal to the AV node (i.e., intra-
r infra-His) with rapid atrial pacing is low (102,110,111,118–
21). Failure to induce distal block cannot be taken as evidence
hat the patient will not develop third-degree AV block in the
uture. However, if atrial pacing induces nonphysiological
nfra-His block, some consider this an indication for pacing
118). Nevertheless, infra-His block that occurs during either
apid atrial pacing or programmed stimulation at short cou-
ling intervals may be physiological and not pathological,
imply reflecting disparity between refractoriness of the AV
ode and His-Purkinje systems (122). aecommendations for Permanent Pacing in Chronic
ifascicular Block
LASS I
. Permanent pacemaker implantation is indicated for advanced
second-degree AV block or intermittent third-degree AV block.
(Level of Evidence: B) (63–68,101)
. Permanent pacemaker implantation is indicated for type II
second-degree AV block. (Level of Evidence: B) (73,75,79,123)
. Permanent pacemaker implantation is indicated for alternating
bundle-branch block. (Level of Evidence: C) (124)
LASS IIa
. Permanent pacemaker implantation is reasonable for syncope
not demonstrated to be due to AV block when other likely causes
have been excluded, specifically ventricular tachycardia (VT).
(Level of Evidence: B) (102–111,113–119,123,125)
. Permanent pacemaker implantation is reasonable for an inciden-
tal finding at electrophysiological study of a markedly prolonged
HV interval (greater than or equal to 100 milliseconds) in
asymptomatic patients. (Level of Evidence: B) (109)
. Permanent pacemaker implantation is reasonable for an inciden-
tal finding at electrophysiological study of pacing-induced infra-
His block that is not physiological. (Level of Evidence: B) (118)
LASS IIb
. Permanent pacemaker implantation may be considered in the
setting of neuromuscular diseases such as myotonic muscular
dystrophy, Erb dystrophy (limb-girdle muscular dystrophy), and
peroneal muscular atrophy with bifascicular block or any fascicular
block, with or without symptoms. (Level of Evidence: C) (91–97)
LASS III
. Permanent pacemaker implantation is not indicated for fascicu-
lar block without AV block or symptoms. (Level of Evidence: B)
(103,107,109,116)
. Permanent pacemaker implantation is not indicated for fascicu-
lar block with first-degree AV block without symptoms. (Level of
Evidence: B) (103,107,109,116)
.1.4. Pacing for Atrioventricular Block Associated
ith Acute Myocardial Infarction
ndications for permanent pacing after myocardial infarc-
ion (MI) in patients experiencing AV block are related in
arge measure to the presence of intraventricular conduction
efects. The criteria for patients with MI and AV block do
ot necessarily depend on the presence of symptoms.
urthermore, the requirement for temporary pacing in AMI
oes not by itself constitute an indication for permanent
acing (see “ACC/AHA Guidelines for the Management of
atients With ST-Elevation Myocardial Infarction” [6]).
he long-term prognosis for survivors of AMI who have
ad AV block is related primarily to the extent of myocar-
ial injury and the character of intraventricular conduction
isturbances rather than the AV block itself (66,126–130).
atients with AMI who have intraventricular conduction
efects, with the exception of isolated left anterior fascicular
lock, have an unfavorable short- and long-term prognosis
nd an increased risk of sudden death (66,79,126,128,130).
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pment of high-grade AV block, although the incidence of
uch block is higher in postinfarction patients with abnor-
al intraventricular conduction (126,131,132).
When AV or intraventricular conduction block compli-
ates AMI, the type of conduction disturbance, location of
nfarction, and relation of electrical disturbance to infarction
ust be considered if permanent pacing is contemplated.
ven with data available, the decision is not always straight-
orward, because the reported incidence and significance of
arious conduction disturbances vary widely (133). Despite
he use of thrombolytic therapy and primary angioplasty,
hich have decreased the incidence of AV block in AMI,
ortality remains high if AV block occurs (130,134–137).
Although more severe disturbances in conduction have
enerally been associated with greater arrhythmic and non-
rrhythmic mortality (126–129,131,133), the impact of
reexisting bundle-branch block on mortality after AMI is
ontroversial (112,133). A particularly ominous prognosis is
ssociated with left bundle-branch block combined with
dvanced second- or third-degree AV block and with right
undle-branch block combined with left anterior or left
osterior fascicular block (105,112,127,129). Regardless of
hether the infarction is anterior or inferior, the develop-
ent of an intraventricular conduction delay reflects exten-
ive myocardial damage rather than an electrical problem in
solation (129). Although AV block that occurs during
nferior MI can be associated with a favorable long-term
linical outcome, in-hospital survival is impaired irrespective
f temporary or permanent pacing in this situation
134,135,138,139). Pacemakers generally should not be
mplanted with inferior MI if the peri-infarctional AV block
s expected to resolve or is not expected to negatively affect
ong-term prognosis (136). When symptomatic high-degree
r third-degree heart block complicates inferior MI, even
hen the QRS is narrow, permanent pacing may be
onsidered if the block does not resolve. For the patient with
ecent MI with a left ventricular ejection fraction (LVEF)
ess than or equal to 35% and an indication for permanent
acing, consideration may be given to use of an ICD, a
RT device that provides pacing but not defibrillation
apability (CRT-P), or a CRT device that incorporates both
acing and defibrillation capabilities (CRT-D) when im-
rovement in LVEF is not anticipated.
ecommendations for Permanent Pacing After the
cute Phase of Myocardial Infarction*
LASS I
. Permanent ventricular pacing is indicated for persistent second-
degree AV block in the His-Purkinje system with alternating
bundle-branch block or third-degree AV block within or below the
His-Purkinje system after ST-segment elevation MI. (Level of
Evidence: B) (79,126–129,131)p
These recommendations are consistent with the “ACC/AHA Guidelines for the
anagement of Patients With ST-Elevation Myocardial Infarction” (6).. Permanent ventricular pacing is indicated for transient advanced
second- or third-degree infranodal AV block and associated
bundle-branch block. If the site of block is uncertain, an electro-
physiological study may be necessary. (Level of Evidence: B)
(126,127)
. Permanent ventricular pacing is indicated for persistent and
symptomatic second- or third-degree AV block. (Level of Evi-
dence: C)
LASS IIb
. Permanent ventricular pacing may be considered for persistent
second- or third-degree AV block at the AV node level, even in the
absence of symptoms. (Level of Evidence: B) (58)
LASS III
. Permanent ventricular pacing is not indicated for transient AV
block in the absence of intraventricular conduction defects.
(Level of Evidence: B) (126)
. Permanent ventricular pacing is not indicated for transient AV
block in the presence of isolated left anterior fascicular block.
(Level of Evidence: B) (128)
. Permanent ventricular pacing is not indicated for new bundle-
branch block or fascicular block in the absence of AV block.
(Level of Evidence: B) (66, 126)
. Permanent ventricular pacing is not indicated for persistent
asymptomatic first-degree AV block in the presence of bundle-
branch or fascicular block. (Level of Evidence: B) (126)
.1.5. Hypersensitive Carotid Sinus Syndrome and
eurocardiogenic Syncope
he hypersensitive carotid sinus syndrome is defined as
yncope or presyncope resulting from an extreme reflex
esponse to carotid sinus stimulation. There are 2 compo-
ents of the reflex:
Cardioinhibitory, which results from increased parasym-
pathetic tone and is manifested by slowing of the sinus
rate or prolongation of the PR interval and advanced
AV block, alone or in combination.
Vasodepressor, which is secondary to a reduction in
sympathetic activity that results in loss of vascular
tone and hypotension. This effect is independent of
heart rate changes.
Before concluding that permanent pacing is clinically
ndicated, the physician should determine the relative con-
ribution of the 2 components of carotid sinus stimulation to
he individual patient’s symptom complex. Hyperactive
esponse to carotid sinus stimulation is defined as asystole
ue to either sinus arrest or AV block of more than 3
econds, a substantial symptomatic decrease in systolic
lood pressure, or both (140). Pauses up to 3 seconds during
arotid sinus massage are considered to be within normal
imits. Such heart rate and hemodynamic responses may
ccur in normal subjects and patients with coronary artery
isease. The cause-and-effect relation between the hyper-
ensitive carotid sinus and the patient’s symptoms must be
rawn with great caution (141). Spontaneous syncope re-
roduced by carotid sinus stimulation should alert the
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ure on the carotid sinus in elderly patients may result in
arked changes in heart rate and blood pressure yet may not
e of clinical significance. Permanent pacing for patients
ith an excessive cardioinhibitory response to carotid stim-
lation is effective in relieving symptoms (142,143). Because
0% to 20% of patients with this syndrome may have an
mportant vasodepressive component of their reflex re-
ponse, it is desirable that this component be defined before
ne concludes that all symptoms are related to asystole
lone. Among patients whose reflex response includes both
ardioinhibitory and vasodepressive components, attention
o the latter is essential for effective therapy in patients
ndergoing pacing.
Carotid sinus hypersensitivity should be considered in
lderly patients who have had otherwise unexplained falls.
n 1 study, 175 elderly patients who had fallen without loss
f consciousness and who had pauses of more than 3
econds during carotid sinus massage (thus fulfilling the
iagnosis of carotid sinus hypersensitivity) were randomized
o pacing or nonpacing therapy. The paced group had a
ignificantly lower likelihood of subsequent falling episodes
uring follow-up (144).
Neurocardiogenic syncope and neurocardiogenic syn-
romes refer to a variety of clinical scenarios in which
riggering of a neural reflex results in a usually self-limited
pisode of systemic hypotension characterized by both
radycardia and peripheral vasodilation (145,146). Neuro-
ardiogenic syncope accounts for an estimated 10% to 40%
f syncope episodes. Vasovagal syncope is a term used to
enote one of the most common clinical scenarios within
he category of neurocardiogenic syncopal syndromes. Pa-
ients classically have a prodrome of nausea and diaphoresis
often absent in the elderly), and there may be a positive
amily history of the condition. Spells may be considered
ituational (e.g., they may be triggered by pain, anxiety,
tress, specific bodily functions, or crowded conditions).
ypically, no evidence of structural heart disease is present.
ther causes of syncope such as LV outflow obstruction,
radyarrhythmias, and tachyarrhythmias should be ex-
luded. Head-up tilt-table testing may be diagnostic.
The role of permanent pacing in refractory neurocar-
iogenic syncope associated with significant bradycardia
r asystole remains controversial. Approximately 25% of
atients have a predominant vasodepressor reaction with-
ut significant bradycardia. Many patients will have a
ixed vasodepressive/cardioinhibitory cause of their
ymptoms. It has been estimated that approximately one
hird of patients will have substantial bradycardia or
systole during head-up tilt testing or during observed
nd recorded spontaneous episodes of syncope. Outcomes
rom clinical trials have not been consistent. Results from
randomized controlled trial (147) in highly symptom-
tic patients with bradycardia demonstrated that perma-
ent pacing increased the time to the first syncopal event.
nother study demonstrated that DDD (a dual-chamberacemaker that senses/paces in the atrium/ventricle and
s inhibited/triggered by intrinsic rhythm) pacing with a
udden bradycardia response function was more effective
han beta blockade in preventing recurrent syncope in
ighly symptomatic patients with vasovagal syncope and
elative bradycardia during tilt-table testing (148). In
PS (Vasovagal Pacemaker Study) (149), the actuarial
ate of recurrent syncope at 1 year was 18.5% for
acemaker patients and 59.7% for control patients. How-
ver, in VPS-II (Vasovagal Pacemaker Study II) (150), a
ouble-blind randomized trial, pacing therapy did not
educe the risk of recurrent syncopal events. In VPS-II,
ll patients received a permanent pacemaker and were
andomized to therapy versus no therapy in contrast to
PS, in which patients were randomized to pacemaker
mplantation versus no pacemaker. On the basis of
PS-II and prevailing expert opinion (145), pacing
herapy is not considered first-line therapy for most
atients with neurocardiogenic syncope. However, pacing
herapy does have a role for some patients, specifically
hose with little or no prodrome before their syncopal
vent, those with profound bradycardia or asystole during
documented event, and those in whom other therapies
ave failed. Dual-chamber pacing, carefully prescribed on
he basis of tilt-table test results with consideration of
lternative medical therapy, may be effective in reducing
ymptoms if the patient has a significant cardioinhibitory
omponent to the cause of their symptoms. Although
pontaneous or provoked prolonged pauses are a concern
n this population, the prognosis without pacing is
xcellent (151).
The evaluation of patients with syncope of undetermined
rigin should take into account clinical status and should
ot overlook other, more serious causes of syncope, such as
entricular tachyarrhythmias.
ecommendations for Permanent Pacing in
ypersensitive Carotid Sinus Syndrome and
eurocardiogenic Syncope
LASS I
. Permanent pacing is indicated for recurrent syncope caused by
spontaneously occurring carotid sinus stimulation and carotid
sinus pressure that induces ventricular asystole of more than 3
seconds. (Level of Evidence: C) (142,152)
LASS IIa
. Permanent pacing is reasonable for syncope without clear,
provocative events and with a hypersensitive cardioinhibitory
response of 3 seconds or longer. (Level of Evidence: C) (142)
LASS IIb
. Permanent pacing may be considered for significantly symptom-
atic neurocardiogenic syncope associated with bradycardia doc-
umented spontaneously or at the time of tilt-table testing. (Level
of Evidence: B) (147,148,150,153)
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. Permanent pacing is not indicated for a hypersensitive
cardioinhibitory response to carotid sinus stimulation without
symptoms or with vague symptoms. (Level of Evidence: C)
. Permanent pacing is not indicated for situational vasovagal
syncope in which avoidance behavior is effective and preferred.
(Level of Evidence: C)
.2. Pacing for Specific Conditions
he following sections on cardiac transplantation, neuro-
uscular diseases, sleep apnea syndromes, and infiltrative
nd inflammatory diseases are provided to recognize devel-
pments in these specific areas and new information that
as been obtained since publication of prior guidelines.
ome of the information has been addressed in prior
ections but herein is explored in more detail.
.2.1. Cardiac Transplantation
he incidence of bradyarrhythmias after cardiac transplan-
ation varies from 8% to 23% (154–156). Most brady-
rrhythmias are associated with SND and are more ominous
fter transplantation, when the basal heart rate should be
igh. Significant bradyarrhythmias and asystole have been
ssociated with reported cases of sudden death (157).
ttempts to treat the bradycardia temporarily with measures
uch as theophylline (158) may minimize the need for
acing. To accelerate rehabilitation, some transplant pro-
rams recommend more liberal use of cardiac pacing for
ersistent postoperative bradycardia, although approxi-
ately 50% of patients show resolution of the bradyarrhyth-
ia within 6 to 12 months (159–161). The role of prophy-
actic pacemaker implantation is unknown for patients who
evelop bradycardia and syncope in the setting of rejection,
hich may be associated with localized inflammation of the
onduction system. Posttransplant patients who have irre-
ersible SND or AV block with previously stated Class I
ndications should have permanent pacemaker implanta-
ion, as the benefits of the atrial rate contribution to cardiac
utput and to chronotropic competence may optimize the
atient’s functional status. When recurrent syncope devel-
ps late after transplantation, pacemaker implantation may
e considered despite repeated negative evaluations, as
udden episodes of bradycardia are often eventually docu-
ented and may be a sign of transplant vasculopathy.
ecommendations for Pacing After Cardiac
ransplantation
LASS I
. Permanent pacing is indicated for persistent inappropriate or
symptomatic bradycardia not expected to resolve and for other
Class I indications for permanent pacing. (Level of Evidence: C)
LASS IIb
. Permanent pacing may be considered when relative bradycardia
is prolonged or recurrent, which limits rehabilitation or discharge
after postoperative recovery from cardiac transplantation. (Level
of Evidence: C) c. Permanent pacing may be considered for syncope after cardiac
transplantation even when bradyarrhythmia has not been docu-
mented. (Level of Evidence: C)
.2.2. Neuromuscular Diseases
onduction system disease with progression to complete
V block is a well-recognized complication of several
euromuscular disorders, including myotonic dystrophy and
mery-Dreifuss muscular dystrophy. Supraventricular and
entricular arrhythmias may also be observed. Implantation
f a permanent pacemaker has been found useful even in
symptomatic patients with an abnormal resting ECG or
ith HV interval prolongation during electrophysiological
tudy (162). Indications for pacing have been addressed in
revious sections on AV block.
.2.3. Sleep Apnea Syndrome
variety of heart rhythm disturbances may occur in
bstructive sleep apnea. Most commonly, these include
inus bradycardia or pauses during hypopneic episodes.
trial tachyarrhythmias may also be observed, particularly
uring the arousal phase that follows the offset of apnea. A
mall retrospective trial of atrial overdrive pacing in the
reatment of sleep apnea demonstrated a decrease “in
pisodes of central or obstructive sleep apnea without
educing the total sleep time” (163). Subsequent random-
zed clinical trials have not validated a role for atrial
verdrive pacing in obstructive sleep apnea (164,165). Fur-
hermore, nasal continuous positive airway pressure therapy
as been shown to be highly effective for obstructive sleep
pnea, whereas atrial overdrive pacing has not (166,167).
hether cardiac pacing is indicated among patients with
bstructive sleep apnea and persistent episodes of bradycar-
ia despite nasal continuous positive airway pressure has not
een established.
Central sleep apnea and Cheyne-Stokes sleep-disordered
reathing frequently accompany systolic heart failure and
re associated with increased mortality (168). CRT has been
hown to reduce central sleep apnea and increase sleep
uality in heart failure patients with ventricular conduction
elay (169). This improvement in sleep-disordered breath-
ng may be due to the beneficial effects of CRT on LV
unction and central hemodynamics, which favorably mod-
fies the neuroendocrine reflex cascade in central sleep apnea.
.2.4. Cardiac Sarcoidosis
ardiac sarcoidosis usually affects individuals aged 20 to 40
ears and is associated with noncaseating granulomas with
n affinity for involvement of the AV conduction system,
hich results in various degrees of AV conduction block.
yocardial involvement occurs in 25% of patients with
arcoidosis, as many as 30% of whom develop complete
eart block. Owing to the possibility of disease progression,
acemaker implantation is recommended even if high-grade or
omplete AV conduction block reverses transiently (170–172).
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entricular arrhythmias with sustained monomorphic VT
ue to myocardial involvement (173–175). Sudden cardiac
rrest may be the initial manifestation of the condition, and
atients may have few if any manifestations of dysfunction
n organ systems other than the heart (173,174). Although
here are no large randomized trials or prospective registries
f patients with cardiac sarcoidosis, the available literature
ndicates that cardiac sarcoidosis with heart block, ventric-
lar arrhythmias, or LV dysfunction is associated with a
oor prognosis. Therapy with steroids or other immuno-
uppressant agents may prevent progression of the cardiac
nvolvement. Bradyarrhythmias warrant pacemaker therapy,
ut they are not effective in preventing or treating life-
hreatening ventricular arrhythmias. Sufficient clinical data
re not available to stratify risk of SCD among patients with
ardiac sarcoidosis. Accordingly, clinicians must use the
vailable literature along with their own clinical experience
nd judgment in making management decisions regarding
CD therapy. Consideration should be given to symptoms
uch as syncope, heart failure status, LV function, and
pontaneous or induced ventricular arrhythmias at electro-
hysiological study to make individualized decisions regard-
ng use of the ICD for primary prevention of SCD.
.3. Prevention and Termination of Arrhythmias
y Pacing
nder certain circumstances, an implanted pacemaker may
e useful to treat or prevent recurrent ventricular and SVTs
176–185). Re-entrant rhythms including atrial flutter,
aroxysmal re-entrant SVT, and VT may be terminated by
variety of pacing techniques, including programmed stim-
lation and short bursts of rapid pacing (186,187). Al-
hough rarely used in contemporary practice after tachycar-
ia detection, these antitachyarrhythmia devices may
utomatically activate a pacing sequence or respond to an
xternal instruction (e.g., application of a magnet).
Prevention of arrhythmias by pacing has been demon-
trated in certain situations. In some patients with long-QT
yndrome, recurrent pause-dependent VT may be prevented
y continuous pacing (188). A combination of pacing and
eta blockade has been reported to shorten the QT interval
nd help prevent SCD (189,190). ICD therapy in combi-
ation with overdrive suppression pacing should be consid-
red in high-risk patients.
Although this technique is rarely used today given the
vailability of catheter ablation and antiarrhythmic drugs,
trial synchronous ventricular pacing may prevent recur-
ences of reentrant SVT (191). Furthermore, although
entricular ectopic activity may be suppressed by pacing in
ther conditions, serious or symptomatic arrhythmias are
arely prevented (192).
Potential recipients of antitachyarrhythmia devices that
nterrupt arrhythmias should undergo extensive testing be-
ore implantation to ensure that the devices safely and
eliably terminate the tachyarrhythmias without accelerating ihe tachycardia or causing proarrhythmia. Patients for
hom an antitachycardia pacemaker has been prescribed
ave usually been unresponsive to antiarrhythmic drugs or
ere receiving agents that could not control their cardiac
rrhythmias. When permanent antitachycardia pacemakers
etect and interrupt SVT, all pacing should be done in the
trium because of the risk of ventricular pacing–induced
roarrhythmia (176,193). Permanent antitachycardia pacing
ATP) as monotherapy for VT is not appropriate given that
TP algorithms are available in tiered-therapy ICDs that
ave the capability for cardioversion and defibrillation in
ases when ATP is ineffective or causes acceleration of the
reated tachycardia.
ecommendations for Permanent Pacemakers That
utomatically Detect and Pace to Terminate
achycardias
LASS IIa
. Permanent pacing is reasonable for symptomatic recurrent SVT
that is reproducibly terminated by pacing when catheter ablation
and/or drugs fail to control the arrhythmia or produce intolerable
side effects. (Level of Evidence: C) (177–179,181,182)
LASS III
. Permanent pacing is not indicated in the presence of an acces-
sory pathway that has the capacity for rapid anterograde con-
duction. (Level of Evidence: C)
.3.1. Pacing to Prevent Atrial Arrhythmias
any patients with indications for pacemaker or ICD
herapy have atrial tachyarrhythmias that are recognized
efore or after device implantation (194). Re-entrant atrial
achyarrhythmias are susceptible to termination with ATP.
dditionally, some atrial tachyarrhythmias that are due to
ocal automaticity may respond to overdrive suppression.
ccordingly, some dual-chamber pacemakers and ICDs
ncorporate suites of atrial therapies that are automatically
pplied upon detection of atrial tachyarrhythmias.
The efficacy of atrial ATP is difficult to measure, primar-
ly because atrial tachyarrhythmias tend to initiate and
erminate spontaneously with a very high frequency. With
evice-classified efficacy criteria, approximately 30% to 60%
f atrial tachyarrhythmias may be terminated with atrial
TP in patients who receive pacemakers for symptomatic
radycardia (195–197). Although this has been associated
ith a reduction in atrial tachyarrhythmia burden over time
n selected patients (195,196), the success of this approach
as not been duplicated reliably in randomized clinical trials
197). Similar efficacy has been demonstrated in ICD
atients (194,198,199) without compromising detection of
T, ventricular fibrillation (VF), or ventricular proarrhyth-
ia (200). In either situation, automatic atrial therapies
hould not be activated until the atrial lead is chronically
table, because dislodgement into the ventricle could result
n the induction of VT/VF.
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he use of cardiac pacing with beta blockade for prevention
f symptoms in patients with the congenital long-QT
yndrome is supported by observational studies (189,201,202).
he primary benefit of pacemaker therapy may be in
atients with pause-dependent initiation of ventricular
achyarrhythmias (203) or those with sinus bradycardia or
dvanced AV block in association with the congenital
ong-QT syndrome (204,205), which is most commonly
ssociated with a sodium channelopathy. Benson et al. (206)
iscuss sinus bradycardia due to a (sodium) channelopathy.
lthough pacemaker implantation may reduce the inci-
ence of symptoms in these patients, the long-term survival
enefit remains to be determined (189,201,204).
ecommendations for Pacing to Prevent Tachycardia
LASS I
. Permanent pacing is indicated for sustained pause-dependent
VT, with or without QT prolongation. (Level of Evidence: C)
(188,189)
LASS IIa
. Permanent pacing is reasonable for high-risk patients with con-
genital long-QT syndrome. (Level of Evidence: C) (188,189)
LASS IIb
. Permanent pacing may be considered for prevention of symptom-
atic, drug-refractory, recurrent AF in patients with coexisting
SND. (Level of Evidence: B) (31,184,207)
LASS III
. Permanent pacing is not indicated for frequent or complex
ventricular ectopic activity without sustained VT in the absence
of the long-QT syndrome. (Level of Evidence: C) (192)
. Permanent pacing is not indicated for torsade de pointes VT due
to reversible causes. (Level of Evidence: A) (190,203)
.3.3. Atrial Fibrillation (Dual-Site, Dual-Chamber,
lternative Pacing Sites)
n some patients with bradycardia-dependent AF, atrial
acing may be effective in reducing the frequency of
ecurrences (208). In MOST, 2010 patients with SND were
andomized between DDDR and VVIR pacing. After a
ean follow-up of 33 months, there was a 21% lower risk of
F (p0.008) in the DDDR group than in the VVIR
roup (209). Other trials are under way to assess the efficacy
f atrial overdrive pacing algorithms and algorithms that
eact to premature atrial complexes in preventing AF, but
ata to date are sparse and inconsistent (197,210). Dual-site
ight atrial pacing or alternate single-site atrial pacing from
nconventional sites (e.g., atrial septum or Bachmann’s
undle) may offer additional benefits to single-site right
trial pacing from the appendage in patients with symptom-
tic drug-refractory AF and concomitant bradyarrhythmias;
owever, results from these studies are also contradictory
nd inconclusive (211,212). Additionally, analysis of the
fficacy of pacing prevention algorithms and alternative lacing sites is limited by short-term follow-up (213). In
atients with sick sinus syndrome and intra-atrial block (P
ave more than 180 milliseconds), biatrial pacing may lower
ecurrence rates of AF (214).
ecommendation for Pacing to Prevent Atrial
ibrillation
LASS III
. Permanent pacing is not indicated for the prevention of AF in
patients without any other indication for pacemaker implanta-
tion. (Level of Evidence: B) (215)
.4. Pacing for Hemodynamic Indications
lthough most commonly used to treat or prevent abnormal
hythms, pacing can alter the activation sequence in the
aced chambers, influencing regional contractility and cen-
ral hemodynamics. These changes are frequently insignif-
cant clinically but can be beneficial or harmful in some
onditions. Pacing to decrease symptoms for patients with
bstructive hypertrophic cardiomyopathy (HCM) is dis-
ussed separately in Section 2.4.2, “Obstructive Hypertro-
hic Cardiomyopathy.”
.4.1. Cardiac Resynchronization Therapy
rogression of LV dysfunction to heart failure with low
VEF is frequently accompanied by impaired electro-
echanical coupling, which may further diminish effective
entricular systolic function. The most common disruptions
re prolonged AV conduction (first-degree AV block) and
rolonged ventricular conduction, most commonly left
undle-branch block. Prolonged ventricular conduction
auses regional mechanical delay within the LV that can
esult in reduced ventricular systolic function with increased
etabolic costs, functional mitral regurgitation, and adverse
emodeling with increased ventricular dilatation. Prolonga-
ion of the QRS interval occurs in approximately one third
f patients with advanced heart failure (216) and has been
ssociated with ventricular electromechanical delay (“dys-
ynchrony”) as identified by multiple sophisticated echocar-
iographic indices. QRS duration and dyssynchrony have
oth been identified as predictors of worsening heart failure,
CD, and total mortality (217).
Modification of ventricular electromechanical delay with
ultisite ventricular pacing (“biventricular pacing and
RT”) can improve ventricular systolic function with re-
uced metabolic costs, ameliorate functional mitral regur-
itation, and, in some patients, induce favorable remodeling
ith reduction of cardiac chamber dimensions (218,219).
unctional improvement has been demonstrated for exercise
apacity with peak oxygen consumption in the range of 1 to
milliliters per kilogram per minute and a 50- to 70-meter
ncrease in 6-minute walk distance, with a 10-point or
reater reduction of heart failure symptoms on the 105-
oint Minnesota scale (220–222).
Meta-analyses of initial clinical experiences and thenarger subsequent trials confirmed an approximately 30%
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May 27, 2008:e1–62 ACC/AHA/HRS Guidelines for Device-Based Therapyecrease in hospitalizations and, more recently, a mortality
enefit of 24% to 36% (223). Resynchronization therapy in
he COMPANION (Comparison of Medical Therapy,
acing, and Defibrillation in Heart Failure) trial directly
ompared pacing with (CRT-D) and without (CRT-P)
efibrillation capability with optimal medical therapy (224).
RT-D reduced mortality by 36% compared with medical
herapy, but there was insufficient evidence to conclude that
RT-P was inferior to CRT-D. The CARE-HF (Cardiac
esynchronization in Heart Failure) trial limited subjects to
QRS greater than 150 milliseconds (89% of patients) or
RS 120 to 150 milliseconds with echocardiographic evi-
ence of dyssynchrony (11% of patients). It was the first
tudy to show a significant (36%) reduction in death for
esynchronization therapy unaccompanied by backup defi-
rillation compared with optimal medical therapy (225).
In 1 clinical trial, approximately two thirds of patients
ho were randomized to CRT showed a clinical response
ompared with approximately one third of patients in the
ontrol arm (222). It remains difficult to predict and explain
he disparity of clinical response. The prevalence of dyssyn-
hrony has been documented in more than 40% of patients
ith dilated cardiomyopathy (DCM) and QRS greater than
20 milliseconds and is higher among patients with QRS
reater than 150 milliseconds. The aggregate clinical expe-
ience has consistently demonstrated that a significant
linical response to CRT is greatest among patients with
RS duration greater than 150 milliseconds, but intraven-
ricular mechanical delay, as identified by several echocar-
iographic techniques, may exist even when the QRS
uration is less than 120 milliseconds. No large trial has yet
emonstrated clinical benefit among patients without QRS
rolongation, even when they have been selected for echo-
ardiographic measures of dyssynchrony (226). The ob-
erved heterogeneity of response also may result from factors
uch as suboptimal lead placement and inexcitable areas of
brosis in the paced segments. These factors may contribute
o the finding of worsening clinical function in some
atients after addition of LV stimulation.
Clinical trials of resynchronization almost exclusively
ncluded patients in sinus rhythm with a left bundle-branch
attern of prolonged ventricular conduction. Limited pro-
pective experience among patients with permanent AF
uggests that benefit may result from biventricular pacing
hen the QRS is prolonged, although it may be most
vident in those patients in whom AV nodal ablation has
een performed, such that right ventricular (RV) pacing is
bligate (227,228).
There is not sufficient evidence yet to provide specific
ecommendations for patients with right bundle-branch
lock, other conduction abnormalities, or QRS prolonga-
ion due to frequent RVA pacing. Furthermore, there are
nsufficient data to make specific recommendations regard-
ng CRT in patients with congenital heart disease (229). In
ddition, patients receiving prophylactic pacemaker-
efibrillators often evolve silently to dominant ventricular iacing, due both to intrinsic chronotropic incompetence and to
he aggressive uptitration of beta-adrenergic blocking agents.
The major experience with resynchronization derives
rom patients with New York Heart Association (NYHA)
lass III symptoms of heart failure and LVEF less than or
qual to 35%. Heart failure symptom status should be
ssessed after medical therapy has been optimized for at
east 3 months, including titration of diuretic therapy to
aintain normal volume status. Patients with Class IV
ymptoms of heart failure have accounted for only 10% of all
atients in clinical trials of resynchronization therapy. These
atients were highly selected, ambulatory outpatients who
ere taking oral medications and had no history of recent
ospitalization (230). Although a benefit has occasionally
een described in patients with more severe acute decom-
ensation that required brief intravenous inotropic therapy
o aid diuresis, resynchronization is not generally used as a
rescue therapy” for such patients. Patients with dependence
n intravenous inotropic therapy, refractory fluid retention,
r progressive renal dysfunction represent the highest-risk
opulation for complications of any procedure and for early
ortality after discharge, and they are also unlikely to
eceive a meaningful mortality benefit from concomitant
efibrillator therapy.
Those patients with NYHA Class IV symptoms of heart
ailure who derive functional benefit from resynchronization
herapy may return to Class III status, in which prevention
f sudden death becomes a relevant goal. Even among the
elected Class IV patients identified within the COMPAN-
ON trial (224), there was no difference in 2-year survival
etween the CRT patients with and without backup defi-
rillation, although more of the deaths in the CRT-P group
ere classified as sudden deaths (230).
Indications for resynchronization therapy have not been
stablished for patients who have marked dyssynchrony and
lass I to II symptoms of heart failure in whom device
lacement is indicated for other reasons. Ongoing studies
re examining the hypothesis that early use of CRT, before
he development of Class III symptoms that limit daily
ctivity, may prevent or reverse remodeling caused by
rolonged ventricular conduction. However, it is not known
hen or whether CRT should be considered at the time of
nitial ICD implantation for patients without intrinsic QRS
rolongation even if frequent ventricular pacing is antici-
ated. Finally, a randomized prospective trial by Beshai et
l. did not confirm the utility of dyssynchrony evaluation by
chocardiography to guide CRT implantation, especially
hen the QRS is not prolonged (226).
Optimal outcomes with CRT require effective placement
f ventricular leads, ongoing heart failure management with
eurohormonal antagonists and diuretic therapy, and, in
ome cases, later reprogramming of device intervals. The
ivotal trials demonstrating the efficacy of CRT took place
n centers that provided this expertise both at implantation
nd during long-term follow-up. The effectiveness of CRT
n improving clinical function and survival would be antic-
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hese specialized care settings.
ecommendations for Cardiac Resynchronization
herapy in Patients With Severe Systolic Heart Failure
LASS I
. For patients who have LVEF less than or equal to 35%, a QRS
duration greater than or equal to 0.12 seconds, and sinus
rhythm, CRT with or without an ICD is indicated for the treatment
of NYHA functional Class III or ambulatory Class IV heart failure
symptoms with optimal recommended medical therapy. (Level of
Evidence: A) (222,224,225,231)
LASS IIa
. For patients who have LVEF less than or equal to 35%, a QRS
duration greater than or equal to 0.12 seconds, and AF, CRT with
or without an ICD is reasonable for the treatment of NYHA
functional Class III or ambulatory Class IV heart failure symp-
toms on optimal recommended medical therapy. (Level of Evi-
dence: B) (220,231)
. For patients with LVEF less than or equal to 35% with NYHA
functional Class III or ambulatory Class IV symptoms who are
receiving optimal recommended medical therapy and who have
frequent dependence on ventricular pacing, CRT is reasonable.
(Level of Evidence: C) (231)
LASS IIb
. For patients with LVEF less than or equal to 35% with NYHA
functional Class I or II symptoms who are receiving optimal
recommended medical therapy and who are undergoing implan-
tation of a permanent pacemaker and/or ICD with anticipated
frequent ventricular pacing, CRT may be considered. (Level of
Evidence: C) (231)
LASS III
. CRT is not indicated for asymptomatic patients with reduced
LVEF in the absence of other indications for pacing. (Level of
Evidence: B) (222,224,225,231)
. CRT is not indicated for patients whose functional status and life
expectancy are limited predominantly by chronic noncardiac
conditions. (Level of Evidence: C) (231)
.4.2. Obstructive Hypertrophic Cardiomyopathy
arly nonrandomized studies demonstrated a fall in the LV
utflow gradient with dual-chamber pacing and a short AV
elay and symptomatic improvement in some patients with
bstructive HCM (232–235). One long-term study (236) in
patients supported the long-term benefit of dual-chamber
acing in this group of patients. The outflow gradient was
educed even after cessation of pacing, which suggests that
ome ventricular remodeling had occurred as a consequence
f pacing. Two randomized trials (235,237) demonstrated
ubjective improvement in approximately 50% of study
articipants, but there was no correlation with gradient
eduction, and a significant placebo effect was present. A
hird randomized, double-blinded trial (238) failed to dem-
nstrate any overall improvement in QOL with pacing,
lthough there was a suggestion that elderly patients (more
han 65 years of age) may derive more benefit from pacing. sIn a small group of patients with symptomatic, hyperten-
ive cardiac hypertrophy with cavity obliteration, VDD
acing with premature excitation statistically improved ex-
rcise capacity, cardiac reserve, and clinical symptoms (239).
ual-chamber pacing may improve symptoms and LV
utflow gradient in pediatric patients. However, rapid atrial
ates, rapid AV conduction, and congenital mitral valve abnor-
alities may preclude effective pacing in some patients (240).
There are currently no data available to support the
ontention that pacing alters the clinical course of the
isease or improves survival or long-term QOL in HCM.
herefore, routine implantation of dual-chamber pacemak-
rs should not be advocated in all patients with symptomatic
bstructive HCM. Patients who may benefit the most are
hose with significant gradients (more than 30 mm Hg at
est or more than 50 mm Hg provoked) (235,241–243).
omplete heart block can develop after transcoronary alco-
ol ablation of septal hypertrophy in patients with HCM
nd should be treated with permanent pacing (244).
For the patient with obstructive HCM who is at high risk
or sudden death and who has an indication for pacemaker
mplantation, consideration should be given to completion
f risk stratification of the patient for SCD and to implan-
ation of an ICD for primary prevention of sudden death. A
ingle risk marker of high risk for sudden cardiac arrest may
e sufficient to justify consideration for prophylactic ICD
mplantation in selected patients with HCM (245).
ecommendations for Pacing in Patients With
ypertrophic Cardiomyopathy
LASS I
. Permanent pacing is indicated for SND or AV block in patients
with HCM as described previously (see Section 2.1.1, “Sinus
Node Dysfunction,” and Section 2.1.2, “Acquired Atrioventricu-
lar Block in Adults”). (Level of Evidence: C)
LASS IIb
. Permanent pacing may be considered in medically refractory
symptomatic patients with HCM and significant resting or pro-
voked LV outflow tract obstruction. (Level of Evidence: A) As for
Class I indications, when risk factors for SCD are present,
consider a DDD ICD (see Section 3, “Indications for Implantable
Cardioverter-Defibrillator Therapy”). (233,235,237,238,246,247)
LASS III
. Permanent pacemaker implantation is not indicated for patients
who are asymptomatic or whose symptoms are medically con-
trolled. (Level of Evidence: C)
. Permanent pacemaker implantation is not indicated for symp-
tomatic patients without evidence of LV outflow tract obstruc-
tion. (Level of Evidence: C)
.5. Pacing in Children, Adolescents, and Patients
ith Congenital Heart Disease
he most common indications for permanent pacemaker
mplantation in children, adolescents, and patients with
ongenital heart disease may be classified as 1) symptomatic
inus bradycardia, 2) the bradycardia-tachycardia syn-
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ither congenital or postsurgical. Although the general
ndications for pacemaker implantation in children and
dolescents (defined as less than 19 years of age) (248) are
imilar to those in adults, there are several important
onsiderations in young patients. First, an increasing num-
er of young patients are long-term survivors of complex
urgical procedures for congenital heart defects that result in
alliation rather than correction of circulatory physiology.
he residua of impaired ventricular function and abnormal
hysiology may result in symptoms due to sinus bradycardia
r loss of AV synchrony at heart rates that do not produce
ymptoms in individuals with normal cardiovascular physi-
logy (249,250). Hence, the indications for pacemaker
mplantation in these patients need to be based on the
orrelation of symptoms with relative bradycardia rather
han absolute heart rate criteria. Second, the clinical signif-
cance of bradycardia is age dependent; whereas a heart rate
f 45 bpm may be a normal finding in an adolescent, the
ame rate in a newborn or infant indicates profound
radycardia. Third, significant technical challenges may
omplicate device and transvenous lead implantation in very
mall patients or those with abnormalities of venous or
ntracardiac anatomy. Epicardial pacemaker lead implanta-
ion represents an alternative technique for these patients;
owever, the risks associated with sternotomy or thoracot-
my and the somewhat higher incidence of lead failure must
e considered when epicardial pacing systems are required
251). Fourth, because there are no randomized clinical
rials of cardiac pacing in pediatric or congenital heart
isease patients, the level of evidence for most recommen-
ations is consensus based (Level of Evidence: C). Diagnoses
hat require pacing in both children and adults, such as
ong-QT syndrome or neuromuscular diseases, are discussed
n specific sections on these topics in this document.
Bradycardia and associated symptoms in children are
ften transient (e.g., sinus arrest or paroxysmal AV block)
nd difficult to document (252). Although SND (sick sinus
yndrome) is recognized in pediatric patients and may be
ssociated with specific genetic channelopathies (206), it is
ot itself an indication for pacemaker implantation. In the
oung patient with sinus bradycardia, the primary criterion
or pacemaker implantation is the concurrent observation of
symptom (e.g., syncope) with bradycardia (e.g., heart rate
ess than 40 bpm or asystole more than 3 seconds)
53,86,253). In general, correlation of symptoms with bra-
ycardia is determined by ambulatory ECG or an implant-
ble loop recorder (254). Symptomatic bradycardia is an
ndication for pacemaker implantation provided that other
auses have been excluded. Alternative causes to be consid-
red include apnea, seizures, medication effects, and neuro-
ardiogenic mechanisms (255,256). In carefully selected
ases, cardiac pacing has been effective in the prevention of
ecurrent seizures and syncope in infants with recurrent
allid breath-holding spells associated with profound bra-
ycardia or asystole (257). aA variant of the bradycardia-tachycardia syndrome, sinus
radycardia that alternates with intra-atrial re-entrant
achycardia, is a significant problem after surgery for con-
enital heart disease. Substantial morbidity and mortality
ave been observed in patients with recurrent or chronic
ntra-atrial re-entrant tachycardia, with the loss of sinus
hythm an independent risk factor for the subsequent
evelopment of this arrhythmia (258,259). Thus, both
ong-term atrial pacing at physiological rates and atrial ATP
ave been reported as potential treatments for sinus brady-
ardia and the prevention or termination of recurrent
pisodes of intra-atrial re-entrant tachycardia (260,261).
he results of either mode of pacing for this arrhythmia
ave been equivocal and remain a topic of considerable
ontroversy (262,263). In other patients, pharmacological
herapy (e.g., sotalol or amiodarone) may be effective in the
ontrol of intra-atrial re-entrant tachycardia but also result
n symptomatic bradycardia (264). In these patients, radio-
requency catheter ablation of the intra-atrial re-entrant
achycardia circuit should be considered as an alternative to
ombined pharmacological and pacemaker therapies (265).
urgical resection of atrial tissue with concomitant atrial
acing has also been advocated for congenital heart disease
atients with intra-atrial re-entrant tachycardia refractory to
ther therapies (266).
The indications for permanent pacing in patients with
ongenital complete AV block continue to evolve on the
asis of improved definition of the natural history of the
isease and advances in pacemaker technology and diagnos-
ic methods. Pacemaker implantation is a Class I indication
n the symptomatic individual with congenital complete AV
lock or the infant with a resting heart rate less than 55
pm, or less than 70 bpm when associated with structural
eart disease (267,268). In the asymptomatic child or
dolescent with congenital complete AV block, several
riteria (average heart rate, pauses in the intrinsic rate,
ssociated structural heart disease, QT interval, and exercise
olerance) must be considered (208,269). Several studies
ave demonstrated that pacemaker implantation is associ-
ted with both improved long-term survival and prevention
f syncopal episodes in asymptomatic patients with congen-
tal complete AV block (270,271). However, periodic eval-
ation of ventricular function is required in patients with
ongenital AV block after pacemaker implantation, because
entricular dysfunction may occur as a consequence of
yocardial autoimmune disease at a young age or
acemaker-associated dyssynchrony years or decades after
acemaker implantation (272,273). The actual incidence of
entricular dysfunction due to pacemaker-related chronic
entricular dyssynchrony remains undefined.
A very poor prognosis has been established for congenital
eart disease patients with permanent postsurgical AV
lock who do not receive permanent pacemakers (209).
herefore, advanced second- or third-degree AV block that
ersists for at least 7 days and that is not expected to resolve
fter cardiac surgery is considered a Class I indication for
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ACC/AHA/HRS Guidelines for Device-Based Therapy May 27, 2008:e1–62acemaker implantation (274). Conversely, patients in
hom AV conduction returns to normal generally have a
avorable prognosis (275). Recent reports have emphasized
hat there is a small but definite risk of late-onset complete
V block years or decades after surgery for congenital heart
isease in patients with transient postoperative AV block
276,277). Limited data suggest that residual bifascicular
onduction block and progressive PR prolongation may
redict late-onset AV block (278). Because of the possibility
f intermittent complete AV block, unexplained syncope is
Class IIa indication for pacing in individuals with a history
f temporary postoperative complete AV block and residual
ifascicular conduction block after a careful evaluation for
oth cardiac and noncardiac causes.
Additional details that need to be considered in pace-
aker implantation in young patients include risk of para-
oxical embolism due to thrombus formation on an endo-
ardial lead system in the presence of residual intracardiac
efects and the lifelong need for permanent cardiac pacing
279). Decisions about pacemaker implantation must also
ake into account the implantation technique (transvenous
ersus epicardial), with preservation of vascular access at a
oung age a primary objective (280).
ecommendations for Permanent Pacing in Children,
dolescents, and Patients With Congenital
eart Disease
LASS I
. Permanent pacemaker implantation is indicated for advanced
second- or third-degree AV block associated with symptomatic
bradycardia, ventricular dysfunction, or low cardiac output.
(Level of Evidence: C)
. Permanent pacemaker implantation is indicated for SND with
correlation of symptoms during age-inappropriate bradycardia.
The definition of bradycardia varies with the patient’s age and
expected heart rate. (Level of Evidence: B) (53,86,253,257)
. Permanent pacemaker implantation is indicated for postopera-
tive advanced second- or third-degree AV block that is not
expected to resolve or that persists at least 7 days after cardiac
surgery. (Level of Evidence: B) (74,209)
. Permanent pacemaker implantation is indicated for congenital
third-degree AV block with a wide QRS escape rhythm, complex
ventricular ectopy, or ventricular dysfunction. (Level of Evidence: B)
(271–273)
. Permanent pacemaker implantation is indicated for congenital
third-degree AV block in the infant with a ventricular rate less
than 55 bpm or with congenital heart disease and a ventricular
rate less than 70 bpm. (Level of Evidence: C) (267,268)
LASS IIa
. Permanent pacemaker implantation is reasonable for patients
with congenital heart disease and sinus bradycardia for the
prevention of recurrent episodes of intra-atrial reentrant tachy-
cardia; SND may be intrinsic or secondary to antiarrhythmic
treatment. (Level of Evidence: C) (260,261,264)
. Permanent pacemaker implantation is reasonable for congenital
third-degree AV block beyond the first year of life with an average
heart rate less than 50 bpm, abrupt pauses in ventricular rate cthat are 2 or 3 times the basic cycle length, or associated with
symptoms due to chronotropic incompetence. (Level of Evi-
dence: B) (208,270)
. Permanent pacemaker implantation is reasonable for sinus bra-
dycardia with complex congenital heart disease with a resting
heart rate less than 40 bpm or pauses in ventricular rate longer
than 3 seconds. (Level of Evidence: C)
. Permanent pacemaker implantation is reasonable for patients with
congenital heart disease and impaired hemodynamics due to sinus
bradycardia or loss of AV synchrony. (Level of Evidence: C) (250)
. Permanent pacemaker implantation is reasonable for unex-
plained syncope in the patient with prior congenital heart surgery
complicated by transient complete heart block with residual
fascicular block after a careful evaluation to exclude other
causes of syncope. (Level of Evidence: B) (273,276–278)
LASS IIb
. Permanent pacemaker implantation may be considered for tran-
sient postoperative third-degree AV block that reverts to sinus
rhythm with residual bifascicular block. (Level of Evidence: C) (275)
. Permanent pacemaker implantation may be considered for con-
genital third-degree AV block in asymptomatic children or ado-
lescents with an acceptable rate, a narrow QRS complex, and
normal ventricular function. (Level of Evidence: B) (270,271)
. Permanent pacemaker implantation may be considered for
asymptomatic sinus bradycardia after biventricular repair of
congenital heart disease with a resting heart rate less than 40
bpm or pauses in ventricular rate longer than 3 seconds. (Level of
Evidence: C)
LASS III
. Permanent pacemaker implantation is not indicated for transient
postoperative AV block with return of normal AV conduction in
the otherwise asymptomatic patient. (Level of Evidence: B)
(274,275)
. Permanent pacemaker implantation is not indicated for asymp-
tomatic bifascicular block with or without first-degree AV block
after surgery for congenital heart disease in the absence of prior
transient complete AV block. (Level of Evidence: C)
. Permanent pacemaker implantation is not indicated for asymp-
tomatic type I second-degree AV block. (Level of Evidence: C)
. Permanent pacemaker implantation is not indicated for asymp-
tomatic sinus bradycardia with the longest relative risk interval
less than 3 seconds and a minimum heart rate more than 40
bpm. (Level of Evidence: C)
.6. Selection of Pacemaker Device
nce the decision has been made to implant a pacemaker in
given patient, the clinician must decide among a large
umber of available pacemaker generators and leads. Gen-
rator choices include single- versus dual-chamber versus
iventricular devices, unipolar versus bipolar pacing/sensing
onfiguration, presence and type of sensor for rate response,
dvanced features such as automatic capture verification,
trial therapies, size, and battery capacity. Lead choices
nclude diameter, polarity, type of insulation material, and
xation mechanism (active versus passive). Other factors
hat importantly influence the choice of pacemaker system
omponents include the capabilities of the pacemaker pro-
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onitoring capabilities.
Even after selecting and implanting the pacing system,
he physician has a number of options for programming the
evice. In modern single-chamber pacemakers, programma-
le features include pacing mode, lower rate, pulse width
nd amplitude, sensitivity, and refractory period. Dual-
hamber pacemakers have the same programmable features,
s well as maximum tracking rate, AV delay, mode-
witching algorithms for atrial arrhythmias, and others.
ate-responsive pacemakers require programmable features
o regulate the relation between sensor output and pacing
ate and to limit the maximum sensor-driven pacing rate.
iventricular pacemakers require the LV pacing output to
e programmed, and often the delay between LV and RV
acing must also be programmed. With the advent of more
ophisticated pacemaker generators, optimal programming
f pacemakers has become increasingly complex and device-
pecific and requires specialized knowledge on the part of
he physician.
Many of these considerations are beyond the scope of this
ocument. Later discussion focuses primarily on the choice
egarding the pacemaker prescription that has the greatest
mpact on procedural time and complexity, follow-up,
atient outcome, and cost: the choice among single-
hamber ventricular pacing, single-chamber atrial pacing,
nd dual-chamber pacing.
Table 2 summarizes the appropriateness of different
acemakers for the most commonly encountered indications
or pacing. Figure 1 is a decision tree for selecting a pacing
ystem for patients with AV block. Figure 2 is a decision
ree for selecting a pacing system for patients with SND.
An important challenge for the physician in selecting a
acemaker system for a given patient is to anticipate
rogression of abnormalities of that patient’s cardiac
utomaticity and conduction and then to select a system
able 2. Choice of Pacemaker Generator in Selected Indication
Pacemaker Generator Sinus Node Dysfunction
ingle-chamber atrial pacemaker No suspected abnormality of atrioventr
conduction and not at increased risk
future atrioventricular block
Maintenance of atrioventricular synchr
during pacing desired
ingle-chamber ventricular
pacemaker
Maintenance of atrioventricular synchr
during pacing not necessary
Rate response available if desired
ual-chamber pacemaker Atrioventricular synchrony during pacin
desired
Suspected abnormality of atrioventricu
conduction or increased risk for futu
atrioventricular block
Rate response available if desired
ingle-lead, atrial-sensing ventricular
pacemaker
Not appropriatehat will best accommodate these developments. Thus, it
s reasonable to select a pacemaker with more extensive
apabilities than needed at the time of implantation but
hat may prove useful in the future. Some patients with
ND and paroxysmal AF, for example, may develop AV
lock in the future (as a result of natural progression of
isease, drug therapy, or catheter ablation) and may
ltimately benefit from a dual-chamber pacemaker with
ode-switching capability.
Similarly, when pacemaker implantation is indicated,
onsideration should be given to implantation of a more
apable device (CRT, CRT-P, or CRT-D) if it is
hought likely that the patient will qualify for the latter
ithin a short time period. For example, a patient who
equires a pacemaker for heart block that occurs in the
etting of MI who also has an extremely low LVEF may
e best served by initial implantation of an ICD rather
han a pacemaker. In such cases, the advantage of
voiding a second upgrade procedure should be balanced
gainst the uncertainty regarding the ultimate need for
he more capable device.
.6.1. Major Trials Comparing Atrial or Dual-Chamber
acing With Ventricular Pacing
ver the past decade, the principal debate with respect to
hoice of pacemaker systems has concerned the relative
erits of dual-chamber pacing, single-chamber ventricular
acing, and single-chamber atrial pacing. The physiological
ationale for atrial and dual-chamber pacing is preservation
f AV synchrony; therefore, trials comparing these modes
ave often combined patients with atrial or dual-chamber
acemakers in a single treatment arm. There have been 5
ajor randomized trials comparing atrial or dual-chamber
acing with ventricular pacing; they are summarized in
able 3. Of the 5 studies, 2 were limited to patients paced
or SND, 1 was limited to patients paced for AV block, and
Pacing
Atrioventricular Block
Neurally Mediated Syncope or
Carotid Sinus Hypersensitivity
Not appropriate Not appropriate
Chronic atrial fibrillation or other atrial
tachyarrhythmia or maintenance of
atrioventricular synchrony during
pacing not necessary
Rate response available if desired
Chronic atrial fibrillation or
other atrial tachyarrhythmia
Rate response available if
desired
Rate response available if desired
Atrioventricular synchrony during
pacing desired
Atrial pacing desired
Sinus mechanism present
Rate response available if
desired
Desire to limit the number of
pacemaker leads
Not appropriates for
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anish study (281) included a true atrial pacing arm; among
atients in the AAI/DDD arm in CTOPP (Canadian Trial
f Physiologic Pacing), only 5.2% had an atrial pacemaker
282). A significant limitation of all of these studies is the
ercentage of patients (up to 37.6%) who crossed over from
treatment arm to another or otherwise dropped out of
heir assigned pacing mode.
An important consideration in the assessment of trials
hat compare pacing modes is the percent of pacing among
he study patients. For example, a patient who is paced only
or very infrequent sinus pauses or infrequent AV block will
robably have a similar outcome with ventricular pacing as
ith dual-chamber pacing, regardless of any differential
ffects between the 2 pacing configurations. With the
xception of the MOST study (31) and limited data in the
K-PACE trial (United Kingdom Pacing and Cardiovas-
ular Events) (283), the trials included in Table 3 do not
nclude information about the percent of atrial or ventricular
acing in the study patients.
.6.2. Quality of Life and Functional Status End Points
umerous studies have shown significant improvement in
igure 1. Selection of Pacemaker Systems for Patients With Atrio
ecisions are illustrated by diamonds. Shaded boxes indicate type of pacemaker. AVeported QOL and functional status after pacemaker im- alantation (22,23,285,286), but there is also a well-
ocumented placebo effect after device implantation (222).
his section will focus on differences between pacing modes
ith respect to these outcomes.
In the subset of patients in the PASE (Pacemaker
election in the Elderly) study who received implants for
ND, dual-chamber pacing was associated with greater
mprovement than was ventricular pacing with regard to a
inority of QOL and functional status measures, but there
ere no such differences among patients paced for AV block
23). In the MOST patients, all of whom received implants
or SND, dual-chamber–paced patients had superior out-
omes in some but not all QOL and functional status
easures (22,286). CTOPP, which included patients who
eceived implants for both SND and AV block, failed to
etect any difference between pacing modes with respect to
OL or functional status in a subset of 269 patients who
nderwent this evaluation; a breakdown by pacing indica-
ion was not reported (284).
Older cross-over studies of dual-chamber versus ventric-
lar pacing, which allowed for intrapatient comparisons
etween the 2 modes, indicate improved functional status
icular Block
ates atrioventricular.ventrnd patient preference for dual-chamber pacing. For in-
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May 27, 2008:e1–62 ACC/AHA/HRS Guidelines for Device-Based Therapytance, Sulke et al. (288) studied 22 patients who received
ual-chamber rate-responsive pacemakers for high-grade
V block and found improved exercise time, functional
tatus, and symptoms with DDDR compared with VVIR
acing, as well as vastly greater patient preference for
DDR pacing.
igure 2. Selection of Pacemaker Systems for Patients With S
ecisions are illustrated by diamonds. Shaded boxes indicate type of pacemaker. AV
able 3. Randomized Trials Comparing Atrium-Based Pacing W
Characteristics
Danish Study
(281)
PASE
(23)
acing indication SND SND and AVB
o. of patients randomized 225 407
ean follow-up (years) 5.5 1.5
acing modes AAI vs. VVI DDDR* vs. VVIR*
trium-based pacing superior
with respect to:
Quality of life or functional
status
NA SND patients: yes
AVB patients: no
Heart failure Yes No
Atrial fibrillation Yes No
Stroke or
thromboembolism
Yes No
Mortality Yes No
ross-over or pacing dropout VVI to AAI/DDD: 4%
AAI to DDD: 5%
AAI to VVI: 10%
VVIR* to DDDR*: 26%
R*added to pacing mode designation indicates rate-responsive pacemakers implanted in all pa
atients.
AAI indicates atrial demand; AVB, atrioventricular block; CTOPP, Canadian Trial of Physiologic Pacing
ND, sinus node dysfunction; UK-PACE, United Kingdom Pacing and Cardiovascular Events; and VVI, ve.6.3. Heart Failure End Points
Danish study showed an improvement in heart failure
tatus among atrially-paced patients compared with ven-
ricularly paced patients, as measured by NYHA functional
lass and diuretic use (281). MOST showed a marginal
Node Dysfunction
ates atrioventricular.
entricular Pacing
CTOPP
(282,284,285)
MOST
(22,31,48,49,286,287)
UK-PACE
(283)
SND and AVB SND AVB
2568 2010 2021
6.4 2.8 3
DDD/AAI vs. VVI(R) DDDR vs. VVIR* DDD(R) vs. VVI(R)
No Yes NA
No Marginal No
Yes Yes No
No No No
No No No
VI(R) dropout: 7%
DD/AAI dropout: 25%
VVIR* to DDDR*: 37.6% VVI(R) to DDD(R): 3.1%
DDD(R) dropout: 8.3%
(R) added to pacing mode designation indicates rate-responsive pacemakers implanted in someinusith V
V
D
tients.; DDD, fully automatic; MOST, Mode Selection Trial; PASE, Pacemaker Selection in the Elderly;
ntricular demand.
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ACC/AHA/HRS Guidelines for Device-Based Therapy May 27, 2008:e1–62mprovement in a similar heart failure score with dual-
hamber versus ventricular pacing, as well as a weak asso-
iation between dual-chamber pacing and fewer heart fail-
re hospitalizations (22). None of the other studies listed in
able 3 detected a difference between pacing modes with
espect to new-onset heart failure, worsening of heart
ailure, or heart failure hospitalization. A meta-analysis of
he 5 studies listed in Table 3 did not show a significant
ifference between atrially paced- or dual-chamber–paced
atients compared with ventricularly paced patients with
espect to heart failure hospitalization (289).
.6.4. Atrial Fibrillation End Points
he Danish study, MOST, and CTOPP showed signifi-
antly less AF among the atrially paced or dual-chamber–
aced patients than the ventricularly paced patients
22,281,282). In MOST, the divergence in AF incidence
ecame apparent at 6 months, whereas in CTOPP, the
ivergence was apparent only at 2 years. PASE, a much
maller study, did not detect any difference in AF between
ts 2 groups (23). The UK-PACE trial did not demonstrate
significant difference in AF between its 2 treatment arms;
owever, a trend toward less AF with dual-chamber pacing
egan to appear at the end of the scheduled 3-year
ollow-up period (28). The meta-analysis of the 5 studies
isted in Table 3 showed a significant decrease in AF with
trial or dual-chamber pacing compared with ventricular
acing, with a hazard ratio (HR) of 0.80 (289).
.6.5. Stroke or Thromboembolism End Points
f the 5 studies listed in Table 3, only the Danish study
etected a difference between pacing modes with respect to
troke or thromboembolism (281). However, the meta-
nalysis of the 5 studies in Table 3 showed a decrease of
orderline statistical significance in stroke with atrial or
ual-chamber pacing compared with ventricular pacing,
ith an HR of 0.81 (289).
.6.6. Mortality End Points
he Danish study showed significant improvement in both
verall mortality and cardiovascular mortality among the
trially paced patients compared with the ventricularly
aced patients (281). None of the other studies showed a
ignificant difference between pacing modes in either overall
r cardiovascular mortality. The meta-analysis of the 5
tudies in Table 3 did not show a significant difference
etween atrially paced or dual-chamber–paced patients
ompared with ventricularly paced patients with respect to
verall mortality (289).
Taken together, the evidence from the 5 studies most
trongly supports the conclusion that dual-chamber or atrial
acing reduces the incidence of AF compared with ventric-
lar pacing in patients paced for either SND or AV block.
here may also be a benefit of dual-chamber or atrial pacing
ith respect to stroke. The evidence also supports a modestmprovement in QOL and functional status with dual- shamber pacing compared with ventricular pacing in pa-
ients with SND. The preponderance of evidence from
hese trials regarding heart failure and mortality argues
gainst any advantage of atrial or dual-chamber pacing for
hese 2 end points.
.6.7. Importance of Minimizing Unnecessary Ventricular
acing
n the past 5 years, there has been increasing recognition of
he deleterious clinical effects of RVA pacing, both in
atients with pacemakers (48,49,215) and in those with
CDs (50,51,290). Among the patients in MOST with a
ormal native QRS duration, the percent of ventricular
acing was correlated with heart failure hospitalization and
ew onset of AF (48). It has been speculated that the more
requent ventricular pacing in patients randomized to
DDR pacing (90%) compared with patients randomized
o VVIR pacing (58%) may have negated whatever positive
ffects may have accrued from the AV synchrony afforded by
ual-chamber pacing in this study. A possible explanation
or the striking benefits of AAI pacing found in the Danish
tudy (281) described above is the obvious absence of
entricular pacing in patients with single-chamber atrial
acemakers (281).
In a subsequent Danish study, patients with SND were
andomized between AAIR pacing, DDDR pacing with a
ong AV delay (300 milliseconds), and DDDR pacing with
short AV delay (less than or equal to 150 milliseconds)
45). The prevalence of ventricular pacing was 17% in the
DDR–long-AV-delay patients and 90% in the DDDR–
hort-AV-delay patients. At 2.9 years of follow-up, the
ncidence of AF was 7.4% in the AAIR group, 17.5% in the
DDR–long-AV-delay group, and 23.3% in the DDDR–
hort-AV-delay group. There were also increases in left
trial and LV dimensions seen in both DDDR groups but
ot the AAIR group. This study supports the superiority of
trial over dual-chamber pacing and indicates that there
ay be deleterious effects from even the modest amount of
entricular pacing that typically occurs with maximally
rogrammed AV delays in the DDD mode.
Patients included in studies showing deleterious effects of
V pacing were either specified as having their RV lead
ositioned at the RV apex (40,43,280) or can be presumed
n most cases to have had the lead positioned there based on
revailing practices of pacemaker and defibrillator implan-
ation (45,46,277). Therefore, conclusions about deleterious
ffects of RV pacing at this time should be limited to
atients with RVA pacing. Studies are currently under way
hat compare the effects of pacing at alternative RV sites
septum, outflow tract) with RVA pacing.
Despite the appeal of atrium-only pacing, there remains
oncern about implanting single-chamber atrial pacemakers
n patients with SND because of the risk of subsequent AV
lock. Also, in the subsequent Danish study comparing
trial with dual-chamber pacing, the incidence of progres-
ion to symptomatic AV block, including syncope, was 1.9%
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May 27, 2008:e1–62 ACC/AHA/HRS Guidelines for Device-Based Therapyer year, even with rigorous screening for risk of AV block
t the time of implantation (45). Programming a dual-
hamber device to the conventional DDD mode with a
aximally programmable AV delay or with AV search
ysteresis does not eliminate frequent ventricular pacing in
significant fraction of patients (291,292). Accordingly,
everal pacing algorithms that avoid ventricular pacing
xcept during periods of high-grade AV block have been
ntroduced recently (293). These new modes dramatically
ecrease the prevalence of ventricular pacing in both pace-
aker and defibrillator patients (294–296). A recent trial
howed the frequency of RV pacing was 9% with one of
hese new algorithms compared with 99% with conventional
ual-chamber pacing, and this decrease in RV pacing was
ssociated with a 40% relative reduction in the incidence of
ersistent AF (296). Additional trials are under way to
ssess the clinical benefits of these new pacing modes (297).
.6.8. Role of Biventricular Pacemakers
s discussed in Section 2.4.1, “Cardiac Resynchronization
herapy,” multiple controlled trials have shown biventricu-
ar pacing to improve both functional capacity and QOL
nd decrease hospitalizations and mortality for selected
atients with Class III to IV symptoms of heart failure.
lthough patients with a conventional indication for pace-
aker implantation were excluded from these trials, it is
easonable to assume that patients who otherwise meet their
nclusion criteria but have QRS prolongation due to ven-
ricular pacing might also benefit from biventricular pacing.
Regardless of the duration of the native QRS complex,
atients with LV dysfunction who have a conventional
ndication for pacing and in whom ventricular pacing is
xpected to predominate may benefit from biventricular
acing. A prospective randomized trial published in 2006
oncerning patients with LV enlargement, LVEF less than
r equal to 40%, and conventional indications for pacing
howed that biventricular pacing was associated with im-
roved functional class, exercise capacity, LVEF, and serum
rain natriuretic peptide levels compared with RV pacing
298). It has also been demonstrated that LV dysfunction in
he setting of chronic RV pacing, and possibly as a result of
V pacing, can be improved with an upgrade to biventricu-
ar pacing (299).
Among patients undergoing AV junction ablation for
hronic AF, the PAVE (Left Ventricular-Based Cardiac
timulation Post AV Nodal Ablation Evaluation) trial
rospectively randomized patients between RVA pacing
nd biventricular pacing (300). The patients with RVA
acing had deterioration in LVEF that was avoided by the
atients with biventricular pacing. The group with biven-
ricular pacing also had improved exercise capacity com-
ared with the group with right apical pacing. The advan-
ages of biventricular pacing were seen predominantly
mong patients with reduced LVEF or heart failure at
aseline. Other studies have shown that among AF patients
ho experience heart failure after AV junction ablation and yV pacing, an upgrade to biventricular pacing results in
mproved symptomatology and improved LV function
301,302).
These findings raise the question of whether patients
ith preserved LV function requiring ventricular pacing
ould benefit from initial implantation with a biventricular
evice (or one with RV pacing at a site with more synchro-
ous ventricular activation than at the RV apex, such as
acing at the RV septum, the RV outflow tract (303,304),
r the area of the His bundle) (305). Some patients with
ormal baseline LV function experience deterioration in
VEF after chronic RV pacing (47,306). The concern over
he effects of long-term RV pacing is naturally greatest
mong younger patients who could be exposed to ventricular
acing for many decades. Studies have suggested that
hronic RVA pacing in young patients, primarily those with
ongenital complete heart block, can lead to adverse histo-
ogical changes, LV dilation, and LV dysfunction
41,306,307).
There is a role for CRT-P in some patients, especially
hose who wish to enhance their QOL without defibrilla-
ion backup. Elderly patients with important comorbidities
re such individuals. Notably, there is an important survival
enefit from CRT-P alone (224,225).
.7. Optimizing Pacemaker Technology and Cost
he cost of a pacemaker system increases with its degree
f complexity and sophistication. For example, the cost of
dual-chamber pacemaker system exceeds that of a
ingle-chamber system with respect to the cost of the
enerator and the second lead (increased by approxi-
ately $2500 [287]), additional implantation time and
upplies (approximately $160 [287]), and additional
ollow-up costs (approximately $550 per year [287]). A
iventricular pacemaker entails even greater costs, with
he hardware alone adding $5000 to $10 000 to the
ystem cost. With respect to battery life, that of a
ual-chamber generator is shorter than that of a single-
hamber generator (287,308) and that of a biventricular
evice is shorter still. There are also QOL concerns
ssociated with the more complex systems, including
ncreased device size and increased frequency of follow-
p. Against these additional costs are the potential
enefits of the more sophisticated systems with respect to
OL, morbidity, and mortality. Furthermore, when a
ingle-chamber system requires upgrading to a dual-
hamber system, the costs are significant; one study
stimated the cost of such an upgrade to be $14 451 (287).
An analysis of MOST found that the cost-effectiveness of
ual-chamber pacemaker implantation compared with ven-
ricular pacemaker implantation (287) was approximately
53 000 per quality-adjusted year of life gained over 4 years
f follow-up. Extended over the expected lifetime of a
ypical patient, the calculated cost-effectiveness of dual-
hamber pacing improved to $6800 per quality-adjusted
ear of life gained.
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ACC/AHA/HRS Guidelines for Device-Based Therapy May 27, 2008:e1–62It has been estimated that 16% to 24% of pacemaker
mplantations are for replacement of generators; of those,
6% are replaced because their batteries have reached their
lective replacement time (309,310). Hardware and soft-
are (i.e., programming) features of pacemaker systems that
rolong useful battery longevity may improve the cost-
ffectiveness of pacing. Leads with steroid elution and/or
igh pacing impedance allow for less current drain. Optimal
rogramming of output voltages, pulse widths, and AV
elays can markedly decrease battery drain; one study
howed that expert programming of pacemaker generators
an have a major impact on longevity, prolonging it by an
verage of 4.2 years compared with nominal settings (311).
enerators that automatically determine whether a pacing
mpulse results in capture allow for pacing outputs closer to
hreshold values than conventional generators. Although
hese and other features arguably should prolong generator
ife, there are other constraints on the useful life of a
acemaker generator, including battery drain not directly
elated to pulse generation and the limited life expectancy of
any pacemaker recipients; rigorous studies supporting the
verall cost-effectiveness of these advanced pacing features
re lacking.
.8. Pacemaker Follow-Up
fter implantation of a pacemaker, careful follow-up and
ontinuity of care are required. The writing committee
onsidered the advisability of extending the scope of these
uidelines to include recommendations for follow-up and
evice replacement but deferred this decision given other
ublished statements and guidelines on this topic. These are
ddressed below as a matter of information; however, no
ndorsement is implied. The HRS has published a series of
eports on antibradycardia pacemaker follow-up (312,
13). The Canadian Working Group in Cardiac Pacing has
lso published a consensus statement on pacemaker follow-up
314). In addition, the Centers for Medicare and Medicaid
ervices has established guidelines for monitoring of patients
overed by Medicare who have antibradycardia pacemakers,
lthough these have not been updated for some time (315).
Many of the same considerations are relevant to
ollow-up of pacemakers, ICDs, and CRT systems. Pro-
ramming undertaken at implantation should be reviewed
efore discharge and changed accordingly at subsequent
ollow-up visits as indicated by interrogation, testing, and
atient needs. With careful attention to programming
acing amplitude, pulse width, and diagnostic functions,
attery life can be enhanced significantly without compro-
ising patient safety. Taking advantage of programmable
ptions also allows optimization of pacemaker function for
he individual patient.
The frequency and method of follow-up are dictated by
ultiple factors, including other cardiovascular or medical
roblems managed by the physician involved, the age of the
acemaker, and geographic accessibility of the patient to
edical care. Some centers may prefer to use remote tonitoring with intermittent clinic evaluations, whereas
thers may prefer to do the majority or all of the patient
ollow-up in a clinic.
For many years, the only “remote” follow-up was trans-
elephonic monitoring (TTM). Available for many years,
TM provides information regarding capture of the cham-
er(s) being paced and battery status. TTM may also
rovide the caregiver with information regarding appropri-
te sensing. However, in recent years, the term “remote
onitoring” has evolved to indicate a technology that is
apable of providing a great deal of additional information.
utomatic features, such as automatic threshold assessment,
ave been incorporated increasingly into newer devices and
acilitate follow-up for patients who live far from follow-up
linics (316). However, these automatic functions are not
niversal and need not and cannot supplant the benefits of
irect patient contact, particularly with regard to history
aking and physical examination.
A more extensive clinic follow-up usually includes assess-
ent of the clinical status of the patient, battery status,
acing threshold and pulse width, sensing function, and lead
ntegrity, as well as optimization of sensor-driven rate
esponse and evaluation of recorded events, such as mode
witching for AF detection and surveillance and ventricular
achyarrhythmia events. The schedule for clinic follow-up
hould be at the discretion of the caregivers who are
roviding pacemaker follow-up. As a guideline, the 1984
ealth Care Financing Administration document suggests
he following: for single-chamber pacemakers, twice in the
rst 6 months after implantation and then once every 12
onths; for dual-chamber pacemakers, twice in the first 6
onths, then once every 6 months (315).
Regulations regarding TTM have not been revised since
984 (315). Guidelines that truly encompass remote mon-
toring of devices have not yet been endorsed by any of the
ajor professional societies. The Centers for Medicare and
edicaid Services have not provided regulations regarding
he use of this technology but have provided limited
irection regarding reimbursement. The Centers for Medi-
are and Medicaid Services have published a statement that
hysicians should use the existing current procedural termi-
ology codes for in-office pacemaker and ICD interrogation
odes for remote monitoring of cardiac devices (317).
learly stated guidelines from professional societies are
ecessary and should be written in such a way as to permit
emote monitoring that achieves specific clinical goals.
uidelines are currently in development given the rapid
dvancement in remote monitoring technology.
Appropriate clinical goals of remote monitoring should
e identified and guidelines developed to give caregivers the
bility to optimize the amount of clinical information that
an be derived from this technology. Appropriate clinical
oals of TTM should be divided into those pieces of
nformation obtainable during nonmagnet (i.e., free-
unning) ECG assessment and assessment of the ECG
racing obtained during magnet application. The same goals
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commercial or noncommercial monitoring service.
Goals of TTM nonmagnet ECG assessment are as
ollows:
Determine whether the patient displays intrinsic rhythm
or is being intermittently or continuously paced at the
programmed settings.
Characterize the patient’s underlying atrial mechanism,
for example, sinus versus AF, atrial tachycardia, etc.
If intrinsic rhythm is displayed, determine that normal
(appropriate) sensing is present for 1 or both chambers
depending on whether it is a single- or dual-chamber
pacemaker and programmed pacing mode.
Goals of TTM ECG assessment during magnet applica-
ion are as follows:
Verify effective capture of the appropriate chamber(s)
depending on whether it is a single- or dual-chamber
pacemaker and verify the programmed pacing mode.
Assess magnet rate. Once magnet rate is determined, the
value should be compared with values obtained on
previous transmissions to determine whether any change
has occurred. The person assessing the TTM should also
be aware of the magnet rate that represents elective
replacement indicators for that pacemaker.
If the pacemaker is one in which pulse width is 1 of the
elective replacement indicators, the pulse width should
also be assessed and compared with previous values.
If the pacemaker has some mechanism to allow transtele-
phonic assessment of threshold (i.e., Threshold Margin
Test [TMT™]) and that function is programmed “on,”
the results of this test should be demonstrated and
analyzed.
If a dual-chamber pacemaker is being assessed and
magnet application results in a change in AV interval
during magnet application, that change should be dem-
onstrated and verified.
.8.1. Length of Electrocardiographic Samples for Storage
t is important that the caregiver(s) providing TTM assess-
ent be able to refer to a paper copy or computer-archived
opy of the transtelephonic assessment for subsequent care.
he length of the ECG sample saved should be based on
he clinical information that is required (e.g., the points
isted above). It is the experience of personnel trained in
TM that a carefully selected ECG sample of 6 to 9
econds can demonstrate all of the points for each of the
ategories listed above (i.e., a 6- to 9-second strip of
onmagnet and 6- to 9-second strip of magnet-applied
CG tracing).
.8.2. Frequency of Transtelephonic Monitoring
he follow-up schedule for TTM varies among centers, and
here is no absolute schedule that need be mandated.
egardless of the schedule to which the center may adhere, MTM may be necessary at unscheduled times if, for exam-
le, the patient experiences symptoms that potentially re-
ect an alteration in rhythm or device function.
The majority of centers with TTM services follow the
chedule established by the Health Care Financing Admin-
stration (now the Centers for Medicare and Medicaid
ervices). In the 1984 Health Care Financing Administra-
ion guidelines, there are 2 broad categories for follow-up
as shown in Table 4): Guideline I, which was thought to
pply to the majority of pacemakers in use at that time, and
uideline II, which would apply to pacemaker systems for
hich sufficient long-term clinical information exists to
nsure that they meet the standards of the Inter-Society
ommission for Heart Disease Resources for longevity and
nd-of-life decay. The standards to which they referred are
0% cumulative survival at 5 years after implantation and an
nd-of-life decay of less than a 50% drop in output voltage
nd less than a 20% deviation in magnet rate, or a drop of
bpm or less, over a period of 3 months or more. As of
000, it appears that most pacemakers would meet the
pecifications in Guideline II.
Note that there is no federal or clinical mandate that
hese TTM guidelines be followed. The ACC, AHA, and
RS have not officially endorsed the Health Care Financ-
ng Administration guidelines. Nevertheless, they may be
seful as a framework for TTM. An experienced center may
hoose to do less frequent TTM and supplement it with
n-clinic evaluations as stated previously.
able 4. Device Monitoring Times Postimplantation: Health
are Financing Administration 1984 Guidelines for
ranstelephonic Monitoring
Postimplantation
Milestone
Monitoring
Time
uideline I
Single chamber
1st month Every 2 weeks
2nd to 36th month Every 8 weeks
37th month to failure Every 4 weeks
Dual chamber
1st month Every 2 weeks
2nd to 6th month Every 4 weeks
7th to 36th month Every 8 weeks
37th month to failure Every 4 weeks
uideline II
Single chamber
1st month Every 2 weeks
2nd to 48th month Every 12 weeks
49th month to failure Every 4 weeks
Dual chamber
1st month Every 2 weeks
2nd to 30th month Every 12 weeks
31st to 48th month Every 8 weeks
49th month to failure Every 4 weeksodified from the U.S. Department of Health and Human Services (315). In the public domain.
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Review all programmed parameters
Review stored events (e.g., counters, histograms, and
electrograms)
If review of programmed parameters or stored events
suggests a need for reprogramming or a change in
therapy, arrange a focused in-clinic appointment.
. Indications for Implantable Cardioverter-
efibrillator Therapy
ndications for ICDs have evolved considerably from initial
mplantation exclusively in patients who had survived 1 or
ore cardiac arrests and failed pharmacological therapy
318). Multiple clinical trials have established that ICD use
esults in improved survival compared with antiarrhythmic
gents for secondary prevention of SCD (16,319–326).
arge prospective, randomized, multicenter studies have
lso established that ICD therapy is effective for primary
revention of sudden death and improves total survival in
elected patient populations who have not previously had a
ardiac arrest or sustained VT (16–19,327–331).
We acknowledge that the “ACC/AHA/ESC 2006
uidelines for Management of Patients With Ventricular
rrhythmias and the Prevention of Sudden Cardiac Death”
16) used an LVEF of less than 40% as a critical point to
ustify ICD implantation for primary prevention of SCD.
he LVEF used in clinical trials assessing the ICD for primary
revention of SCD ranged from less than or equal to 40% in
USTT (Multicenter Unsustained Ventricular Tachycardia
rial) to less than or equal to 30% in MADIT II (Multicenter
utomatic Defibrillator Implantation Trial II) (329,332). Two
rials, MADIT I (Multicenter Automatic Defibrillator Im-
lantation Trial I) (327) and SCD-HeFT (Sudden Cardiac
eath in Heart Failure Trial) (333), used LVEFs of less than
r equal to 35% as entry criteria. The present writing commit-
ee reached the consensus that it would be best to have ICDs
ffered to patients with clinical profiles as similar to those
ncluded in the trials as possible. Having given careful consid-
ration to the issues related to LVEF for these updated ICD
uidelines, we have written these indications for ICDs based
n the specific inclusion criteria for LVEF in the trials. Because
f this, there may be some variation from previously published
uidelines (16).
We also acknowledge that the determination of LVEF
acks a “gold standard” and that there may be variation
mong the commonly used clinical techniques of LVEF
etermination. All clinical methods of LVEF determination
ack precision, and the accuracy of techniques varies amongst
aboratories and institutions. Given these considerations, the
resent writing committee recommends that the clinician use
he LVEF determination that they believe is the most clinically
ccurate and appropriate in their institution.
Patient selection, device and lead implantation, follow-
p, and replacement are parts of a complex process that yequires familiarity with device capabilities, adequate case
olume, continuing education, and skill in the management
f ventricular arrhythmias, thus mandating appropriate
raining and credentialing. Training program requirements
or certification programs in clinical cardiac electrophysiol-
gy that include ICD implantation have been established by
he American Board of Internal Medicine and the American
steopathic Board of Internal Medicine. Individuals with
asic certification in pediatric cardiology and cardiac surgery
ay receive similar training in ICD implantation. In 2004,
equirements for an “alternate training pathway” for those
ith substantial prior experience in pacemaker implantation
ere proposed by the HRS with a scheduled expiration for
his alternate pathway in 2008 (11,12). Fifteen percent of
hysicians who implanted ICDs in 2006 reported in the
ational ICD registry that they had no formal training
electrophysiology fellowship, cardiac surgical training, or
ompletion of the alternate pathway recommendation)
11,12,334).
The options for management of patients with ventricular
rrhythmias include antiarrhythmic agents, catheter abla-
ion, and surgery. The “ACC/AHA/ESC 2006 Guidelines
or Management of Patients With Ventricular Arrhythmias
nd the Prevention of Sudden Cardiac Death” have been
ublished with a comprehensive review of management
ptions, including antiarrhythmic agents, catheter ablation,
urgery, and ICD therapy (16).
.1. Secondary Prevention of Sudden
ardiac Death
.1.1. Implantable Cardioverter-Defibrillator Therapy
or Secondary Prevention of Cardiac Arrest and
ustained Ventricular Tachycardia
econdary prevention refers to prevention of SCD in those
atients who have survived a prior sudden cardiac arrest or
ustained VT (16). Evidence from multiple randomized
ontrolled trials supports the use of ICDs for secondary
revention of sudden cardiac arrest regardless of the type of
nderlying structural heart disease. In patients resuscitated
rom cardiac arrest, the ICD is associated with clinically and
tatistically significant reductions in sudden death and total
ortality compared with antiarrhythmic drug therapy in
rospective randomized controlled trials (16,319–326).
Trials of the ICD in patients who have been resuscitated
rom cardiac arrest demonstrate survival benefits with ICD
herapy compared with electrophysiologically guided drug
herapy with Class I agents, sotalol, and empirical amioda-
one therapy (320,323). A large prospective, randomized
econdary prevention trial comparing ICD therapy with
lass III antiarrhythmic drug therapy (predominantly em-
irical amiodarone) demonstrated improved survival with
CD therapy (319). Unadjusted survival estimates for the
CD group and the antiarrhythmic drug group, respectively,
ere 89.3% versus 82.3% at 1 year, 81.6% versus 74.7% at 2
ears, and 75.4% versus 64.1% at 3 years (p0.02). Esti-
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95% CI 19% to 59%) at 1 year, 27% (95% CI 6% to 48%)
t 2 years, and 31% (95% CI 10% to 52%) at 3 years. Two
ther reports of large prospective trials in similar patient
roups have shown similar results (322,323).
The effectiveness of ICDs on outcomes in the recent
arge, prospective secondary prevention trials—AVID (An-
iarrhythmics Versus Implantable Defibrillators) (319),
ASH (Cardiac Arrest Study Hamburg) (321), and CIDS
Canadian Implantable Defibrillator Study) (322)—were
onsistent with prior investigations (320). Specifically, the
CD was associated with a 50% relative risk reduction for
rrhythmic death and a 25% relative risk reduction for
ll-cause mortality (324). Thus, the secondary prevention
rials have been robust and have shown a consistent effect of
mproved survival with ICD therapy compared with antiar-
hythmic drug therapy across studies (324).
Some individuals are resuscitated from cardiac arrest due
o possible transient reversible causes. In such patients,
yocardial revascularization may be performed when ap-
ropriate to reduce the risk of recurrent sudden death, with
ndividualized decisions made with regard to the need for
CD therapy (16). Sustained monomorphic VT with prior
I is unlikely to be affected by revascularization (16).
yocardial revascularization may be sufficient therapy in
atients surviving VF in association with myocardial isch-
mia when ventricular function is normal and there is no
istory of an MI (16).
Unless electrolyte abnormalities are proven to be the sole
ause of cardiac arrest, survivors of cardiac arrest in whom
lectrolyte abnormalities are discovered in general should be
reated in a manner similar to that of cardiac arrest survivors
ithout electrolyte abnormalities (16). Patients who expe-
ience sustained monomorphic VT in the presence of
ntiarrhythmic drugs or electrolyte abnormalities should
lso be evaluated and treated in a manner similar to patients
ith VT or VF without electrolyte abnormalities or antiar-
hythmic drugs (16).
.1.2. Specific Disease States and Secondary Prevention
f Cardiac Arrest or Sustained Ventricular Tachycardia
he majority of patients included in prior prospective
andomized trials of patients resuscitated from cardiac arrest
ave had coronary artery disease with impaired ventricular
unction (320,322,323,325,326). Patients with other types
f structural heart disease constitute a minority of patients
n the secondary prevention trials. However, supplemental
bservational and registry data support the ICD as the
referred strategy over antiarrhythmic drug therapy for
econdary prevention for patients resuscitated from cardiac
rrest due to VT or fibrillation with coronary artery disease
nd other underlying structural heart disease.
.1.3. Coronary Artery Disease
atients with coronary artery disease represent the majority
f patients receiving devices in prior reports of patients iurviving cardiac arrest. Evidence strongly supports a sur-
ival benefit in such patients with an ICD compared with
ther therapy options (319,322,323). Between 73% and
3% of patients enrolled in the AVID, CASH, and CIDS
rials had underlying coronary artery disease (319,321,322).
he mean LVEF ranged from 32% to 45% in these trials,
hich indicates prior MI in the majority of patients
319,322,323). Multiple analyses have supported the notion
hat patients with reduced LV function may experience
reater benefit with ICD therapy than with drug therapy
320,335–338). All patients undergoing evaluation for ICD
herapy should be given optimum medical treatment for
heir underlying cardiovascular condition (16).
Patients experiencing cardiac arrest due to VF that occurs
ore than 48 hours after an MI may be at risk for recurrent
ardiac arrest (16). It is recommended that such patients be
valuated and optimally treated for ischemia (16). If there is
vidence that directly and clearly implicates ischemia im-
ediately preceding the onset of VF without evidence of a
rior MI, the primary therapy should be complete coronary
evascularization (16). If coronary revascularization is not
ossible and there is evidence of significant LV dysfunction,
he primary therapy for patients resuscitated from VF
hould be the ICD (16).
Patients with coronary artery disease who present with
ustained monomorphic VT or VF and low-level elevations
f cardiac biomarkers of myocyte injury/necrosis should be
reated similarly to patients who have sustained VT and no
ocumented rise in biomarkers (16). Prolonged episodes of
ustained monomorphic VT or VF may be associated with
rise in cardiac troponin and creatine phosphokinase levels
ue to myocardial metabolic demands that exceed supply in
atients with coronary artery disease. Evaluation for isch-
mia should be undertaken in such patients (16). However,
hen sustained VT or VF is accompanied by modest
levations of cardiac enzymes, it should not be assumed that
new MI was the cause of the sustained VT (16). Without
ther clinical data to support the occurrence of a new MI, it
s reasonable to consider that such patients are at risk for
ecurrent sustained VT or VF (16). With these consider-
tions in mind, these patients should be treated for this
rrhythmia in the same manner as patients without biomar-
er release accompanying VT (16).
.1.4. Nonischemic Dilated Cardiomyopathy
atients with nonischemic DCM and prior episodes of
F or sustained VT are at high risk for recurrent cardiac
rrest. Empirical antiarrhythmic therapy or drug therapy
uided by electrophysiological testing has not been dem-
nstrated to improve survival in these patients. The ICD
as been shown to be superior to amiodarone for second-
ry prevention of VT and VF in studies in which the majority
f patients had coronary artery disease (322,323,336), but the
ubgroups with nonischemic DCM in these studies bene-
ted similarly (319,322,323) or more than the group withschemic heart failure (324). On the basis of these data, the
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mic DCM resuscitated from prior cardiac arrest from VF
r VT.
.1.5. Hypertrophic Cardiomyopathy
CM is an inherited heart muscle disease that affects
pproximately 1 of every 500 persons in the general popu-
ation and is the most common cause of cardiac arrest in
ndividuals younger than 40 years of age (339). HCM
hould be suspected as the cause of cardiac arrest in young
ndividuals during exertion, because exercise increases the
isk of life-threatening ventricular arrhythmias with this
ondition (339). Sudden death may also be the first mani-
estation of the disease in a previously asymptomatic indi-
idual. A history of prior cardiac arrest indicates a substan-
ial risk of future VT or VF with this condition (339).
rospective randomized trials of ICD versus pharmacolog-
cal therapy for patients with prior cardiac arrest and HCM
ave not been performed; however, registry data and obser-
ational trials are available (339,340).
In those patients with HCM resuscitated from prior
ardiac arrest, there is a high frequency of subsequent ICD
herapy for life-threatening ventricular arrhythmias (339).
n the basis of these data, the ICD is the preferred therapy
or such patients with HCM resuscitated from prior cardiac
rrest (339,340).
.1.6. Arrhythmogenic Right Ventricular Dysplasia/
ardiomyopathy
rrhythmogenic RV dysplasia/cardiomyopathy (ARVD/C) is
genetic condition characterized by fibrofatty infiltration of
he RV and less commonly the LV. It usually manifests
linically with sustained monomorphic VT with left bundle
orphology in young individuals during exercise. There are
o prospective randomized trials of pharmacological therapy
ersus ICD therapy in patients with ARVD/C for second-
ry prevention of SCD; however, observational reports from
ultiple centers consistently demonstrate a high frequency
f appropriate ICD use for life-threatening ventricular
rrhythmias and a very low rate of arrhythmic death in
atients with ARVD/C treated with an ICD (341–348).
.1.7. Genetic Arrhythmia Syndromes
enetic syndromes that predispose to sustained VT or VF
nclude the long- and short-QT syndromes, Brugada syn-
rome, idiopathic VF, and catecholaminergic polymorphic
T (338,349–356). These primary electrical conditions
ypically exist in the absence of any underlying structural
eart disease and predispose to cardiac arrest. Although
ontroversy still exists with regard to risk factors for sudden
eath with these conditions, there is consensus that those
ith prior cardiac arrest or syncope are at very high risk for
ecurrent arrhythmic events. On the basis of the absence of
ny clear or consistent survival benefit of pharmacological
herapy for those individuals with these genetic arrhythmia
yndromes, the ICD is the preferred therapy for those with crior episodes of sustained VT or VF and may also be
onsidered for primary prevention for some patients with a
ery strong family history of early mortality (see Sections
.2.4, “Hypertrophic Cardiomyopathy,” and 3.2.7, “Primary
lectrical Disease”).
.1.8. Syncope With Inducible Sustained Ventricular
achycardia
atients with syncope of undetermined origin in whom
linically relevant VT/VF is induced at electrophysiological
tudy should be considered candidates for ICD therapy. In
hese patients, the induced arrhythmia is presumed to be the
ause of syncope (341,357–366). In patients with hemody-
amically significant and symptomatic inducible sustained
T, ICD therapy can be a primary treatment option.
ppropriate ICD therapy of VT and VF documented by
tored electrograms lends support to ICD therapy as a
rimary treatment for DCM patients with syncope
341,367).
.2. Primary Prevention of Sudden Cardiac Death
rimary prevention of SCD refers to the use of ICDs in
ndividuals who are at risk for but have not yet had an
pisode of sustained VT, VF, or resuscitated cardiac arrest.
linical trials have evaluated the risks and benefits of the
CD in prevention of sudden death and have improved
urvival in multiple patient populations, including those
ith prior MI and heart failure due to either coronary artery
isease or nonischemic DCM. Prospective registry data are
ess robust but still useful for risk stratification and recom-
endations for ICD implantation in selected other patient
opulations, such as those with HCM, ARVD/C, and the
ong-QT syndrome. In less common conditions (e.g., Bru-
ada syndrome, catecholaminergic polymorphic VT, cardiac
arcoidosis, and LV noncompaction), clinical reports and
etrospectively analyzed series provide less rigorous evidence in
upport of current recommendations for ICD use, but this
onstitutes the best available evidence for these conditions.
.2.1. Coronary Artery Disease
here now exists a substantial body of clinical trial data that
upport the use of ICDs in patients with chronic ischemic
eart disease. A variety of risk factors have been used to
dentify a high-risk population for these studies. MADIT I
327) and MUSTT (329) required a history of MI, spon-
aneous nonsustained VT, inducible VT at electrophysio-
ogical study, and a depressed LVEF (less than or equal to
5% or less than or equal to 40%, respectively) to enter the
tudy. MADIT I showed a major relative risk reduction of
4% with the ICD. MUSTT was not specifically a trial of
CD therapy, because it compared no therapy with electro-
hysiologically guided therapy, but in the group randomized
o electrophysiologically guided therapy, benefit was seen
nly among those who received an ICD.
MADIT II (332) enrolled 1232 patients with ischemicardiomyopathy and an LVEF less than or equal to 30%.
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nrollment. All-cause mortality was 20% in the control
roup and 14.2% in the ICD group (relative risk 31%;
0.016). SCD-HeFT included patients with both isch-
mic and nonischemic cardiomyopathies, an LVEF less
han or equal to 35%, and NYHA Class II or III congestive
eart failure (333). Among the 1486 patients with ischemic
eart disease randomized to either placebo or ICD therapy,
he 5-year event rates were 0.432 and 0.359, respectively
HR 0.79; p0.05). Two recent meta-analyses of these
rials have supported the overall conclusion that ICD
herapy in high-risk individuals with coronary artery disease
esults in a net risk reduction for total mortality of between
0% and 30% (325,368).
Two trials, however, have failed to show improved
urvival with ICD therapy in patients either at the time of
urgical revascularization or within 40 days of an acute MI.
n the CABG-Patch (Coronary Artery Bypass Graft-Patch)
rial (328), routine ICD insertion did not improve survival
n patients with coronary artery disease undergoing bypass
urgery who were believed to be at high risk of sudden death
n the basis of an abnormal signal-averaged ECG and
evere LV dysfunction (LVEF less than or equal to 35%).
imilar data about the effects of percutaneous revasculariza-
ion are not available. In DINAMIT (Defibrillator in Acute
yocardial Infarction Trial) (331), 674 patients with a
ecent MI (within 6 to 40 days), reduced LV function
LVEF less than or equal to 35%), and impaired cardiac
utonomic function (depressed heart rate variability or
levated average heart rate) were randomized to either ICD
herapy or no ICD therapy. Although arrhythmic death was
educed in the ICD group, there was no difference in total
ortality (18.7% versus 17.0%; HR for death in the ICD
roup 1.08; p0.66). See Table 5 for further information.
able 5. Major Implantable Cardioverter-Defibrillator Trials for P
Trial Year
Patients
(n)
Inclusion Criterion:
LVEF % Less Than or
Equal to
ADIT I (327) 1996 196 35
ADIT II (332) 2002 1232 30
ABG-Patch (328) 1997 900 36
EFINITE (369) 2004 485 35
INAMIT (331) 2004 674 35
CD-HeFT (333) 2005 1676 35
VID (319) 1997 1016 40
ASH† (323) 2000 191 M: 4518 at baseline
IDS (322) 2000 659 35
Hazard ratios for death due to any cause in the implantable cardioverter-defibrillator gro
ardioverter-defibrillator and amiodarone patients from CASH. ‡Upper bound of 97.5% confiden
AVID indicates Antiarrhythmics Versus Implantable Defibrillators; CABG, coronary artery bypas
EFINITE, Defibrillators in Nonischemic Cardiomyopathy Treatment Evaluation; DINAMIT, Defibrill
eft ventricular dysfunction; LVEF, left ventricular ejection fraction; MADIT I, Multicenter Automati
yocardial infarction; NA, not applicable; NICM, nonischemic cardiomyopathy; NS, not statistically sig
AECG, signal-averaged electrocardiogram; and SCD-HeFT, Sudden Cardiac Death in Heart Failure Tria.2.2. Nonischemic Dilated Cardiomyopathy
ultiple randomized prospective trials now supplement the
vailable observational studies that have reported on the role
f the ICD in primary prevention of SCD in patients with
onischemic DCM (16,224,333,369–379). Observational
tudies suggest that up to 30% of deaths in patients with
CM are sudden (380). Mortality in medically treated
atients with DCM and a prior history of syncope may
xceed 30% at 2 years, whereas those treated with an ICD
xperience a high frequency of appropriate ICD therapy
16,372,373).
CAT (Cardiomyopathy Trial) enrolled patients with
ecently diagnosed DCM with randomization to medical
herapy versus medical therapy with an ICD (377). The
tudy was terminated before the primary end point was
eached because of a lower-than-expected incidence of
ll-cause mortality (377). There was no statistical probabil-
ty of finding a significant survival advantage with either
trategy. With 50 patients in the ICD arm and 54 in the
ontrol group, the study was underpowered to find a
ifference in survival with ICD therapy. At the time of
-year follow-up, there were fewer deaths in the ICD group
han in the control group (13 versus 17, respectively) (377).
Another inconclusive trial was the AMIOVIRT (Amio-
arone Versus Implantable Defibrillator in Patients with
onischemic Cardiomyopathy and Asymptomatic Nonsus-
ained Ventricular Tachycardia) study (378). The trial
andomized 103 patients with DCM, LVEF less than or
qual to 35%, and nonsustained VT to amiodarone or ICD.
he study was stopped prematurely due to statistical futility
n reaching the primary end point of reduced total mortality
378). The DEFINITE (Defibrillators in Nonischemic
ardiomyopathy Treatment Evaluation) trial randomized
ntion of Sudden Cardiac Death
Other Inclusion
Criteria
Hazard
Ratio*
95%
Confidence
Interval p
NSVT and positive EP 0.46 0.26 to 0.82 0.009
Prior MI 0.69 0.51 to 0.93 0.016
Positive SAECG and
CABG
1.07 0.81 to 1.42 0.64
NICM, PVCs, or NSVT 0.65 0.40 to 1.06 0.08
6 to 40 days after MI
and impaired HRV
1.08 0.76 to 1.55 0.66
Prior MI or NICM 0.77 0.62 to 0.96 0.007
Prior cardiac arrest 0.62 0.43 to 0.82 0.02
Prior cardiac arrest 0.77 1.112‡ 0.081§
Prior cardiac arrest,
syncope
0.82 0.60 to 1.10 NS
pared with the non-implantable cardioverter-defibrillator group. †Includes only implantable
val. §One-tailed.
surgery; CASH, Cardiac Arrest Study Hamburg; CIDS, Canadian Implantable Defibrillator Study;
Acute Myocardial Infarction Trial; EP, electrophysiological study; HRV, heart rate variability; LVD,
rillator Implantation Trial I; MADIT II, Multicenter Automatic Defibrillator Implantation Trial II; MI,reve
up com
ce inter
s graft
ator in
c Defibnificant; NSVT, nonsustained ventricular tachycardia; PVCs, premature ventricular complexes;
l.
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lass I to III heart failure, LVEF less than or equal to 35%,
nd more than 10 premature ventricular complexes per hour
r nonsustained VT to optimal medical therapy with or
ithout an ICD (369). With a primary end point of
ll-cause mortality, statistical significance was not reached,
ut there was a strong trend toward reduction of mortality
ith ICD therapy (p0.08). After 2 years, mortality was
4.1% in the standard therapy group versus 7.9% among
hose receiving an ICD, which resulted in a 6.2% absolute
eduction and a 35% relative risk reduction with ICD
mplantation (369). The results were consistent and com-
arable to those of other similar trials (16,333,379).
SCD-HeFT compared amiodarone, ICD, and optimal
edical therapy in 2521 patients with coronary artery
isease or nonischemic cardiomyopathy with NYHA func-
ional Class II or III heart failure and LVEF less than or
qual to 35% (333). The amiodarone treatment group
eceived the drug by way of a double-blinded, placebo-
ontrolled design (333). The median follow-up was 45.5
onths. The absolute mortality decrease in the medical
roup was 7.2% after 5 years in the overall population. The
CD group experienced a decreased risk of death of 23%
ompared with the placebo group (HR 0.77, 97.5% CI 0.62
o 0.96), and total mortality in the medical group was 7.2%
er year, with a risk reduction of 23% in the ICD group
ersus placebo (95% CI 0.62 to 0.96; p0.007). Relative
isk reduction was comparable for the group with LV
ysfunction due to prior MI and the nonischemic group,
ut absolute mortality was lower in the nonischemic group.
his resulted in a greater number needed to treat per life
aved among ischemic patients. There was no mortality
ifference between the amiodarone and placebo groups.
urther risk stratification may decrease the number of
ndividuals needed to undergo ICD implantation to save a
ife in this population.
With the exception of DEFINITE (25% in the ICD
rm), trials assessing ICD therapy in primary prophylaxis of
CM have not generally included asymptomatic patients in
YHA functional Class I; therefore, the efficacy of ICDs in
his population is not fully known. Because mortality may be
ow in this subgroup, the benefit of ICD therapy is
oderate at best (369).
The COMPANION trial randomized patients with
lass III or IV heart failure, ischemic or nonischemic
CM, and QRS duration greater than 120 milliseconds in
1:2:2 ratio to receive optimal pharmacological therapy
lone or in combination with CRT with either a pacemaker
r a pacemaker-defibrillator (224). Of the 1520 patients
andomized in the trial, 903 were allocated to either the
edical therapy or defibrillator arms; of this subset, 397
44%) had DCM. Cardiac resynchronization with an ICD
ignificantly reduced all-cause mortality compared with
harmacological therapy alone in patients with DCM (HR
or all-cause death 0.50, 95% CI 0.29 to 0.88; p0.015) (224). sTwo studies have evaluated the time dependence of risk
or sudden death relative to the time of diagnosis of
onischemic DCM (369,381). An analysis of the DEFI-
ITE study demonstrated that those who have a recent
ardiomyopathy diagnosis do not benefit less from use of an
CD than those with a remote diagnosis (369). On the basis
f these data, ICD therapy should be considered in such
atients provided that a reversible cause of transient LV
unction has been excluded and their response to optimal
edical therapy has been assessed. The optimal time re-
uired for this assessment is uncertain; however, another
nalysis determined that patients with nonischemic DCM
xperienced equivalent occurrences of treated and poten-
ially lethal arrhythmias irrespective of diagnosis duration
381). These findings suggest that use of a time qualifier
elative to the time since diagnosis of a nonischemic DCM
ay not reliably discriminate patients at high risk for SCD
n this selected population (381). Given these consider-
tions, physicians should consider the timing of defibrillator
mplantation carefully.
.2.3. Long-QT Syndrome
he long-QT syndromes represent a complex spectrum of
lectrophysiological disorders characterized by a propensity
or development of malignant ventricular arrhythmias, es-
ecially polymorphic VT (382,383). Because this is a
rimary electrical disorder, with most patients having no
vidence of structural heart disease or LV dysfunction, the
ong-term prognosis is excellent if arrhythmia is controlled.
ong-term treatment with beta blockers, permanent pacing,
r left cervicothoracic sympathectomy may be helpful (384–
86). ICD implantation is recommended for selected pa-
ients with recurrent syncope despite drug therapy, sus-
ained ventricular arrhythmias, or sudden cardiac arrest
349,351,352,387,388). Furthermore, use of the ICD for
rimary prevention of SCD may be considered when there
s a strong family history of SCD or when compliance or
ntolerance to drugs is a concern (349,351,352,387,388).
The clinical manifestations of a long-QT mutation may
e influenced by the specific gene involved and the func-
ional consequences of the mutation in that gene. Risk
tratification of patients with long-QT syndrome continues
o evolve, with data from genetic analysis becoming increas-
ngly useful for clinical decision making (389–394).
.2.4. Hypertrophic Cardiomyopathy
ost individuals with HCM are asymptomatic, and the
rst manifestation of the condition may be SCD (245,395–
00). SCD in patients with HCM is generally related to
entricular arrhythmia thought to be triggered by factors
uch as ischemia, outflow obstruction, or AF (339). SCD is
ess frequently due to bradycardia (16,339). Among selected
igh-risk patients, the annual mortality from HCM has
een estimated to be as high as 6% in reports from tertiary
enters (245,395–398). However, community-based studies
uggest a more benign disease in the majority of individuals,
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16,401–403).
Risk factors for SCD have been derived from multiple
bservational studies and registries (339,404–408). A con-
ensus document on HCM from the ACC and the Euro-
ean Society of Cardiology categorized known risk factors
or SCD as “major” and “possible” in individual patients
395). The major risk factors include prior cardiac arrest,
pontaneous sustained VT, spontaneous nonsustained VT,
amily history of SCD, syncope, LV thickness greater than
r equal to 30 mm, and an abnormal blood pressure
esponse to exercise (395). This consensus document also
oted possible risk factors, which included AF, myocardial
schemia, LV outflow obstruction, high-risk mutations, and
ntense (competitive) physical exertion (395). The severity
f other symptoms, such as dyspnea, chest pain, and effort
ntolerance, has not been correlated with increased risk of
CD (16,395). A flat or hypotensive response to upright or
upine exercise testing in patients younger than 40 years old
as been shown to be a risk factor for SCD, although the
ositive predictive value of this finding is low (395). A
ormal blood pressure response identifies a low-risk group
16,395). The presence of nonsustained VT on Holter
onitoring has been associated with a higher risk of SCD,
lthough the positive predictive accuracy is relatively low
395). Recent analyses indicate that in a high-risk HCM
ohort, ICD interventions were frequent and were highly
ffective in restoring normal sinus rhythm (245). However,
n important proportion of ICD discharges occur in pri-
ary prevention patients who undergo implantation of the
CD for a single risk factor. Therefore, a single risk marker
f high risk for sudden cardiac arrest may be sufficient to
ustify consideration for prophylactic ICD implantation in
elected patients (245).
Although no randomized studies are available, the ICD
as been used in patients with cardiac arrest, sustained VT,
r VF, with a high percentage of patients receiving appro-
riate ICD discharge during follow-up at a rate of 11% per
ear (245,339). In a nonrandomized study of ICD implan-
ation in HCM, ICD implantation in a subgroup of patients
or primary prophylaxis on the basis of perceived high risk
or SCD (syncope, family history of SCD, nonsustained
T, inducible VT, or septal thickness greater than or equal
o 30 mm) resulted in a lower rate of appropriate discharge
f 5% per year (245,339). The ICD is not indicated in the
ajority of asymptomatic patients with HCM, who will
ave a relatively benign course. Its role is individualized in
he patient considered to be at high risk for SCD
245,339,395). Although precise risk stratification has not
een validated, patients with multiple risk factors (especially
evere septal hypertrophy, greater than or equal to 30 mm)
nd those with SCD (especially multiple SCDs) in close
elatives appear to be at sufficiently high risk to merit
onsideration of ICD therapy (16,245). a.2.5. Arrhythmogenic Right Ventricular Dysplasia/
ardiomyopathy
elected patients with ARVD/C may be at risk for SCD.
ecause clinical series have reported favorable outcomes
ith this therapy for primary prevention of SCD in
RVD/C, the ICD has assumed a larger role in therapy
16,341,342,345–348,409,410). On the basis of the avail-
ble clinical data from observational studies, it is reasonable
o conclude that the ICD is a reasonable therapy for
econdary prevention of sudden cardiac arrest in patients
ith ARVD/C (16,341,342,345–348,409,410).
When the ICD is being considered for primary preven-
ion, it should be kept in mind that predictive markers of
CD in patients with ARVD/C have not yet been defined
n large prospective studies focusing on survival
16,341,342,345–348,409,410). Risk factors that have clin-
cal utility in identifying patients with ARVD/C who are at
isk for life-threatening ventricular arrhythmias include
nduction of VT during electrophysiological testing, detec-
ion of nonsustained VT on noninvasive monitoring, male
ender, severe RV dilation, and extensive RV involvement
16,341,342,345–348,409,410). Young age at presentation
less than 5 years), LV involvement, prior cardiac arrest, and
nexplained syncope serve as markers of risk (341,342,346–
48,411,412). Patients with genotypes of ARVD/C associ-
ted with a high risk for SCD should be considered for ICD
herapy (345).
Although the role of ICD therapy for primary prevention
f sudden death in patients with ischemic heart disease and
ilated, nonischemic cardiomyopathy is well established on
he basis of multiple clinical trials with a consistent finding
f benefit, the data supporting ICD use in patients with
RVD/C are less extensive (16,341,342,345–348,409,410).
ome authorities have proposed that an ICD should be
mplanted in patients with ARVD/C and an increased risk
or SCD based on the presence of a previous cardiac arrest,
yncope due to VT, evidence of extensive RV disease, LV
nvolvement, or presentation with polymorphic VT and
VA aneurysm, which is associated with a genetic locus on
hromosome 1q42-43 (16,341,342,345–348,409,410).
It is evident that there is not yet clear consensus on the
pecific risk factors that identify those patients with
RVD/C in whom the probability of SCD is sufficiently
igh to warrant an ICD for primary prevention. In the
uture, the results of large prospective registries with rigor-
us enrollment criteria for patients with ARVD/C in whom
CDs have been placed for primary prevention will give
nsights into the optimal risk stratification techniques for
rimary prevention. In the meantime, individualized deci-
ions for primary prevention of SCD must be based on
xperience, judgment, and the available data. In considering
his decision, the clinician should be mindful that in
atients with ARVD/C, the ICD has proved safe and
eliable in sensing and terminating sustained ventricular
rrhythmias. Sudden death is rare in the available clinical
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41,342,345–348,409,410).
.2.6. Noncompaction of the Left Ventricle
oncompaction of the LV is a rare congenital cardiomyop-
thy characterized anatomically by excessive prominent
rabeculae and deep intertrabecular recesses in the LV
ithout other major congenital cardiac malfunction
410,413–421). The origin of the anatomic abnormalities is
ikely due to an arrest of normal embryogenesis of the
ndocardium and epicardium of the ventricle during devel-
pment. This leads to suspension of the normal compaction
rocess of the loose myocardial meshwork. Diagnosis is
ifficult and is frequently missed or delayed owing to lack of
nowledge about this uncommon disease. Echocardio-
raphy is considered by many to be the diagnostic procedure
f choice, but some cases are detected by computed tomog-
aphy or magnetic resonance imaging. Abnormalities in the
esting ECG, including bundle-branch block or ST-
egment depression, are found in most patients, but the
ndings do not have a high degree of sensitivity or speci-
city (410,413–421).
Ventricular arrhythmias and sudden death are among the
ajor complications of this disorder. Sudden death can
ccur at any age, and there are currently no techniques
linically useful for risk stratification for life-threatening
entricular arrhythmias with noncompaction. Although
here is no impairment of systolic function, ventricular
rrhythmias are frequent in noncompaction. Approximately
0% of children with noncompaction demonstrate complex
entricular arrhythmias. Available clinical data indicate that
udden death is the most common cause of mortality.
lthough there are no prospective trials or registry data,
here are sufficient observational data to indicate that
lacement of an ICD as a strategy to reduce the risk of
udden death is a reasonable clinical strategy (410,413–421).
.2.7. Primary Electrical Disease (Idiopathic Ventricular
ibrillation, Short-QT Syndrome, Brugada Syndrome,
nd Catecholaminergic Polymorphic Ventricular
achycardia)
he Brugada syndrome is characterized by ST-segment
levation across the right precordial leads in association with
high risk of SCD (16,422–425). Although the Brugada-
attern ECG most commonly shows J-point segment ele-
ation in leads V1 to V3 and right bundle-branch block, the
CG pattern can be intermittent (16). Less commonly, the
-point elevation occurs in the inferior leads (16). Patients
ith the Brugada syndrome have a structurally normal heart
ith a primary channelopathy (16,426). This is transmitted
ith an autosomal dominant pattern of inheritance, and
ore than 90% of those affected are male. The genetic basis
or the Brugada syndrome involves the cardiac sodium
hannel gene (SCN5A) (16,426).
Cardiac events such as syncope or cardiac arrest occur
redominantly in the third and fourth decades of life, although presentation with cardiac arrest in neonates or
hildren has been reported (16,422,424). Fever can acutely
redispose to cardiac arrest in the Brugada syndrome
16,422–424).
Risk stratification for SCD in patients with the Brugada
yndrome is of clinical importance, because implantation of
n ICD is the only prophylactic measure able to prevent
CD (16,422–424). As with long-QT syndrome, there are
o data showing that family history predicts cardiac events
mong family members with the Brugada syndrome (16).
ccordingly, asymptomatic individuals with the character-
stic ECG but with no family history are not necessarily at
ow risk (16). Additionally, family members of an individual
ith SCD due to Brugada syndrome should not be assumed
o be at increased risk of SCD (16). Patients with a
pontaneous Brugada pattern have a worse prognosis than
ndividuals in whom the typical ECG is observed only after
harmacological drug challenge (16,422–424). Patients
ith syncope and the ECG pattern of spontaneous ST-
egment elevation have a 6-fold higher risk of cardiac arrest
han patients without syncope and the spontaneous ECG
attern (16,422,424).
The role of electrophysiological testing remains contro-
ersial in the Brugada syndrome. Although some investiga-
ors suggest that electrophysiological testing has a useful
ole in risk stratification, others have not confirmed this
bservation. Electrophysiological testing had a low positive
redictive value (23%), but over a 3-year follow-up, it had a
ery high negative predictive value (93%) (16,422,424). By
ontrast, Priori et al. reported that electrophysiological
esting has a low accuracy in predicting individuals who will
xperience cardiac arrest (16,410). Priori et al. have pro-
osed that noninvasive risk stratification based on the ECG
nd symptoms provides an accurate alternative for risk
tratification (16,410).
Because only a single gene has been linked to the Brugada
yndrome, there is still insufficient information about the
ontribution of genetic defects in predicting clinical out-
ome (16,410,426). Specific mutations in the SCN5A gene
o not identify a subset of patients at higher risk of cardiac
vents (16,410,426). SCD is caused by rapid polymorphic
T or VF that frequently occurs at rest or during sleep (16).
atients with Brugada syndrome usually do not have ven-
ricular extrasystoles or nonsustained runs of VT at Holter
ecording. Therefore, the therapeutic approach for these
atients is centered on the prevention of cardiac arrest.
Catecholaminergic polymorphic VT is characterized by
entricular tachyarrhythmias that develop in relation to phys-
cal or emotional stress in the presence of a resting ECG that
hows no diagnostic abnormalities at rest (16,428–431). The
nitial symptoms often manifest during childhood, although
ate-onset cases have been described (16,385,410,427–431).
atecholaminergic polymorphic VT is transmitted by either
n autosomal dominant or recessive inheritance pattern.
pproximately one-half of the autosomal dominant casesre caused by mutations in the gene encoding the cardiac
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May 27, 2008:e1–62 ACC/AHA/HRS Guidelines for Device-Based Therapyyanodine receptor (RyR2) (16). This receptor is responsible
or calcium release from the stores of the sarcoplasmic
eticulum (16). Mutations in the gene that encodes calse-
uestrin (CASQ2), a calcium buffering protein in the
arcoplasmic reticulum, have been associated with the re-
essive form of catecholaminergic polymorphic VT (16).
Risk stratification for SCD in catecholaminergic poly-
orphic VT is not possible given the relatively small
umber of patients reported. Most clinical reports indicate
hat beta blockers appear to be an effective treatment.
atients who have had an episode of VF are considered at
igher risk and are usually treated with an ICD in addition
o beta-blocker therapy (16,385,410,431). The recurrence of
ustained VT, hemodynamically untolerated VT, or syncope
or which causes other than VT are excluded while the
atient is receiving a beta blocker are similarly considered
arkers of higher risk (16). In such patients, an ICD is a
ommonly used and reasonable approach (16). Further-
ore, electrophysiological testing is not useful in the man-
gement of patients with catecholaminergic polymorphic
T since the arrhythmia is usually not inducible with
rogrammed ventricular stimulation (16,385,410,431).
oth supraventricular and ventricular arrhythmias are usu-
lly reproducibly induced by exercise stress test (16,385,
10,431). Isolated premature ventricular complexes gener-
lly precede runs of nonsustained VT (16). With continued
xercise, the runs of VT typically increase in duration, and
T may become sustained (16). A beat-to-beat alternating
RS axis that changes by 180° (“bidirectional VT”) is a
ypical pattern of catecholaminergic polymorphic VT-
elated arrhythmias (16). Catecholaminergic polymorphic
T patients can also present with irregular polymorphic VT
r VF (16). Beta blockers are generally effective in prevent-
ng recurrences of syncope even when arrhythmias can still
e elicited during an exercise stress test (16). If syncope
ccurs in a patient taking a beta blocker, implantation of an
CD is recommended (16).
VF has been reported in patients with abnormal repolar-
zation due to ion channel mutations that result in a
arkedly shortened QT interval (432). Only a few small
eries of such patients have been described, and at present,
vidence-based recommendations about management of
symptomatic individuals with a short QT interval cannot
e made. Some patients who survive a clinical episode of VF
ave no identifiable structural heart disease, no documented
ransient cause for arrhythmia, and no known ion channel
efect. In such patients, VF is termed “idiopathic.” ICD
herapy is appropriate for secondary prevention in patients
ith the short-QT syndrome and idiopathic VF.
.2.8. Idiopathic Ventricular Tachycardias
onomorphic VT may be seen in individuals with struc-
urally normal hearts who have no known ion channelopa-
hies. The most common sites of origin are the RV outflow
ract, the fascicular region of the LV, structures in the LV wutflow tract, and the mitral annular region. The risk for
udden death related to these arrhythmias is low (433).
.2.9. Advanced Heart Failure and Cardiac Transplantation
atients with moderate to severe heart failure face the twin
isks of terminal heart failure decompensation and death
ue to unanticipated ventricular tachyarrhythmias. When
CD or CRT-D implantation is discussed with these
atients, the likelihood of both life-saving and inappropriate
hocks should be placed in the context of the overall
nticipated mortality with heart failure, the expected dura-
ion of life prolongation after effective therapies, and the
ikely evolution to limiting symptoms and ultimately death
ue to pump failure (434). The relative contribution of
reventable sudden death to mortality decreases with re-
eated hospitalizations and multiple comorbidities, partic-
larly in the setting of kidney dysfunction or advanced age.
hese factors, whether cardiac or noncardiac, also influence
he value that patients place on quality versus length of life
emaining. However, individual preferences cannot be as-
umed and should be explored with each patient.
Candidates for transplantation constitute a special case of
evere heart failure because of the likelihood of prolonged
urvival after transplantation, with 50% of patients currently
urviving at 10 years after transplantation. The high rate of
udden death on the transplant waiting list merits ICD
mplantation in most candidates with heart failure who are
waiting transplantation out of the hospital. The ICD has
een highly effective as a bridge to transplantation for these
ndividuals both with and without a prior history of life-
hreatening arrhythmias.
Class IV status itself is a heterogenous and dynamic state
435) in which the absolute incidence of sudden death
ncreases but the proportion of sudden deaths prevented by
CDs declines, and heart failure deaths account for a greater
roportion of overall mortality. Once patients have persis-
ent or frequently recurrent Class IV symptoms despite
ptimal management, life expectancy is less than 12
onths, and ICD implantation is not indicated, regardless
f patient and family preferences. Occasionally, patients
annot be weaned from intravenous inotropic infusions and
re discharged with chronic inotropic infusion therapy for
ymptom palliation, with the expectation that death due to
eart failure will likely occur within the next 6 months.
espite the proarrhythmic potential of inotropic agents,
hese patients receiving chronic infusions should not be
iven an ICD (unless awaiting transplantation or other
efinitive therapy).
Often, patients hospitalized with Class IV symptoms will
ndergo substantial improvement and can be discharged on
ral therapy with minimal or no symptoms at rest. For these
atients who can remain stable at 1 month after discharge,
ithout evidence of recurrent congestion or worsening renal
unction, survival is similar to that of other Class III patients
ho have not been recently hospitalized. In this situation,
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mprove survival.
Patients with Class IV symptoms of heart failure with
rolonged QRS duration and optimal lead placement may
eturn to Class III status or better for both function and
urvival, at which point prevention of sudden death again
ecomes a relevant goal. Information on this group is
imited because only 10% of the almost 4000 patients in
esynchronization trials have had Class IV symptoms. In the
OMPANION trial (224), there were Class IV patients for
hom resynchronization improved QOL and reduced re-
ospitalization and mortality; however, these patients had
een stable at home before study entry and may not
epresent typical Class IV patients. Even in this selected
roup, there was no difference in 2-year survival between
RT patients with and without the defibrillator feature
230). In patients with Class IV symptoms in whom
esynchronization is inadequate to restore clinical stability,
he presence of a defibrillator often complicates the impend-
ng transition to end-of-life care.
ecommendations for Implantable Cardioverter
efibrillators
econdary prevention refers to the prevention of SCD in
hose patients who have survived a prior cardiac arrest or
ustained VT. Primary prevention refers to the prevention
f SCD in individuals without a history of cardiac arrest or
ustained VT. Patients with cardiac conditions associated
ith a high risk of sudden death who have unexplained
yncope that is likely to be due to ventricular arrhythmias are
onsidered to have a secondary indication.
Recommendations for consideration of ICD therapy,
articularly those for primary prevention, apply only to
atients who are receiving optimal medical therapy and have
reasonable expectation of survival with a good functional
tatus for more than 1 year. It is difficult to estimate survival
ith heart failure in the general population, for whom
omorbidities and age differ from those in trial populations
rom which the predictive models have been derived. Pa-
ients with repeated heart failure hospitalizations, particu-
arly in the presence of reduced renal function, are at high
isk for early death due to heart failure (436–438). See
bove for discussion regarding the use of LVEFs based on
rial inclusion criteria.
We acknowledge that the “ACC/AHA/ESC 2006
uidelines for Management of Patients With Ventricular
rrhythmias and the Prevention of Sudden Cardiac Death”
16) used the LVEF of less than 40% as a critical point to
ustify ICD implantation for primary prevention of SCD.
he LVEF used in clinical trials assessing the ICD for
rimary prevention of SCD ranged from less than or equal
o 40% in MUSTT to less than or equal to 30% in MADIT
I (329,332). Two trials, MADIT I (18) and SCD-HeFT
19) used LVEFs of less than or equal to 35% as entry
riteria for the trial. This writing committee reached con-
ensus that it would be best to have ICDs offered to patients
†
fith clinical profiles as similar to those included in the trials
s possible. Having given careful consideration to the issues
elated to LVEF for these updated ICD guidelines, we have
ritten these indications for ICDs on the basis of the
pecific inclusion criteria for LVEF in the trials. Because of
his, there may be some variation from previously published
uidelines (16).
We also acknowledge that the determination of LVEF
acks a “gold standard” and that there may be variation
mong the commonly used clinical techniques of LVEF
etermination. All clinical methods of LVEF determination
ack precision and the accuracy of techniques varies amongst
aboratories and institutions. Based on these considerations,
his writing committee recommends that the clinician use
he LVEF determination that they feel is the most clinically
ccurate and appropriate in their institution.
LASS I
. ICD therapy is indicated in patients who are survivors of cardiac
arrest due to VF or hemodynamically unstable sustained VT after
evaluation to define the cause of the event and to exclude any
completely reversible causes. (Level of Evidence: A) (16,319–324)
. ICD therapy is indicated in patients with structural heart disease
and spontaneous sustained VT, whether hemodynamically stable
or unstable. (Level of Evidence: B) (16,319–324)
. ICD therapy is indicated in patients with syncope of undeter-
mined origin with clinically relevant, hemodynamically signifi-
cant sustained VT or VF induced at electrophysiological study.
(Level of Evidence: B) (16,322)
. ICD therapy is indicated in patients with LVEF less than or equal to
35% due to prior MI who are at least 40 days post-MI and are in
NYHA functional Class II or III. (Level of Evidence: A) (16,333)
. ICD therapy is indicated in patients with nonischemic DCM who
have an LVEF less than or equal to 35% and who are in NYHA
functional Class II or III. (Level of Evidence: B) (16,333,369,379)
. ICD therapy is indicated in patients with LV dysfunction due to
prior MI who are at least 40 days post-MI, have an LVEF less than
or equal to 30%, and are in NYHA functional Class I. (Level of
Evidence: A) (16,332)
. ICD therapy is indicated in patients with nonsustained VT due to
prior MI, LVEF less than or equal to 40%, and inducible VF or
sustained VT at electrophysiological study. (Level of Evidence:
B) (16,327,329)
LASS IIa
. ICD implantation is reasonable for patients with unexplained
syncope, significant LV dysfunction, and nonischemic DCM.
(Level of Evidence: C)
. ICD implantation is reasonable for patients with sustained VT
and normal or near-normal ventricular function. (Level of Evi-
dence: C)
. ICD implantation is reasonable for patients with HCM who have
1 or more major† risk factors for SCD. (Level of Evidence: C)
. ICD implantation is reasonable for the prevention of SCD in
patients with ARVD/C who have 1 or more risk factors for SCD.
(Level of Evidence: C)See Section 3.2.4, “Hypertrophic Cardiomyopathy,” for definition of major risk
actors.
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long-QT syndrome who are experiencing syncope and/or VT while
receiving beta blockers. (Level of Evidence: B) (349–354)
. ICD implantation is reasonable for non hospitalized patients
awaiting transplantation. (Level of Evidence: C)
. ICD implantation is reasonable for patients with Brugada syn-
drome who have had syncope. (Level of Evidence: C)
. ICD implantation is reasonable for patients with Brugada syn-
drome who have documented VT that has not resulted in cardiac
arrest. (Level of Evidence: C)
. ICD implantation is reasonable for patients with catecholamin-
ergic polymorphic VT who have syncope and/or documented
sustained VT while receiving beta blockers. (Level of Evidence: C)
0. ICD implantation is reasonable for patients with cardiac sar-
coidosis, giant cell myocarditis, or Chagas disease. (Level of
Evidence: C)
LASS IIb
. ICD therapy may be considered in patients with nonischemic
heart disease who have an LVEF of less than or equal to 35% and
who are in NYHA functional Class I. (Level of Evidence: C)
. ICD therapy may be considered for patients with long-QT syn-
drome and risk factors for SCD. (Level of Evidence: B) (16,349–354)
. ICD therapy may be considered in patients with syncope and
advanced structural heart disease in whom thorough invasive
and noninvasive investigations have failed to define a cause.
(Level of Evidence: C)
. ICD therapy may be considered in patients with a familial
cardiomyopathy associated with sudden death. (Level of Evi-
dence: C)
. ICD therapy may be considered in patients with LV noncompac-
tion. (Level of Evidence: C)
LASS III
. ICD therapy is not indicated for patients who do not have a
reasonable expectation of survival with an acceptable functional
status for at least 1 year, even if they meet ICD implantation
criteria specified in the Class I, IIa, and IIb recommendations
above. (Level of Evidence: C)
. ICD therapy is not indicated for patients with incessant VT or VF.
(Level of Evidence: C)
. ICD therapy is not indicated in patients with significant psychi-
atric illnesses that may be aggravated by device implantation or
that may preclude systematic follow-up. (Level of Evidence: C)
. ICD therapy is not indicated for NYHA Class IV patients with
drug-refractory congestive heart failure who are not candidates
for cardiac transplantation or CRT-D. (Level of Evidence: C)
. ICD therapy is not indicated for syncope of undetermined cause
in a patient without inducible ventricular tachyarrhythmias and
without structural heart disease. (Level of Evidence: C)
. ICD therapy is not indicated when VF or VT is amenable to
surgical or catheter ablation (e.g., atrial arrhythmias associated
with the Wolff-Parkinson-White syndrome, RV or LV outflow tract
VT, idiopathic VT, or fascicular VT in the absence of structural
heart disease). (Level of Evidence: C)
. ICD therapy is not indicated for patients with ventricular tachy-
arrhythmias due to a completely reversible disorder in the
absence of structural heart disease (e.g., electrolyte imbalance,
drugs, or trauma). (Level of Evidence: B) (16) (.3. Implantable Cardioverter-Defibrillators in
hildren, Adolescents, and Patients With
ongenital Heart Disease
he indications for ICD implantation in young patients and
hose with congenital heart disease have evolved over the
ast 15 years based on data derived primarily from adult
andomized clinical trials. Similar to adults, ICD indica-
ions have evolved from the secondary prevention of SCD to
he treatment of patients with sustained ventricular arrhyth-
ias to the current use of ICDs for primary prevention in
atients with an increased risk of SCD. However, in
ontrast to adults, there are minimal prospective data
egarding ICD survival benefit, because fewer than 1% of all
CDs are implanted in pediatric or congenital heart disease
atients (439). Considerations such as the cumulative life-
ime risk of SCD in high-risk patients and the need for
ecades of antiarrhythmic therapy make the ICD an im-
ortant treatment option for young patients.
SCD in childhood and adolescence is associated with 3
rincipal forms of cardiovascular disease: 1) congenital heart
isease, 2) cardiomyopathies, and 3) genetic arrhythmia
yndromes (440,441). Prospective identification and treat-
ent of young patients at risk for sudden death is crucial
ecause compared with adults, a very low percentage of
hildren undergoing resuscitation survive to hospital dis-
harge (442).
The indications for ICD therapy in pediatric patients
ho have been resuscitated or who are at high risk for SCD
re similar to those for adults. Data from nonrandomized
tudies provide support for the Class I recommendation that
oung patients who have been resuscitated from SCD
hould undergo ICD implantation after a careful evaluation
o exclude any potentially reversible causes (440,443–445).
pontaneous sustained VT or unexplained syncope with
nducible sustained hypotensive VT in patients with con-
enital heart disease are also considered Class I ICD
ndications when other remediable causes (hemodynamic or
rrhythmic) have been excluded (446). Catheter ablation or
urgical therapies may provide an alternative to use of an
CD in patients with congenital heart disease and recurrent
T (447).
Recommendations regarding ICD implantation for pri-
ary prevention of SCD in young patients are based on
imited clinical experience and extrapolation of data from
dult studies. No randomized clinical trials have been
erformed to date, and given the relative infrequency of
CD in young patients, they are unlikely to be completed in
he near future. Because the risk of unexpected sudden
eath is greater in young patients than in adults with genetic
iseases such as HCM or the long-QT syndrome, a family
istory of sudden death, possibly with genetic confirmation,
ay influence the decision to implant an ICD for primary
revention. Additional risk factors to be considered in these
iseases are discussed in specific sections in this document
354,382,448).
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ACC/AHA/HRS Guidelines for Device-Based Therapy May 27, 2008:e1–62With regard to primary prevention of SCD in patients
ith congenital heart disease, the marked heterogeneity of
efects precludes generalization of risk stratification. Unex-
ected sudden death is reported in 1.2% to 3.0% of patients
er decade after surgical treatment of tetralogy of Fallot,
ith risk factors including ventricular dysfunction, QRS
uration, and atrial and ventricular arrhythmias (249). A
ignificantly greater risk of SCD has been identified for
atients with transposition of the great arteries or aortic
tenosis, with most cases presumed to be due to a malignant
entricular arrhythmia associated with ischemia, ventricular
ysfunction, or a rapid ventricular response to atrial flutter
r fibrillation (449–451).
The risk of SCD associated with systemic ventricular
ysfunction in congenital heart disease patients remains
ontroversial (452,453). The ability to define the risk
ssociated with impaired function is complicated by the fact
hat right (pulmonary) ventricular dysfunction is more
ommon than left (systemic) ventricular dysfunction and
hat a variety of atrial arrhythmias and conduction blocks
ay independently predispose these patients to arrhythmias
r syncope. The lack of prospective and randomized clinical
rials precludes exact recommendations regarding risk strat-
fication and indications for ICD implantation for primary
revention of SCD in patients with postoperative congenital
eart disease and ventricular dysfunction. One other poten-
ial ICD indication in young patients, which is similar to
dults, is the patient with congenital coronary anomalies or
oronary aneurysms or stenoses after Kawasaki disease, in
hich an ischemic substrate for malignant arrhythmias may
e present (441).
Because of concern about drug-induced proarrhythmia
nd myocardial depression, an ICD (with or without CRT)
ay be preferable to antiarrhythmic drugs in young patients
ith DCM or other causes of impaired ventricular function
ho experience syncope or sustained ventricular arrhyth-
ias. ICDs may also be considered as a bridge to orthotopic
eart transplantation in pediatric patients, particularly given
he longer times to donor procurement in younger patients
454,455).
ecommendations for Implantable Cardioverter-
efibrillators in Pediatric Patients and Patients With
ongenital Heart Disease
LASS I
. ICD implantation is indicated in the survivor of cardiac arrest
after evaluation to define the cause of the event and to exclude
any reversible causes. (Level of Evidence: B) (440,443–445)
. ICD implantation is indicated for patients with symptomatic
sustained VT in association with congenital heart disease who
have undergone hemodynamic and electrophysiological evalua-
tion. Catheter ablation or surgical repair may offer possible alterna-
tives in carefully selected patients. (Level of Evidence: C) (447)
LASS IIa
. ICD implantation is reasonable for patients with congenital heart
disease with recurrent syncope of undetermined origin in the mpresence of either ventricular dysfunction or inducible ventricular
arrhythmias at electrophysiological study. (Level of Evidence: B)
(18,446)
LASS IIb
. ICD implantation may be considered for patients with recurrent
syncope associated with complex congenital heart disease and
advanced systemic ventricular dysfunction when thorough inva-
sive and noninvasive investigations have failed to define a cause.
(Level of Evidence: C) (451,454)
LASS III
. All Class III recommendations found in Section 3, “Indications for
Implantable Cardioverter-Defibrillator Therapy,” apply to pediat-
ric patients and patients with congenital heart disease, and ICD
implantation is not indicated in these patient populations. (Level
of Evidence: C)
.3.1. Hypertrophic Cardiomyopathy
rior studies of ICD therapy for primary and secondary
revention of SCD in HCM are discussed in Sections 3.1.5
nd 3.2.4; most of these studies have included both pediatric
nd adult patients. The indications for ICDs in pediatric
atients with HCM for primary and secondary prevention
f sudden cardiac arrest are the same as those for adults.
linical decisions should be based on risks and benefits that
ay be unique to pediatric patients. In the pediatric
opulation, recommendations for ICD therapy should be
ade with careful consideration of the risks of device
mplantation, which may be increased on the basis of body
ize. Additionally, consideration should be given to the
dditional years of benefit that could potentially result from
revention of SCD in this population.
.4. Limitations and Other Considerations
.4.1. Impact on Quality of Life (Inappropriate Shocks)
espite its life-saving potential, the use of ICD therapy
arries a risk for psychological consequences and may lead to
decrement in QOL, particularly among patients who have
xperienced shocks (456). Reports of significant behavioral
isorders, including anxiety, device dependence, or social
ithdrawal, have been described with ICD implantation
457–459). However, QOL substudies from large, random-
zed clinical trials of ICD therapy demonstrated that overall,
OL was no different or was somewhat better among
atients randomized to ICD therapy than among those in
he control groups, with decreases in physical, emotional,
nd psychological measures of health-related QOL concen-
rated among patients who experienced ICD shocks
328,367,460). Given the broader indication for and marked
ncrease in implantation of ICDs for primary prevention
hat is being driven by the results of the SCD-HeFT and
ADIT II trials (332,333), understanding the frequency
nd causes of inappropriate shocks and devising manage-
ent strategies to mitigate both inappropriate therapies and
t
t
p
t
t
i
p
S
i
l
d
p
e
p
v
r
u
m
4
a
Q
4
P
i
d
o
r
a
i
d
i
o
r
r
d
d
c
p
d
b
p
s
R
b
t
i
c
0
d
t
t
d
r
c
e
a
R
t
b
e
(
3
S
s
m
s
a
2
p
v
3
t
p
(
m
o
t
s
i
o
l
l
d
a
t
p
c
e
p
t
I
p
d
p
h
L
c
r
a
m
a
m
l
o
(
e39JACC Vol. 51, No. 21, 2008 Epstein et al.
May 27, 2008:e1–62 ACC/AHA/HRS Guidelines for Device-Based Therapyheir psychological and QOL consequences will be impor-
ant for an increasingly large segment of the population.
A systematic review summarized the frequency of inap-
ropriate ICD therapies reported in randomized clinical
rials of primary and secondary prevention (461). In these
rials, during follow-up that ranged from 20 to 45 months,
nappropriate ICD therapy was delivered in 10% to 24% of
atients. In the PainFREE Rx II (Pacing Fast VT Reduces
hock Therapies II) trial, in which patients were random-
zed to either ATP or shocks as first therapy for fast VT, at
east 1 inappropriate detection occurred in 15% of patients
uring approximately 11 months of follow-up (294). The
roportion of detections that were inappropriate was mod-
stly but not significantly higher among primary prevention
atients than among secondary prevention patients (46%
ersus 34%; p0.09). Both older and more recent registry
eports suggest similar rates of inappropriate therapy in
nselected populations (462,463).
By far, the leading cause of inappropriate therapy is the
isclassification of SVT, most commonly AF (294,358,
62,463). But ICD lead malfunction and other causes, such
s oversensing of T waves, double counting of prolonged
RS, and electromagnetic interference, may account for
% to 30% of inappropriate therapy (305,367,462,464).
atients with multiple ICD shocks should be evaluated
mmediately to determine the cause of the shocks and to
irect urgent management. Short-term therapy with anxi-
lytic drugs may be instituted early for patients after
ecurrent device firings to minimize acute and delayed
nxiety reactions.
A variety of approaches to reduce the occurrence of
nappropriate shocks are currently available, and selection
epends on the cause of the shocks and the type of device
mplanted. Although there has been debate as to the utility
f dual-chamber versus single-chamber devices in reducing
ates of inappropriate ICD therapy, a recently published
andomized trial suggests that optimal programming of
ual-chamber devices can reduce the rate of inappropriate
etections and therapies due to SVTs (465). In the multi-
enter Detect Supraventricular Tachycardia Study, 400
atients with a clinical indication for an ICD received
ual-chamber devices and were randomized in a single-
lind fashion to optimal single- or dual-chamber detection
rogramming. SVT occurred in 34% of subjects (31% in the
ingle-chamber arm and 37% in the dual-chamber arm).
ates of inappropriate detection of SVT were substantial in
oth arms (39.5% in the single-chamber arm and 30.9% in
he dual-chamber arm), but the adjusted odds ratio of
nappropriate detection of SVT in the dual-chamber arm
ompared with the single-chamber arm was 0.53 (95% CI
.30 to 0.94; p0.03). This reduction in inappropriate
etection translated to a similar reduction in inappropriate
herapy, with no compromise of VT detection, which makes
his trial the first to show superiority of dual-chamber
evices when optimally programmed. Other areas of active
esearch include the development of enhanced mathemati- mally modeled detection protocols for evaluation of internal
lectrograms to improve discrimination of SVT from VT
nd to increase the ability to detect lead failures (466–468).
egardless of the cause of or solution for inappropriate ICD
herapy (particularly shocks), careful attention to a team-
ased approach that includes the patient and family in
motional and psychological support is also recommended
456,469).
.4.2. Surgical Needs
urgically placed epicardial pacing leads are indicated in
elected instances when standard transvenous lead place-
ent is either not feasible or contraindicated. Examples of
uch circumstances include: 1) inability or failure to place an
dequate LV lead in patients requiring biventricular pacing,
) indications for permanent pacing in certain pediatric
atients and in pediatric or adult patients with tricuspid
alve prostheses or recurrent or prolonged bacteremia, and
) congenital acquired venous anomalies that preclude
ransvenous access to the heart.
The reported success rate of coronary venous lead im-
lantation for biventricular pacing ranges from 81% to 99%
470,471). Causes of failed percutaneous lead placement
ay be anatomic (superior vena cava or coronary sinus
bstruction or inadequate coronary venous anatomy) or
echnical (failure to cannulate the coronary sinus, coronary
inus dissection, inadequately high pacing thresholds with
ntermittent capture, diaphragmatic pacing due to proximity
f the phrenic nerve to the target coronary sinus branch, or
ead dislodgement) (470,472,473). When coronary sinus
ead implantation fails, several nonrandomized studies have
emonstrated that surgical LV lead placement is almost
lways successful (470–473). In this setting, the key advan-
age of surgical lead placement is access to the entire
osterior and lateral walls of the LV, which enables the
hoice of the best pacing site (471,474). The combination of
chocardiography with tissue Doppler imaging and electro-
hysiological measurements may facilitate the choice of a
ransthoracically directed LV epicardial pacing site (473).
mplantation of 2 epicardial leads may be considered to
rovide backup capability if 1 lead should fail or become
islodged (475). Steroid-eluting epicardial leads may be
referable to screw-on leads (473).
The choice of surgical procedure appears to influence
ospital morbidity. Surgical approaches for placement of
V epicardial leads include left thoracotomy, left thoracos-
opy, and robotically assisted port-based placement. Tho-
acotomy in fragile patients with heart failure has been
ssociated with bleeding, stroke, hypotension, and arrhyth-
ias (470,476). In contrast, thoracoscopic and robotic
pproaches have been reported to be associated with mini-
al morbidity and may be preferred (472,473,475). These
ess invasive procedures generally require 60 to 90 minutes
f operative time and a mean hospital stay of 4 to 5 days
472). However, not all patients are candidates for mini-
ally invasive or robotic procedures. Subjects who have
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ave limited pericardial/epicardial accessibility.
In certain instances, it may be advisable to place an LV
picardial lead at the time of concomitant cardiac surgery. In
atients who are currently or in the future may be candidates
or CRT who require coronary artery bypass grafting or
itral valve surgery and have medically refractory, symp-
omatic heart failure, ischemic cardiomyopathy or DCM,
rolonged QRS interval, LV end-diastolic diameter greater
han or equal to 55 mm, and LVEF less than or equal to
5%, the surgeon may elect to place an LV epicardial lead
477). The lead is tunneled to a prepectoral pocket for
ntraoperative or postoperative attachment to an appropriate
acing generator. This approach is probably not indicated
or the patient who is expected to have substantial improve-
ent in LVEF after cardiac surgery (e.g., the patient with
xtensive viable myocardium who is undergoing revascular-
zation). There are limited data documenting outcomes of
his “preemptive” strategy.
Epicardial leads may be necessary in some pediatric patients.
he most common indications for permanent pacemaker
mplantation in the pediatric population are SND or AV block
fter surgery for congenital heart disease and congenital AV
lock (478). In most instances, such pacing systems can be
laced by standard transvenous techniques (479). However,
picardial leads may be needed in children as a result of their
mall size, the presence of congenital heart defects with a
ight-to-left shunt, or an inability to pace the chamber desired
ecause of anatomic barriers (e.g., after a Fontan procedure)
478–480). In such instances, steroid-eluting leads provide
xcellent durability (479).
Epicardial leads are suggested in some pediatric or adult
atients who need pacing and who have recurrent or
rolonged bacteremia (481). For a single episode of device-
elated bacteremia, extraction of all hardware followed by
eimplantation by the transvenous route at a later date is
ppropriate.
Implantation of permanent epicardial pacing leads is
ndicated in the pacemaker-dependent patient undergoing
echanical tricuspid valve replacement. A prosthetic me-
hanical tricuspid valve represents an absolute contraindica-
ion to placement of transvenous RV leads, because such
eads will cross the valve and may interfere with valve
unction. This scenario occurs commonly in patients with
ricuspid valve endocarditis and a transvenous pacemaker.
t surgery, all hardware should be removed. If the tricuspid
alve is repairable, standard transvenous pacing leads can be
laced postoperatively. However, if tricuspid valve replace-
ent is necessary, epicardial ventricular leads should be
mplanted at the time of surgery.
.4.3. Patient Longevity and Comorbidities
hysicians, patients, and their families increasingly will be
aced with decisions about device-based therapies (ICD and
RT) in elderly patients who meet conventional criteria formplantation. These decisions require not only evidence of flinical benefit demonstrated in randomized clinical trials
ut also estimates of life expectancy, consideration of
omorbidities and procedural risk, and patient preferences.
lthough these factors are important when device implan-
ation is considered in any age group, they assume greater
eight in clinical decision-making among the elderly.
Unfortunately, few clinical trials of device-based therapy
ave enrolled enough elderly patients (age greater than 75
ears) to reliably estimate the benefits of device-based
herapy in this group. Indeed, patients in device trials have
enerally had an average age less than 65 years and little
omorbidity. In contrast, the average patient hospitalized
ith heart failure and low LVEF is 75 years old with 2
omorbidities. The 1-year mortality rate for this population
s in the range of 30% to 50%, with a 2-fold higher risk of
eath in patients with estimated creatinine clearance less
han 60 ml per minute (326,482). The presence of chronic
ulmonary disease and dementia further increases the risk
or death. Fewer than 10% of deaths in this population
ould be attributed to presumed SCD in patients living
ndependently (482). After 3 hospitalizations for heart
ailure in a community population, median survival declines
o 1 year and would be prolonged by only 0.3 years even if
ll presumed SCDs were prevented (5). For all patients, the
ikelihood of meaningful prolongation of life by prevention
f SCD must be assessed against the background of other
actors that limit patient function and survival.
Among 204 elderly patients with prior MI and LVEF
ess than or equal to 30% enrolled in MADIT II (total
1223), a trial of primary prevention of SCD with ICD
herapy, the HR for mortality with ICD therapy was 0.56
95% CI 0.29 to 1.08; p0.08), which was similar to that
or younger patients (HR 0.63, 95% CI 0.45 to 0.88;
0.01) (482a). Furthermore, QOL scores were similar
mong older and younger patients. Subgroup analyses by
ge (less than or equal to 65 versus greater than 65 years)
rom COMPANION and SCD-HeFT showed some ero-
ion of benefit among the older group, but there were no
ignificant treatment interactions with age (224,333).
In a study of 107 consecutive patients greater than 80
ears old (82% with ischemic cardiomyopathy) and 241
onsecutive patients 60 to 70 years of age (80% with
schemic cardiomyopathy), life expectancy after device im-
lantation (predominantly ICD alone) among the octoge-
arians was 4.2 years compared with 7 years among those 60
o 70 years old (483). Thus, although survival after implan-
ation is shorter among the elderly than among younger
roups, survival is substantial, and age itself should not be
he predominant consideration in the use of device-based
herapy among the elderly.
The presence and number of noncardiac comorbidities
re another important consideration in the decision to
roceed with device-based therapy in the elderly. In one
egistry, although age greater than 75 years and heart failure
ere important predictors of death at 1 and 2 years ofollow-up, after adjustment for age, heart failure, and
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tatistically significantly associated with survival among
467 patients who received ICD therapy (484). The pres-
nce of 3 or more noncardiac comorbidities was associated
ith a nearly 3-fold increase in the hazard for mortality (HR
.98, 95% CI 1.74 to 5.10). Therefore, as much as age, the
resence and number of noncardiac comorbidities are crit-
cal considerations in the decision to use device-based
herapy.
A meta-analysis of secondary prevention trials (AVID,
ASH, and CIDS) revealed that although ICD therapy
educed all-cause and arrhythmic death among patients less
han 75 years old, among 252 patients older than 75 years,
he HR for all-cause mortality (predominantly due to
rogressive heart failure) was 1.06 (95% CI 0.69 to 1.64;
0.79), and for arrhythmic death, it was 0.90 (95% CI
.42 to 1.95; p0.79) (485). The interaction p value was
.09, which suggests that the elderly may derive less benefit
rom ICD therapy in secondary prevention than younger
atients.
In summary, these data suggest that although age is an
mportant predictor of outcome after ICD therapy, mean
urvival of more than 4 years may be expected even among
ctogenarians, and age alone should not be used as a sole
riterion to withhold device-based therapy. However, im-
ortant considerations in the decision to use device-based
herapy should include the indication for device implanta-
ion (for ICDs, primary versus secondary prevention), the
umber of comorbidities, and patient preferences.
Considerations specific to elderly patients are also rele-
ant to pacing, CRT, and ICD therapies. Similar to
nrollment in ICD trials, few patients older than 75 years
ave been enrolled in trials of CRT. However, subgroup
nalyses from CARE-HF (age less than 66.4 versus greater
han or equal to 66.4 years) and COMPANION (age less
han or equal to 65 versus greater than 65 years) suggest that
lder patients derive similar benefit from CRT as younger
atients (224,225).
The “ACC/AHA/ESC 2006 Guidelines for Manage-
ent of Patients With Ventricular Arrhythmias and the
revention of Sudden Cardiac Death” addressed ICD
mplantation in the elderly (16). Many of those consider-
tions are relevant to other types of device implantation.
ecause of underrepresentation of the elderly in clinical
rials, much of the rationale for implanting devices in these
atients rests on subgroup analyses that were not prespeci-
ed and is therefore relatively weak. Furthermore, not only
elative efficacy but also procedural complication rates in
lder versus younger patients are largely unexplored. These
nknowns must be balanced against the fact that many
lderly patients remain functional until shortly before death
nd reasonably deserve similar treatment options as younger
atients in many cases. The ethical principles of autonomy,
eneficence (“do good and avoid evil”), and nonmaleficence
“do no harm”) must always prevail..4.4. Terminal Care
n the United States, the withholding and withdrawal of
ife-sustaining treatments (e.g., cardiopulmonary resuscita-
ion, mechanical ventilation, or hemodialysis) from termi-
ally ill patients who do not want the treatments is ethical
nd legal (486). Honoring these requests is an integral
spect of patient-centered care and should not be regarded
s physician-assisted suicide or euthanasia.
When terminally ill patients (or their surrogates) request
acemaker, ICD, or CRT deactivation, questions related to
he ethics of device deactivation may arise. Questions
ommonly asked include: Are implantable devices life-
ustaining treatments? Is deactivation the same as
hysician-assisted suicide or euthanasia? Is deactivation
thical? Is it legal? Under what conditions (e.g., code status)
hould deactivation be performed? Who should carry out
eactivation? What documentation should exist?
The prevalence of implantable devices in patients dying of
oncardiac diseases makes this an increasingly encountered
linical issue. Patients and families fear that devices will
rolong the dying process, and some dying patients with
CDs fear uncomfortable defibrillations. In fact, investiga-
ors have found that some patients with ICDs experience
ncomfortable defibrillations throughout the dying process,
ncluding moments before death. Cardiologists who im-
lant devices do not commonly have discussions with
atients about end-of-life issues and device deactivation.
urthermore, published experience with deactivation of
evices is limited (487).
There is general consensus regarding the ethical and legal
ermissibility of deactivating ICDs in dying patients who
equest deactivation (488). However, caregivers involved in
evice management generally make a distinction between
eactivating a pacemaker and deactivating an ICD or CRT
evice. Given the clinical context, all 3 can be considered
ife-sustaining treatments. Notably, all of these devices may
e refused by patients, and to impose them on patients who
o not want them is unethical and illegal (battery). Further-
ore, ethics and law make no distinction between with-
olding and withdrawing treatments.
An approach to dying patients who request pacemaker,
CD, or CRT deactivation should include the following:
A dying patient (or, if the patient lacks decision-making
capacity, the patient’s surrogate decision maker) who
requests device deactivation should be fully informed of
the consequences and alternatives to device deactivation,
and a summary of the conversation should be recorded in
the medical record.
An order for device deactivation should be accompanied
by a do-not-resuscitate (DNR) order; these orders should
be recorded in the patient’s medical record.
Psychiatric consultation should be sought in any situation
in which a dying patient who requests device deactivation
is thought to have impaired decision-making capacity.
••
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which the clinician or clinicians disagree, based on their
clinical judgment, with a request for device deactivation.
If the clinician asked to deactivate a device has personal
beliefs that prohibit him or her from carrying out device
deactivation (conscientious objection), then the patient
should be referred to another clinician.
If the patient is remote from the implanting medical
center, the clinician who is responsible for the patient’s
care at the local site should document the information
noted above in the medical record, and someone capable
of programming the device to “inactive” status should be
recruited to reprogram the device under the direction of
the local physician.
Clinicians involved in device education at the time of
mplantation may need to provide more comprehensive
nformation with regard to end-of-life issues. For example,
linicians should encourage patients undergoing device im-
lantation to complete advanced directives and specifically
ddress the matter of device management and deactivation
f the patient is terminally ill.
.5. Cost-Effectiveness of Implantable
ardioverter-Defibrillator Therapy
ong-term follow-up studies have consistently demon-
trated that cumulative medical costs are increased substan-
ially among patients receiving an ICD (17–19,489–491).
everal studies have attempted to weigh whether these
dded costs are worthwhile in light of the potential for
mproved survival among patients receiving ICD therapy
492). These studies calculate a cost-effectiveness ratio that
s defined as the difference in the total cost of patients
eceiving an ICD and patients receiving alternative therapy,
ivided by the additional life-years of survival provided by
n ICD compared with alternative therapy. A benchmark
or comparison is provided by renal dialysis, which costs
pproximately $50 000 to add 1 life-year of survival. Cost-
ffectiveness, like other outcome measures in clinical re-
earch studies, must be interpreted in light of the charac-
eristics of the study populations and the length of
ollow-up available.
The early studies of ICD cost-effectiveness were based on
athematical models and relied on nonrandomized studies
o estimate clinical efficacy and cost. These studies found
ost-effectiveness ratios of $17 000 (493), $18 100 (494),
nd $29 200 per year of life saved (495). Another model
ncorporated costs of nonthoracotomy ICDs and efficacy
stimates based on randomized trials and found ICD
ost-effectiveness was between $27 300 and $54 000 per
ife-year gained, which corresponded to risk reductions of
0% and 20%, respectively (496).
Several randomized clinical trials have measured bothost and clinical outcomes and thus can directly estimate cCD cost-effectiveness. MADIT found a 54% reduction in
otal mortality and a cost-effectiveness ratio of $27 000 per
ife-year added (18). In contrast, CIDS found a 20%
eduction in total mortality and a cost-effectiveness ratio
f $139 000 per life-year added (322,490). The cost-
ffectiveness ratio from the AVID trial was $66 677 per
ife-year added (491). MADIT II found a 32% reduction in
otal mortality and $39 200 higher costs among ICD-
ssigned patients than among those treated with conven-
ional therapy (17). The cost-effectiveness ratio in MADIT
I was measured as $235 000 per year of life added at 2 years
f follow-up but was projected to be between $78 600 and
114 000 per year of life added by 12 years of follow-up.
CD-HeFT reported that total mortality was reduced by
3% and costs increased by $19 000 over 5 years of
ollow-up in patients assigned to ICDs compared with
atients assigned to placebo (19). SCD-HeFT estimated
he lifetime cost-effectiveness ratio of the ICD strategy was
38 400 per year of life added. This range of results from
andomized studies is primarily due to different estimates of
he effectiveness of the ICD in reducing mortality, because
ll showed similar increases in the cost of care among ICD
ecipients. When the results of all clinical trials were used in
model that used a consistent framework to project the full
ain in life expectancy and lifetime costs in each trial (497),
he cost-effectiveness of the ICD ranged from $25 300 to
50 700 per life-year added in the randomized trials in
hich the ICD reduced mortality. In the CABG-Patch trial
nd DINAMIT, however, patients assigned to an ICD had
ower survival and higher costs than patients assigned to
onventional therapy, and the ICD strategy was not cost-
ffective. The evidence suggests that proper patient selection
s necessary for ICD implantation to be cost-effective; when
CD implantation is restricted to appropriately selected
atients, it has a cost-effectiveness ratio similar to other
ccepted cardiovascular therapies and compares well to the
tandard benchmark of renal dialysis ($30 000 to $50 000
er year of life saved). In principle, ICD implantation will
e more cost-effective when used for patients at high risk of
rrhythmic death and at low risk of other causes of death.
dditional risk stratification of patients with a reduced
VEF may improve patient selection for the ICD and
hereby enhance its cost-effectiveness (498). Cost-
ffectiveness of the ICD would also be improved by lower-
ng the cost of the device itself and further improving its
eliability and longevity.
The cost-effectiveness of CRT has not been evaluated
xtensively. A CRT-P device reduces hospitalization for
eart failure patients, and these cost savings partially offset
he initial cost of device implantation. CRT-P devices are
lso effective in improving QOL and may improve survival.
he cost-effectiveness of CRT-P devices versus medical
herapy appears to be favorable. There are few data on the
ost-effectiveness of CRT-D compared with CRT-P devices.
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efibrillator Generators
single RV lead for sensing and defibrillation is mandatory
or all currently available ICD systems. Single-chamber
CD systems are capable of bradycardia support in the
entricle and ATP. Dual-chamber ICD systems (right atrial
nd RV leads) are additionally capable of AV sequential
acing. Triple-chamber ICD systems (right atrial, RV, and
V leads) are capable of CRT (CRT-D). Despite these
ncreasing complexities, the optimal hardware system for
CD indications derived from mortality studies has not been
ully evaluated. There is increasing evidence that choice of
ardware may affect important outcomes in ICD patients.
his relates primarily to 2 considerations: 1) management of
entricular pacing and 2) pain associated with high-voltage
hocks. Conventional ICD therapy in any form may be
ssociated with worsening heart failure, VT, VF, and
oncardiac death that can be related to the adverse effects of
VA pacing (50,51). This is consistent with the increased
isks of AF and heart failure attributable to RVA pacing in
acemaker trials (45,48). The issue of QOL in the ICD
atient population has been evaluated extensively (460,499–
02). Although ICD therapy is generally well tolerated by
ost patients, approximately 30% to 50% experience some
egree of psychological distress after implantation (503).
ne of the principal limitations of ICD therapy is the
iscomfort associated with high-voltage shocks. Several
tudies have noted a direct correlation between poor QOL
cores and the experience of ICD shocks (460,499–501).
Any hardware system that increases unnecessary ventric-
lar pacing from any site may increase the risk of heart
ailure, particularly in patients with poor cardiac ventricular
ystolic function (293). The risk of heart failure is increased
ven in hearts with initially normal ventricular systolic
unction and with part-time ventricular pacing. RVA pacing
reates abnormal contraction, reduced ventricular systolic
unction, hypertrophy, and ultrastructural abnormalities.
he magnitude of the effect relates to the frequency of
entricular pacing and the degree of pacing-induced me-
hanical dyssynchrony rather than the hardware system
49). Although these effects have been demonstrated most
learly during RVA pacing, biventricular or LV pacing may
lso induce dyssynchrony in hearts with normal ventricular
onduction (504) and can reduce LV systolic function in
atients with no baseline dyssynchrony (505).
In patients with no AV block and no intraventricular
onduction abnormalities, ventricular pacing should be
voided as much as possible. For many ICD patients who
o not have an indication for bradycardia support, this can
e achieved by programming a very low backup ventricular
acing rate (i.e., 30 to 40 bpm). The optimal management
f cardiac pacing in ICD patients in whom bradycardia
upport is required, desired, or emerges is unknown. For
CD patients with SND in whom bradycardia support is fequired or desired, ventricular pacing may be minimized by
se of newer techniques specifically designed to promote
ntrinsic conduction (292,506). In patients with AV block,
lternate single-site RV or LV pacing or biventricular
acing (CRT-P/CRT-D) may be superior to RVA pacing.
fforts to optimize pacing mode or site should be greater in
atients with longer expected duration of pacing, poorer
ardiac function, and larger mechanical asynchrony. Aware-
ess of the problem of dyssynchrony should also lead to
ore regular monitoring of cardiac ventricular systolic
unction and mechanical asynchrony in any patient with
entricular pacing.
ATP refers to the use of pacing stimulation techniques
or termination of tachyarrhythmias. Tachycardias that
equire reentry to persist are susceptible to termination with
acing. The most common mechanism of VT in ICD
atients is scar-related reentry. The sine qua non of a
e-entrant arrhythmia is the ability to reproducibly initiate
nd terminate the tachycardia by critically timed extra-
timuli (124). Therefore, the possibility of successful termi-
ation of tachycardias with pacing can be anticipated on the
asis of the mechanism. Such techniques can be applied
utomatically with ICDs and offer the potential for painless
ermination of VT.
Adjudicated analysis of stored electrograms has revealed
hat the majority (approximately 85% to 90%) of spontane-
us ventricular tachyarrhythmias in ICD patients are due to
T and fast VT, whereas only approximately 10% are due to
F (507,508). Numerous older studies have consistently
emonstrated that ATP can reliably terminate approxi-
ately 85% to 90% of slow VTs (cycle lengths less than 300
illiseconds to 320 milliseconds) with a low risk of accel-
ration (1% to 5%) (509–511). More recently, similarly high
ates of success and low acceleration and syncope rates for
ast VTs (average cycle length 240 milliseconds to 320
illiseconds) have been demonstrated (507,508). These
bservations have repositioned the ICD as primarily an
TP device with defibrillation backup only as needed.
eduction in painful shocks may improve patient QOL
508) and extend ICD pulse-generator longevity. It is not
et clear whether important differences in optimal applica-
ion of ATP exist in different ICD patient populations. In
eneral, secondary prevention patients have a greater fre-
uency of spontaneous ventricular arrhythmia than primary
revention patients. However, differences in the incidence
f specific ventricular rhythms (VT, fast VT, and VF),
esponse to therapy (ATP or shocks), and susceptibility to
purious therapies due to SVT are incompletely character-
zed (294,512). Differences in substrate may be important as
ell. Monomorphic VT associated with chronic ischemic
eart disease is most commonly due to classic reentry and is
herefore susceptible to termination by ATP. Monomorphic
T is less commonly due to reentry and occurs with lowerrequency in nonischemic DCM.
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ll patients with ICDs require periodic and meticulous
ollow-up to ensure safety and optimal device performance, as
ell as to monitor a patient’s clinical status (513). The goals of
CD follow-up include monitoring of device system function;
ptimization of performance for maximal clinical effectiveness
nd system longevity; minimization of complications; antici-
ation of replacement of system components and tracking
evices under advisory; ensuring timely intervention for clinical
roblems; patient tracking, education, and support; and main-
enance of ICD system records. The importance of device
urveillance and management should be discussed with patients
efore ICD implantation. Compliance with device follow-up is
n important element in the evaluation of appropriate candidates
or device therapy and to obtain the best long-term result.
ICD follow-up is best achieved in an organized program
nalogous to pacemaker follow-up at outpatient clinics
312). Physicians and institutions performing implantation
f these devices should maintain follow-up facilities for
npatient and outpatient use. Such facilities should obtain
nd maintain implantation and follow-up support devices
or all ICDs used at that facility. The facility should be
taffed or supported by a cardiologist and/or electrophysi-
logist, who may work in conjunction with trained associ-
ted professionals (312,514,515). Continuous access to
hese services should be available as much as feasible on both
regularly scheduled and more emergent basis. The im-
lantation and/or follow-up facility should be able to locate
nd track patients who have received ICDs or who have
ntered the follow-up program.
.7.1. Elements of Implantable Cardioverter-Defibrillator
ollow-Up
he follow-up of an ICD patient must be individualized in
ccordance with the patient’s clinical status and conducted by a
hysician fully trained in ICD follow-up (12); if this is not a
hysician fully trained in all aspects of ICD implantation and
ollow-up, then such an individual should be available for any
roblems that may develop. Direct patient contact is ideal,
llowing for interval history taking, physical examination of the
mplantation site, and device programming changes that may
e warranted. Six-month intervals for device follow-up appear
o be safe (516), but more frequent evaluations may be required
epending on the device characteristics and the patient’s
linical status. Manufacturers’ guidelines for device follow-up
ay vary with individual models and should be available.
evice automaticity has facilitated follow-up (316), as has the
mplementation of remote monitoring techniques (513,517).
epending on the manufacturer, remote device interrogation
s achieved through Internet-based systems or via radiofre-
uency transmissions from the ICD via a phone device to a
entral monitoring center; remote reprogramming of devices is
ot available currently. Remote monitoring may lessen the
ependence on clinic visits, particularly in patients who live at
considerable distance from the follow-up clinic, and may dllow for the earlier detection of real or potential problems
ssociated with the device. Guidelines for remote monitoring
ave yet to be established. It should be recognized, further-
ore, that remote monitoring is an adjunct to follow-up and
annot entirely supplant clinic visits (518,519).
In general, device programming is initiated at implantation
nd may be reviewed periodically. It is often necessary to
eprogram the initially selected parameters either in the out-
atient clinic or during electrophysiological testing. When
evice function or concomitant antiarrhythmic therapy is
odified, electrophysiological testing may be warranted to
valuate sensing, pacing, or defibrillation functions of the
evice. Particular attention should be given to review of sensing
arameters, programmed defibrillation and pacing therapies,
evice activation, and event logs. Technical elements that
equire review include battery status, lead system parameters,
nd elective replacement indicators. Intervening evaluation of
evice function is often necessary. In general, when ICD
herapy is delivered, the device should be interrogated.
After implantation of a device, its performance should be
eviewed, limitations on the patient’s specific physical activities
stablished, and registration accomplished. Current policies on
riving advise patients with an ICD implanted for secondary
revention to avoid operating a motor vehicle for 6 months
fter the last arrhythmic event if it was associated with loss or
ear loss of consciousness to determine the pattern of recurrent
T/VF (520,521). For patients with ICDs implanted for
rimary prevention, avoidance of driving for at least 7 days to
llow healing has been recommended (522). Interactions with
lectromagnetic interference sources potentially affect employ-
ent. Sports involvement (523) and recommendations regard-
ng safeguards for future surgical procedures (524) should be
iscussed. There are currently not enough data to make
ecommendations regarding antibiotic prophylaxis for proce-
ures or operations required in the first 6 months after ICD
mplantation; physicians must weigh the risks and benefits of
ntibiotic prophylaxis and use their judgment in each case.
CD recipients should be encouraged to carry proper identifi-
ation and information about their device at all times. Patients
eceiving these devices can experience transient or sustained
evice-related anxiety. Education and psychological support
efore, during, and after ICD insertion are highly desirable and
an improve the patient’s QOL (457,458).
Increasing attention has been paid to the safety and efficacy
f implantable devices. It is incumbent upon the follow-up
hysician to be aware of advisories issued in relation to
otential device malfunction (2). Specific recommendations for
linicians managing such advisories are to consider lead/device
eplacement if death is a likely result of device malfunction; the
echanism of device/lead failure is known, potentially recur-
ent, and possibly life-threatening; the patient is pacemaker-
ependent; the risk of replacement is substantially lower than
he risk of device malfunction; or the device is approaching its
lective replacement indicator (3). Complications related to
eplacement of ICD generators under advisory have been well
ocumented, including infection, the need for reoperation, and
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ood of mortality resulting from device failure must be
eighed against the risk of procedural morbidity and mortality
ssociated with device replacement. In general, for pacemaker-
ependent patients, advisory device failure rates in excess of
.3% warrant consideration of device replacement; in patients
ith ICD generators under advisory, an estimated failure rate
f 3% favors replacement in the majority of cases, decreasing to
% when procedural mortality rates are 0.1% or less and/or risk
f fatal arrhythmias increases to 20% per year (526). It is
nticipated that the above general recommendations and esti-
ates will vary as a function of the specific nature of the
dvisory, how the malfunction presents, whether early detec-
ion and/or reprogramming may be employed in addressing
he potential device failure, and whether the lead (versus the
enerator) is affected. This has been demonstrated, for exam-
le, in the case of a recent lead advisory associated with
purious shocks attributable to lead fracture, oversensing, and
igh impedance; reprogramming to minimize overdetection of
oise, enabling of alert features to detect changes in imped-
nce, and increasing utilization of remote monitoring to follow
uch leads may have an effect on future rates of invasive lead
eplacement and/or extraction (527).
.7.2. Focus on Heart Failure After First Appropriate
mplantable Cardioverter-Defibrillator Therapy
n patients with heart failure who have not previously had a
ife-threatening arrhythmia, the first event identifies them as
eing at higher risk than before for both sudden death and
eath due to heart failure, with the majority of patients
urviving less than 2 years (17,19). It is not known to what
xtent these herald events serve as markers or as contributors to
rogression of disease. They should trigger reevaluation of
reatable causes of heart failure and of the medical regimen. In
ddition, the treatment regimen should be evaluated for inter-
entions that may decrease the risk of arrhythmia recurrence.
articular care should be paid to the titration of beta-
drenergic blockers. These agents have been shown to decrease
isease progression and improve outcomes, but uptitration can
ead to heart failure exacerbation and must be attempted
radually in small dose increments. Many patients with symp-
omatic heart failure cannot tolerate “target doses” of beta-
drenergic blockers, whether used primarily for the indication
f heart failure or to prevent recurrent arrhythmias. Although
atients with heart failure who have had device therapy would
deally be followed up by specialists in both arrhythmia
anagement and heart failure management, most patients do
ot have routine access to such settings. To maximize the
enefit after a sudden death has been prevented, it is crucial
hat the management team evaluate the heart failure profile,
eview the medical regimen, and plan for ongoing care.
. Areas in Need of Further Research
he ACC/AHA Task Force on Practice Guidelines has
harged writing committees to suggest areas in need of Lurther research. To this end, the present writing committee
ffers the following suggestions. They are presented in
abular form for ease of readability. Their order does not
mply any order of priority.
. Optimal access to device therapy should be provided to
all eligible populations irrespective of sex and ethnicity.
. Risk stratification of patients meeting current clinical
indications for primary prevention ICD implantation
should be improved to better target therapy to those
most likely to benefit from it.
. Identification of patients most likely to benefit from/
respond to CRT must be improved.
. Identify patients without current pacemaker or ICD
indications among those who may benefit from such
therapies.
. Indicators should be identified that provide direction
about when it is safe to not replace an ICD that has
reached the end of its effective battery life.
. The cost-effectiveness of device therapy should be ex-
plored further.
. Guidelines for remote monitoring should be developed.
. Ways to improve reliability and longevity of leads and
generators must be found, as well as methods to ensure
discovery of performance issues when they arise.
. Representation of the elderly in clinical trials should be
increased.
0. The influence of age on procedural complication rates
and the risk/benefit ratio for device implantation should
be defined.
1. The effect (positive, negative, or neutral) of biventricu-
lar or LV stimulation in patients with normal ventric-
ular function should be determined.
2. The need for pacing after MI in the current era should
be determined.
3. Long-term outcomes and risk factors for patients re-
ceiving ICDs in general practice compared with trial
populations and at academic centers should be identi-
fied and described.
4. Guidelines for device management in patients with
terminal illness or other requests to terminate device
therapy should be developed.
5. The role of ICDs in primary prevention for children
with genetic channelopathies, cardiomyopathies, and con-
genital heart defects should be defined more precisely.
6. The efficacy of biventricular pacing in children with
congenital heart disease and dilated cardiomyopathy
should be determined.
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